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1 Introduction 
1.1 General classification of diarylheptanoids 
Diarylheptanoids are a class of secondary plant metabolites with a structure generally 
consisting of two aromatic rings connected by a seven membered aliphatic chain. They can 
be further subdivided into linear and cyclic diarylheptanoids where the latter are 
represented by meta,para-bridged diphenyl ether type and meta,meta-bridged biphenyls.1 
A special group represent compounds with an additional cycle in the connecting chain,2 
e.g. cyclocurcumin (4). Typical examples of all four types are depicted in Fig. 1.  
 
Fig. 1: Characteristic representatives of diarylheptanoid classes: linear (curcumin, 1), cyclic of 
diphenyl ether type (juglanin A, 2), biphenyl cyclic type (acerogenin E, 3) and diarylheptanoids 
with cyclized C7-chain (cyclocurcumin, 4). 
 
1.2 Occurrence and structure of diarylheptanoids 
Compounds of the diarylheptanoid family can be typically found in the (inner) stem and 
the root bark of parent trees and shrubs, in the rhizomes of herbs,3 but also in extracts of 
leaves and twigs.4 Juglanin A (2) and B (17), two cyclic compounds from Juglans regia L., 
were isolated from the green pericarps of walnuts.5 Due to the phenolic nature of 
diarylheptanoids, MeOH, MeOH/CH2Cl2 mixtures6 or EtOH are normally used for their 
extraction. In some cases, e.g. for the extraction of Betula platyphylla leaves, acetone was 
used as solvent.7 
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Table 1: Occurrence of diarylheptanoids in plants based on Keserü et al.,1 Claeson et al.2 and Lv et 
al.3, 8 
Family Genus Diarylheptanoids 
linear diphenyl 
ethers 
biphenyls with cyclized 
C7 chain 
Aceraceae Acer + + + - 
Betulaceae Alnus 
Betula 
Corylus 
Carpinus 
Ostrya 
+ 
+ 
- 
- 
- 
+ 
+ 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
Burseraceae Garuga 
Boswellia 
- 
- 
+ 
+ 
+ 
- 
- 
- 
Casuarinaceae Casuarina - - + - 
Dioscoreaceae Dioscorea 
Tacca 
+ 
+ 
- 
- 
- 
- 
+ 
+ 
Juglandaceae Juglans 
Platycarya 
Rhoiptelea 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
Leguminosae Centrolobium + - - + 
Myricaceae Myrica - + + - 
Santalaceae Viscum + - - - 
Zingiberaceae Alpinia 
Curcuma 
Zingiber 
Amomum 
Aframomum 
Etlingera 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
+ 
+ 
+ 
+ 
- 
- 
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There is evidence on approximately 400 compounds of this kind (state 2011) which were 
discovered among several plant families.8 Interestingly, not all of the plant families, in 
which diarylheptanoids occur, are taxonomically relative and thus similar derivatives can 
be found in Zingiberaceae (order Zingiberales, clade monocots) as well as in Betulaceae 
(order Fagales, clade eudicots). Table 1 provides a summary of the distribution in nature 
for all four types. 
Besides terrestrial plants, two cyclic diarylheptanoids named tedaren A (5) and tedaren B 
(6) were isolated from the marine sponge Tedania ignis. The second one was identified as 
the smallest natural product with planar, central and axial chirality.9 Another example of 
unusual appearance was the extraction of alnusone (7) and its five congeners from Nidus 
vespae, the nest of paper wasp (Polistes), which is commonly used in Traditional Chinese 
Medicine. Since animals normally do not produce such secondary metabolites, the isolated 
compounds have to originate from plant material processed by the insects (Fig. 2).10 
 
Fig. 2: Examples of diarylheptanoids which were not isolated from terrestrial plants. 
 
Concerning the structural motifs, linear diarylheptanoids typically exhibit hydroxyl and 
methoxy substituents on one or both aromatic rings, mostly in positions 3’, 3’’, 4’, 4’’, 5’ 
and 5’’, rarely in positions 2’ and 2’’ (Fig. 3).8 Compounds without aromatic OH-groups 
were discovered only in few cases in Curcuma, Alpinia and Alnus species.2 Phenolic 
glycosylation was observed, comprising mainly mono- and diglycosides with e.g. glucose 
or apiose.11 The substitution of the tethered chain is more distinct. Since 
phenylpropanoids are their biosynthetic precursors, oxygenation prevails in position 3 
and 5, however, examples of natural products, oxygenated at carbon(s) 1, 2, 6 or 7, were 
described.8 The hydroxyl derivatives can be acylated, glycosylated or sulfated.8 The 
aliphatic chain is either fully saturated or contains up to three double bonds.2, 8 
Conjugations with other units, such as chalcones,12 flavonoids12 or phenethyl,13 are rare 
but possible (Fig. 3). 
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Fig. 3: Common substitutions of linear diarylheptanoids on the example of acerogenin G (8) and 
two examples of unusual conjugations with other phenolic compounds (9, 10)  
 
The structural diversity among the diphenyl ether type is high, nevertheless, certain 
structural similarities in terms of phenolic substitution can be found within botanical 
families (Fig. 4). In the Aceraceae family, mono-hydroxylation in position 2 can typically be 
seen (e.g. acerogenin C, 11), whereas Garuga species (Burseraceae) exhibit multiple 
methoxylations and hydroxylations in positions 2, 3 or 4 (garuganin I (12), garuganin IV 
(13)) (Fig. 4).14 Myricaceae are more known for their biphenyl type diarylheptanoids, 
although even here exceptions exist like galeon (14) with 2-hydroxyl-16-methoxy 
substitution.15 Finally, the diaryl ethers are represented in the Juglandaceae family by 
compounds like juglanin A (2)5 or pterocarine (15), isolated from trees of the genus 
Pterocarya (Fig. 4).16 As for their linear congeners, a glycosylation of phenolic and aliphatic 
OH-groups was observed.2 
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Fig. 4: Typical representatives of the diphenyl ether type diarylheptanoids 
 
In analogy to the diphenyl ether cyclic diarylheptanoids, the biphenyl compounds exhibit a 
limited diversity of aryl substituents (Fig. 5). Natural products isolated from Aceraceae, 
Casuarinaceae, Burseraceae and the majority of the biphenyls from Betulaceae are 
characteristic due to their 3,17-dihydroxyl substitution, e.g. acerogenin K (16). Additional 
methoxy group in position 4 occurs in walnut (Juglandaceae, juglanin B (17))5 and in a few 
derivatives from Myrica (e.g. myricananin C (18)).17 The highest variety of aryl substituent 
patterns shows the genus Myrica with typical 17-hydroxy-3,4-dimethoxy motifs, 
supplemented by either a methoxy, hydroxyl or O-sugar moieties in position 5.18 The 
tethered chain is mostly, but not exclusively, oxygenated in position 11. A double bond 
occurs mostly in conjugation with a keto functionality affording an enone, e.g. in alnusone 
(7) or myricananin D (20) (Fig. 5). 
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Fig. 5: Examples of biphenyl type cyclic diarylheptanoids 
 
The last group of diarylheptanois consists of compounds employing extra rings within the 
seven carbon connecting chain (Fig. 6). These compounds show an interesting variability 
regarding the aliphatic part. A typical example is the Curcuma longa diarylheptanoid 
cyclocurcumin (4), i.e. derivative of curcumin (1) with a 2,3-dihydro-4H-pyran-4-one ring 
formed by a intramolecular cyclization. Alpinia blepharocalyx contains numerous 
substances with a tetrahydropyran ring, of which some are conjugated with chalcones or 
flavonoids. Another source of diarylheptanoids with cyclized C7-chain is ginger (Zingiber 
officinale), a close relative of the above mentioned plants. Diarylheptanoids with a 
tetrahydrofuran ring in the tethered chain were discovered in Renealmia exaltata, a 
Brazilian medicinal plant of the ginger family.19 A completely different structure shows 
bicyclic diarylheptanoid 22 from the fruits of Musa × paradisiaca, a cultivated sort of 
banana tree. This compound was accompanied by three 9-phenylphenalenones,20 
emphasizing the biosynthetic relation of diarylheptanoids and the latter.1 Finally, the 
compound 24 (Fig. 6) with a tetrahydro-5H-benzo[7]annulen moiety was found in greater 
cardamom (Amomum subulatum Roxb.)21 and is so far the only isolated representative of 
this kind. 
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Fig. 6: Representatives of diarylheptanoids with cyclized C7-chain 
 
1.3 Biosynthesis of diarylheptanoids 
Curcumin (1), the most prominent linear diarylheptanoid, is often referred to as diferuloyl 
methane. This name indicates its biosynthetic origin from two cinnamate (ferulate) units 
(C6-C3) with a central methylene group provided by a malonate unit (Scheme 1).22 
 
Scheme 1: Biosynthesis of linear diarylheptanoids - Route 1 
However, investigations carried out by Roughley and Whiting using radioisotope labeled 
acetate and malonate revealed that an alternative pathway has to be involved in the 
biosynthesis of curcumin since the radioactivity was distributed among other carbons of 
the heptane chain and the aryl ring.23 This discovery led to the postulation of a competing 
 Introduction  
8 
 
mechanism which incorporates polyketide extension of a cinnamate unit with five acetate 
(or malonate) units followed by a cyclization (Scheme 2).22-23  
 
Scheme 2: Alternative biosynthetic pathway incorporating a polyketide synthase proposed by 
Roughley and Whiting – Route 2  
 
Mechanistic studies were performed for the diphenyl ether type compound acerogenin A 
(26) from the bark of Acer nikoense (Scheme 3). Feeding of young shoots of this tree with 
14C-labeled phenylalanine, cinnamic acid, sodium acetate and malonic acid showed that 
two cinnamate units are combined with a C1-unit from malonate to form (-)-centrolobol 
(25) which is then further cyclized to acerogenin A (26) (Scheme 3).24 This mechanism 
agrees with the pathway described in Scheme 1 and is in contrast to the route proposed by 
Roughley and Whiting for the biosynthesis of curcumin (1).22 The cyclization step was not 
discussed by the authors.24 
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Scheme 3: Biosynthesis of acerogenin A (26) according to Inoue et al. 24 
 
The biosynthesis of the biphenyl type cyclic diarylheptanoids was investigated using the 
example of myricanone (19) and myricanole (29) (Scheme 4). 13C-labeled p-coumaric acid 
(27) was administrated to young shoots of Myrica rubra and its extract was analyzed with 
GC-MS. The results were consistent with those obtained for acerogenin A (26), namely 
that two molecules of the C6-C3 acid are involved in the formation of the linear precursor 
(Route 1, Scheme 1).25 Further investigation by the same group with the aid of NMR 
spectroscopy and MS revealed that 3-(4-hydroxy)-propionic acid (28), the reduced 
equivalent of p-coumaric acid (27), was preferably incorporated in myricanol (29) and 
thus the mechanism was modified to the pathway described in Scheme 4.   
 
Scheme 4: Biosynthesis of the biphenyl type cyclic diarylheptanoids myricanone (19) and 
myricanol (29) in Myrica rubra 
Altogether, the biosynthesis of diarylheptanoids most likely differs from plant to plant, 
following one of the two routes described above (Scheme 1 and Scheme 2). The actual 
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cyclization mechanism towards both types of cyclic derivatives is not completely known 
yet, but a phenolic oxidative coupling, as in the case of the lignan biosynthesis,26 is possibly 
involved. According to this theory, a phenolic oxidative C-C coupling would lead to 
meta,meta-bridged biphenyls whereas the corresponding C-O coupling would preferably 
result in the formation of meta,para-bridged diphenyl ethers (Scheme 5). This indeed 
corresponds with the isolated natural products.27 
 
Scheme 5: Proposed mechanism for the cyclization of diarylheptanoids 
 
1.4 Synthesis of diarylheptanoids 
Due to the relatively simple nature of opened chain diarylheptanoids, many synthetic 
strategies were developed over the years. Different approaches have to be applied 
depending on the number of oxygenated carbons in the tethered chain. Typically, the 
aliphatic part bears either one (e.g. centrolobol, 25), two (e.g. curcumin, 1) or three (e.g. 
yashabushiketodiol A), extremely rarely four, oxygen atoms.27 
Mono-oxygenated acyclic diarylheptanoids exhibit the oxygenation in position 3 due to 
their biosynthetic origin from phenylpropanoids. This can be synthetically achieved, for 
instance, by nucleophilic additions to aldehydes,28 by aldol condensations,29 by the 
incorporation of Umpolung strategy with dithians28 or by Wittig-type reactions (Scheme 
6).29 
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Scheme 6: Retrosynthetic considerations towards mono-oxygenated linear diarylheptanoids 
  
Double-oxygenated diarylheptanoids can be considered as the closest relatives of 
curcumin (1). Such curcuminoids are usually substituted with hydroxyl or keto groups in 
positions 3 and 5. The first synthesis of curcumin (1) was accomplished in 1918 by V. 
Lampe using carbomethoxyferuloyl chloride (30) and acetoacetate. This reaction yielded a 
diketone 31, which upon a treatment with another carbomethoxyferuloyl chloride (30) 
and a loss of acetic acid gave the desired natural product 1 (Scheme 7).30 
 
Scheme 7: The first synthesis of curcumin (1) by V. Lampe in 191830 
 
The first industrial synthesis was later developed by Pavolini (1937) and improved by 
Pabon31 in 1964 (Scheme 8). This method incorporates acetylacetone 33 and two 
equivalents of vanillin 35. To avoid an undesired Knoevenagel condensation, the carbon 3 
of the acetylacetone has to be protected as a complex 34 with boric anhydride. The 
formation of curcumin (1) is then carried out in the presence of triisopropylborate and 
butylamine to afford the product in 80% yield. 
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Scheme 8: Industrial synthesis of curcumin (1) according to Pavolini and Pabon 
 
This method offers a unified strategy towards symmetric curcuminoids and was applied 
for the synthesis of electron rich curcumin derivatives32 as well as for a library of 
compounds with various linkers and heteroaryl rings.33 
The last group of linear diarylheptanoids is represented by compounds with three 
oxygenations in the tethered chain. As an example for the preparation of this relatively 
rare derivatives might be used the asymmetric synthesis of (+)-yashabushitriol (36),34 a 
natural product from Alnus sieboldiana (Scheme 9).35 The core reactions were the 
asymmetric reductions of synthons 40 and 38 with the aid of ruthenium catalysis, 
providing enantiomerically pure 36 and its 5-epimer in 11 steps.34   
 
Scheme 9: The retrosynthesis of (+)-yashabushitriol (36), a linear diarylheptanoid with 3 
oxygenations 
 
A bigger challenge than the synthesis of the opened chain diarylheptanoids offers the 
preparation of their cyclic derivatives (Scheme 10). The key step in the formation of the 
latter is the ring closing reaction. This can be performed either by a connection of two 
alkyl or two aryl rests, yielding both aryl ethers and biphenyls. Both strategies were 
investigated and with more or less success applied in the synthesis of different cyclic 
natural products of the diarylheptanoid family.27 
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Scheme 10: General approaches towards cyclic diarylheptanoids 
 
The first macrocyclization strategy, incorporating the connection of the aliphatic rests, 
was explored mostly in the synthesis of the diphenyl ether type diarylheptanoids. 
Especially the groups of Nógrádi and Keserü contributed important findings to this field. 
On the way to acerogenin A (26), an attempted intramolecular Claisen-Schmidt 
condensation of 43 afforded no product 44, whereas a Wittig-Horner olefination of the 
aldehyde-phosphonate 45 resulted in the cyclic dimer 46 (Scheme 11). 
 
Scheme 11: Failed aldol condensation and Wittig-Horner reaction towards acerogenin A 
precursors 
 
An elegant alternative to the linear substrates 43 and 45 was the incorporation of 
isoxazole 47, a surrogate of a 1,3-diketone unit, which upon the use of a Wurtz (Scheme 
12) or a Wittig (Scheme 13) reaction led to garugamblin-1 (50)36 or garuganin III (54),37 
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respectively. Although the presence of the isoxazole moiety helped to preorganize the 
molecule for the intramolecular reaction in these actual cases, the application of this 
method for other substrates failed, clearly showing its limited scope. 
 
Scheme 12: Wurtz reaction applied in the synthesis of garugamblin-1 (50) 
 
 
Scheme 13: Intramolecular Wittig reaction of isoxazole 51, a precursor of garuganin III (54) 
 
More examples can be found in the literature for the macrocyclization via an aryl-ether 
bond formation. Zhu et al. developed a strategy based on a nucleophilic aromatic 
substitution (Scheme 14). Acerogenins A (26)38 and C (11)39 were obtained by this 
method, using linear compound with a hydroxylated A-ring and a B-ring with 4-fluoro-3-
nitro substitution (55). The cyclization reaction was promoted by CsF or potassium 
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carbonate and provided the nitrated product 56 in almost quantitative yield. The 
conversion was then finished by the reduction of the nitro group to the corresponding 
amine (57), followed by a deamination (Scheme 14).39 
 
Scheme 14: Synthesis of acerogenin C (11) by an intramolecular nucleophilic aromatic substitution 
 
Another method widely used for the formation of the diphenyl ether type cyclic 
diarylheptanoids provides an intramolecular Ullmann reaction (Scheme 15). This protocol, 
originally applied by Nógrádi et al. for the synthesis of acerogenins A (26) and C (11),40 
was later optimized and extended by more working groups16, 41 and represents a state of 
the art methodology for this class of compounds. The synthesis of juglanin A (2) by Salih 
and Beaudry16 depicted in Scheme 15 illustrates the versatility of this strategy. 
 
Scheme 15: Synthesis of juglanin A (2) via an intramolecular Ullmann reaction 
 
In contrast to the 15-membered meta,para-cyclophane ring of the diphenyl ethers, the 
meta,meta-bridged biphenyl diarylheptanoids exhibit merely a 13-membred ring. The 
higher ring-strain of such system might be the reason for relatively limited literature 
evidence for the synthesis of latter. The first example was the synthesis of alnusone (7) by 
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Semmelhack et al., where a biphenyl coupling via a zerovalent nickel catalyzed Ullmann 
reaction was applied.42 A diiodinated linear precursor acted as a substrate and the 
cyclization step proceeded in 47% yield (Scheme 16).  
 
Scheme 16: Synthesis of alnusone (7) by a Ni(0) catalyzed Ullmann reaction 
 
Semmelhack’s protocol, developed in the early 1980s, was at the same time employed by 
Whiting and Wood for the synthesis of myricanone (19) and myricanol (29) reaching, 
however, only 7-10% yields. The authors pointed out lower ring strain of alnusone (7) in 
contrast to myricanone (19) due to the presence of three sp2 carbons in the heptane 
linkage of 7 and higher steric hindrance adjacent to the biphenyl in case of 19 (Scheme 
17).43 
 
Scheme 17: Key steps in the synthesis of myricanone (19) and myricanol (29) 
 
To avoid the drawbacks of Semmelhack’s and Whiting’s method, an alternative approach 
via an intramolecular Thorpe-Ziegler condensation was examined by Dansou et al 
(Scheme 18). This strategy employed a biphenyl coupling using a Suzuki reaction at the 
early stage of the synthetic pathway and dinitriles 64 and 67 as cyclization substrates. 
Unfortunately, the attempted ring-closure afforded a dimeric compound 68 instead of the 
envisioned diarylheptanoid.44 
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Scheme 18: Attempted synthesis of myricanone (19) via a Thorpe-Ziegler condensation 
 
The last contribution to this topic was the synthesis of acerogenin E (3) and K (16) by 
Ogura and Usuki in 2013 (Scheme 19).29 Herein, the Ni(0)-catalyzed Ullmann coupling was 
replaced by a more recent methodology, namely by a domino sequence of a Miyaura 
arylborylation and an intramolecular Suzuki reaction.45 Using this concept, the first total 
synthesis of the two biphenyl type cyclic diarylheptanoids from Acer nikoense was 
accomplished, using diiodinated linear precursors 69 as a substrate for the 
macrocyclization.29 
 
Scheme 19: Total synthesis of acerogenin E (3) and K (16) by Ogura and Usuki29 
 
All in all, the linear diarylheptanoids have become accessible by many of methods over the 
decades27 but in particular new asymmetric strategies for the synthesis of chiral 
compounds attract currently the focus of the scientific community.46 The number of 
publications on the synthesis of diaryl ether type cyclic compounds is rising due to their 
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accesibility by CuO-catalyzed Ullmann reaction.16, 47 More attention is being dedicated to 
the unique properties of this cyclophanes such as the ring strain and axial chirality.47 
Within the class of diarylheptanoids with a cyclized C7-chain, in particular  compounds of 
the cyclocurcumin type48 and natural products from Alpinia blepharocalyx49 have gained 
interest since their discovery in the early 1990s. The last group of the biphenyl type cyclic 
compounds remains, besides very few exceptions,29, 42, 43b synthetically unexplored, most 
likely because of the difficulties in the formation of the extremely strained cycle. 
1.5 Biological activity of diarylheptanoids 
The parent plants of diarylheptanoids find a broad use in traditional medicines of Asia, 
South America and Africa. For example, the rhizome of turmeric (Curcuma longa L.) is 
known in Indian (Ayurvedic) and Traditional Chinese Medicine for the treatment of 
biliary, skin or stomach diseases,50 as well as for hepatoprotective51 and anticarcinogenic52 
activity. Multiple review articles cover this field, above all publications by the group of B. 
Aggarwal.53 Another plant of the Zingiberaceae family, Alpinia blepharocalyx, is 
traditionally used in southwest of China against stomach disorders. Calyxins, 
diarylheptanoids with cyclized C7-chain, were isolated from the seeds of this plant and 
might thus contribute to the beneficial health effects of Alpina.12 Roots of Korean walnut 
Juglans sinensis, which contain cyclic diarylheptanoids of the juglanin class, are 
traditionally applied in the folk medicine of Korea as a remedy for inflammatory diseases.4  
Another example is the use of the stem bark of Acer nikoense, rich on acerogenin-type 
cyclic diarylheptanoids, for the treatment of hepatic disorders and as eyewash.54 
Herein, an overview on published pharmacological effects of various diarylheptanoids is 
presented, with a special focus on cyclic compounds of both types. 
1.5.1 Anticarcinogenic and anticancer effects 
The anticarcinogenic activity of curcumin was shown in many publications. An influence 
on the cell cycle and the tumor suppressor protein p53,55 as well as effects on pro- and 
anti-inflammatory signaling pathways (NF-κB56, Nrf257) were described. Further relative 
compounds of curcumin exhibited cytotoxicity against different cancer cell lines. Linear 
diarylheptanoid glycosides from the inner bark of Betula papyrifera suppressed the 
proliferation of human colorectal cancer cells (DLD-1) with IC50-values of 10.3 – 13.8 µM.58 
Another open chained derivative from Viscum cruciatum showed cytotoxic activity against 
melanoma (UACC-62), renal (TK-10) and breast (MCF-7) cancer cell lines.59 Moreover, 
blepharocalyxins D and E, i.e. compounds with cyclized tethered chain included in Alpinia 
blepharocalys, had an strong antiproliferative effect against colon carcinoma (26-L5) and 
fibrosarcoma (HT-1080) cells, respectively. 
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Chemopreventive properties of cyclic diarylheptanoids were studied by Ishida and co-
workers, pointing out a high antitumor-promoting potential of myricanone (19) and 13-
oxomyricanol. These two compounds exerted the same inhibitory effect as curcumin. A 
structure-activity comparison among 11 compounds revealed that the oxo-functionality in 
position 11 as well as the 5,17-dihydroxy substitution were important for the suppression 
of the tumor promotion.60 Furthermore, the diphenyl ether type cyclic diarylheptanoid 
galeon (14) from the roots of Juglans mandshurica was significantly cytotoxic when 
exposed to human colon carcinoma (HT29) and human lung carcinoma (A-549) cell 
lines.61 Finally, juglanin A (2) and B (17), isolated from pericarps of walnut, exhibited a 
cytotoxic activity against human hepatoma (HepG2) cells.5 
1.5.2 Anti-inflammatory activity 
The use of turmeric as a remedy of inflammatory diseases was mentioned above, as well 
as the interactions of curcumin (1) with the transcription factor NF-κB. The signaling 
pathway of NF-κB can be affected by 1 at various points. On the one hand, 1 can prevent 
the binding of pro-inflammatory stimuli such as LPS to the cellular receptors. In the 
intracellular space, it attenuates the activation of kinase IKK which cannot phosphorylate 
its substrate, the IκBα protein. This protein is the inhibitory unit of NF-κB. When the IKK 
phosphorylates IκBα, the p50/p65 dimer is released and can translocate to the nucleus 
where it triggers the transcription of pro-inflammatory genes. Curcumin (1) can block the 
p50/p65-DNA binding and thus reduce the levels of pro-inflammatory cytokines, such as 
TNF, IL-8 and IFNγ, as well as the expression of COX-2 or iNOS (Scheme 20).62 
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Scheme 20: A simplified illustration of the NF-κB signaling pathway and interactions with 
curcumin, modified according to Rimbach et al.62 
 
Even other diarylheptanoids besides curcumin were shown to inhibit inflammatory 
processes. For instance, acyclic derivative hirsutenone (71) (Fig. 7), ubiquitous in different 
Alnus species, reduced the LPS-stimulated inflammation by suppressing the Toll-like 
receptor 4 (TL4) mediated NF-κB activation that is regulated by the ERK pathway.63 The 
same effect exhibited this compound against TNF-induced activation of the pro-
inflammatory signaling pathway NF-κB.64 Another linear compound from Alnus formosana, 
namely oregonin (72), possessed anti-inflammatory activity by the reduction of LPS-
induced, NF-κB-mediated expression of iNOS. At the same time, 71 appeared to the induce 
production of the anti-inflammatory enzyme heme oxygenase 1 (HO-1).65 
 
Fig. 7: Anti-inflammatory linear diarylheptanoids hirsutenone (71) and oregonin (72)  
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Among the cyclic compounds, biphenyl and diphenyl ether type diarylheptanoids from 
Acer nikoense MAXIM. could reduce the TPA-induced inflammation in mice,66 as well as the 
production of nitric oxide (NO), a known pro-inflammatory mediator, in macrophages 
stimulated by LPS.67 The suppression of the NO production was additionally observed for 
cyclic biphenyls from Myrica rubra68 and Myrica nana.17 
1.5.3 Antioxidant activity 
Free radicals cause cellular damage by peroxidation of lipid membranes and DNA. The 
effects triggered by free radicals, commonly referred to as oxidative stress, can be 
attenuated by phenolic compounds such as flavonoids or diarylheptanoids. The literature 
on this topic often distinguishes between direct and indirect antioxidants. The first are 
small molecules which undergo direct redox reactions with reactive oxygen and nitrogen 
species. Upon this interaction, they are being consumed or modified and thus have to be 
regenerated. The indirect antioxidants exert their effects by upregulation of cytoprotective 
proteins, such as HO-1 or γ-GCS (γ-glutamylcysteine synthetase), which catalyze 
detoxification reactions.69 
Curcumin, the molecule with the best explored pharmacological properties, exhibits both 
direct and indirect antioxidant effects. Its radical-scavenging capacity can be assigned to 
the presence of phenolic hydroxyl and methoxy groups, as well as the β-diketone moiety.70 
The indirect antioxidant activity is mediated by the activation of the Nrf2 cascade, which 
leads to the induction of HO-1 and γ-GCS, i.e. the key enzyme in the biosynthesis of the 
cytosolic antioxidant glutathione (GSH).62 
Other linear diarylheptanoids isolated from Alnus japonica, i.a. hirsutenone (71) and 
oregonin (72) (Fig. 7), showed a good direct antioxidant potential in the TOSC (total 
oxidant scavenging capacity) assay.71 In a different study, the capability of scavenging 
superoxide radicals was described for derivatives with a cyclized heptane chain from 
rhizomes of Zingiber officinale.72 Finally, antioxidant activity within the group of cyclic 
diarylheptanoids possessed, e.g., myricanol (29),18 myricanone (19)18 or acerogenin M.73     
1.5.4 Antimicrobial activity 
Numerous disorders, which are traditionally treated by turmeric in the Indian folk 
medicine, are caused by microbial infections. Hence, the antimicrobial effects of 1 were 
investigated in various studies. Curcumin (1) displayed antifungal properties against 14 
Candida strains,74 as well as antiviral activity against coxsackievirus.75 Furthermore, 
antimalarial,76 antiparasitic77 and nematocidal78 effects of 1 were described.  
In another study, the activity of linear diarylheptanoids from Alnus japonica against the 
papain-like protease (PLpro) was examined. This protein represents a promising target in 
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the treatment of corona-virus induced severe acute respiratory syndrome (SARS). A 
structure-activity relationship for nine diarylheptanoids was determined revealing that 
the enone and the catechol moiety of hirsutenone (71) were essential for the biological 
effect.79 Moreover, hirsutenone could effectively inhibit methicillin-resistant 
Staphylococcus aureus.80 
 
Fig. 8: Antitubercular diarylheptanoids from Engelhardia roxburghiana 
 
Among the cyclic diarylheptanoids, diphenyl ether type compounds engelhardiols A (73) 
and B (74) (Fig. 8) from the stem of Engelhardia roxburghiana (Juglandaceae) displayed 
antitubercular properties,80 whereas biphenyl type compounds from various Betula 
species exhibited antileishmanial activity.81    
1.5.5 Estrogenic activity 
Phytoestrogens are natural product with estrogen-like activity, which is mainly exerted by 
a specific binding to estrogen receptors. These effects could be shown for several 
secondary plant metabolites, e.g genistein, 8-prenylnaringenin (Fig. 9) or some 
diarylheptanoids.  
 
Fig. 9: Natural occurring phytoestrogens 
 
For instance, open chained compounds from Curcuma comosa induced Bcl-xL and estrogen 
receptor β (ERβ) gene expression, which are genes closely associated with an estrogenic 
activity.82 Further investigations on these diarylheptanoids resulted in the identification of 
compound 77 as a potent, ERα selective phytoestrogen in vitro and in vivo.83    
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1.5.6 Hepatoprotective activity 
Hepatoprotective activity refers to the ability of some substances to prevent liver damage. 
This effect could be demonstrated for curcumin (1) when acting against different inducers 
of liver injuries, such as heavy metals,84 chronic alcohol intake85 and carbon 
tetrachloride.86 The activity can be attributed to its general antioxidant87 and anti-
inflammatory properties, especially the Nrf2-mediated induction of the HO-1 expression88 
and the attenuation of the pro-inflammatory NF-κB pathway.89 
Besides 1, a 50% aqueous methanolic extract from the bark of Betula platyphylla showed 
inhibitory effects against CCl4-induced liver injury in vivo. It was identified upon further 
isolation and in vitro testing that three linear diarylheptanoids from this extract 
significantly contributed to the hepatoprotective activity.90 Additionally, open chained 
compounds from Alnus hirsuta exhibited a protective activity against t-BuOOH-induced 
hepatotoxicity in HepG2 cells.91   
1.5.7 Neuroprotective activity 
Neuroinflammation can be triggered by several stimuli, such as bacterial and viral 
infections, hypoxia/ischemia or neurodegenerative diseases. Upon activation by these 
stimuli, primary immune cells in the brain (microglia) start to produce pro-inflammatory 
cytokines, like TNF or IL-1β.62 Long term stimulation of the immune system, accompanied 
by an astrogliosis,92 leads to permanent changes in the neuronal balance and finally to 
neurodegeneration.62 
In Alzheimer’s disease (AD), the chronic inflammation goes along with an extracellular 
accumulation of amyloid β peptide (Aβ plaque) and a neurofibrillary tangle. In addition, 
overstimulation of N-methyl-D-aspartat (NMDA) receptors by the neurotransmitter 
glutamate followed by a massive increase of the intracellular Ca2+ concentration, also 
referred to as excitotoxicity, is often associated with AD. In response to the excitotoxicity, 
mitochondrial damage and oxidative stress occur which, all together, result in neuronal 
loss.62 
The treatment of AD is only symptomatic and incorporates acetylcholinesterase inhibitors 
and antagonists of NMDA receptors. Since the impact of this treatment is only limited and 
new therapeutic agents are being searched, natural antioxidants like the polyphenols 
resveratrol or curcumin (1) are getting in the focus. The limiting factor is, however, the 
bioavailability of these compounds. Especially 1 undergoes a high first-pass effect and a 
rapid metabolization, therefore, it has to be administrated over a long period of time in 
large doses to reach the therapeutically effective concentrations in the brain tissue.93 Once 
in the brain, 1 inhibits the extracellular aggregation of Aβ plaque,94 supports the integrity 
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of mitochondrial membranes,95 prevents the expression of pro-inflammatory stimuli (e.g. 
IL-1β)94 and alleviates the effects of excitotoxicity.96 Altogether, due to the promising 
neuroprotective effects in animal models and in vitro 1 remains a good lead compound for 
further development of optimized structures.97  
Although the most attention in terms of neuroprotection was dedicated to 1, a few 
diarylheptanoids from other sources were investigated too. Hirsutenone (71) from Alnus 
japonica protected retinal ganglion cells, neurons from the inner surface of the eye, against 
oxidative stress induced by L-buthionine-(S,R)-sulfoximine/glutamate.98 Standardized 
extract from Betula platyphylla bark ameliorated the scopolamine-induced amnesia in 
rodents, as well as the glutamate-induced neurotoxicity in HT22 cells.99 Moreover, an 
extract of Alpinia katsumadai, which consisted predominantly of flavonoids, stilbens, 
chalcones and diarylheptanoids, was able to protecte hippocampal neurons from ischemic 
damage.100 Finally, biphenyl type cyclic diarylheptanoid juglanin C and diphenyl ether type 
compound juglanin A, both from the leaves of Juglans sinensis, effectively diminished 
neuronal cell death of HT22 cells stressed by glutamate. The glutathione level, significantly 
reduced after the glutamate exposure, was restored by the compounds, but not the level of  
antioxidant enzyme superoxide dismutase (SOD).4 
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2 Aim of the project 
Diarylheptanoids attract ambiguous attention in both synthesis and pharmacology. 
Whereas literature concerning curcuminoids is of an enormous size (6745 hits for search 
term “curcumin” in PubMed, state 2014-07-01), the cyclic diarylheptanoids appear to be 
rather neglected. The reason might be the limited availability of these compounds. The 
isolation of the cyclic diarylheptanoids from the stem bark of selected trees requires a big 
amount of plant material and multiple extraction and chromatographic steps, eventually 
affording the desired substances in a lower milligram range. Convenient synthetic 
methods were established for the diphenyl ether type diarylheptanoids16, 41 but not for the 
cyclic compounds of the biphenyl type. 
Due to this, the aim of the presented work was to explore and develop a synthetic strategy 
towards linear and biphenyl type cyclic diarylheptanoids. The synthesis of linear 
derivatives was focused on monocarbonyl analogues of curcumin (MACs) with a natural 
product-like aromatic substitution, such as (±)-centrolobol (25), in order to obtain a 
library of compounds for structure-activity relationship investigations. Upon the cyclic 
diarylheptanoids, special attention was given to the natural products of acerogenin and 
myricananin type (acerogenin E (3), acerogenin K (16) and myricananin C (18), Fig. 10). 
The challenging aspect of their synthesis was the formation of the strained 13-membered 
ring with the meta,meta-bridged biphenyl moiety.  
 
Fig. 10: Natural products synthesized for the evaluation of their potential neuroprotective activity. 
 
Focus of the pharmacological testing was dedicated to potential neuroprotective effects of 
the synthetized compounds. Yang et al. observed attenuation of the glutamate-induced 
toxicity by cyclic diarylheptanoids isolated from Juglans sinensis.4 Hence, protective 
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activity of the prepared linear and cyclic diarylheptanoids against oxidative stress was 
tested in the murine hippocampal cells HT22 to compare and evaluate biological effects of 
both substance classes. 
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3 Results and discussion 
3.1 Synthesis of linear diarylheptanoids 
3.1.1 Retrosynthetic approach towards linear diarylheptanoids  
The linear diarylheptanoids are biosynthetic precursors of their cyclic counterparts.25 A 
general synthetic strategy towards monocarbonyl analogues of curcumin (MACs) was 
therefore developed (Scheme 21) to eventually allow for a comparison of pharmacological 
properties of both classes.  
 
Scheme 21: Retrosynthetic strategy towards linear diarylheptanoids 
 
For the synthesis of linear diarylheptanoids, several methods can be taken in account 
depending on the desired substitution of the tethered chain.  A common feature for the 
cyclic diarylheptanoids of interest was an oxygen in position 11, corresponding to the 
position 3 in the acyclic compounds. The linear molecules are, in comparison to curcumin 
(1), asymmetric and hence, the classical curcumin synthesis combining two molecules of 
vanillin with acetylacetone31 cannot be applied. Different approaches were prospected, 
leading eventually to a modification of strategy used in the synthesis of engelhardione by 
Shen and Sun,101 combining phenylpropanoid units (C6-C3) from hydroxycinnamic acids 
with three carbons provided by acetone (C3) and vanillin or 4-hydroxybenzaldehyde (C6-
C1 unit) (Scheme 21). 
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3.1.2 Formation of the C6-C3 building block 
In order to prepare hydroxy- and methoxylated cinnamic aldehydes as C6-C3 building 
blocks, two different reaction sequences were carried out. Common for both strategies 
was the protection of phenolic OH-groups as base stable methoxymethyl ethers. The 
unprotected hydroxyl group in the para-position of the benzaldehyde increases the 
electron density of the aromatic system under basic conditions and lowers thus the ability 
of aldol condensation with ketones in further stages of the synthesis. The protection of 
vanillin (35) and 4-hydroxybenzaldehyde (78) proceeded quantitatively using MOM 
chloride in presence of Hunig’s base (DIPEA) (Scheme 22).102 
 
Scheme 22: Synthesis of hydroxycinnamic aldehyds via Wittig olefination 
 
The first elongations towards desired C6-C3 aldehydes were performed via a Wittig 
olefination of aldehydes 79 and 80 with commercially available ylidens,103 affording the 
aldehydes 81 and 82 in 40% and 13% yield, respectively (Scheme 22). This strategy 
suffered from low selectivity since the obtained aldehydes could react with the olefination 
reagent towards side product 83 and 84. Therefore, the purification of the reaction 
mixtures was slightly complicated and the resulting yields unsatisfactory. 
The second synthetic route used p-coumaric (27) or ferulic (85) acid as starting material 
(Scheme 23). These phenylpropanoids already contain the desired C6-C3 unit, only in a 
different oxidative state. Even though a selective reduction of esters to corresponding 
aldehydes with diisobutylaluminium hydride (DIBAl-H)104 and lithium aluminium hydride 
(LiAlH4)55 is known, more common conversion is the reduction of the acid to the alcohol 
followed by a mild oxidation towards the desired aldehyde. 
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Scheme 23: Optimized synthetic route towards hydroxycinnamic aldehydes 
 
Firstly, the OH-group of the ferulic (85) and p-coumaric (27) acid was protected as a 
MOM-ether,102 whilst an esterification of the carboxylic group occurred. These 
methoxymethyl esters (86 and 87), obtained in almost quantitative yields, were reduced 
with lithium aluminium hydride105 to the allylic alcohols 88 (96%) and 89 (99%), which 
were subsequently oxidized with manganese dioxide105 to aldehydes 81 and 82 in 68% 
and 73% yields, respectively (Scheme 23). Although this synthetic strategy towards the 
hydroxycinnamic aldehydes 81 and 82 requires three instead of two steps compared with 
the first method, the higher overall yield (62 - 72% over 3 steps vs. 13 - 38% over 2 steps) 
and easier product purification due to the absence of “over-olefination” side products 
justified its use. 
3.1.3 Construction of the C6-C6 ketones 
 
Scheme 24: Formation of the C6-C6 unit via Claisen-Schmidt condensation 
 
With the C6-C3 aldehydes in hand, elongation of their aliphatic chains towards C6-C6 
ketones 90 and 91 was envisioned (Scheme 24). This was achieved by a Claisen-Schmidt 
condensation with  acetone in presence of NaOH as base101 in reasonable yields (69% and 
71%, respectively).  
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Scheme 25: Hydrogenation of the unsaturated ketones 90 and 91 
 
The next step was the hydrogenation of the two double bonds (Scheme 25). To prevent 
reduction of the oxo-group, a reaction protocol developed by Mori et al. was applied. In 
this method, the reactivity of the Pd/C hydrogenation catalyst is lowered by 
diphenylsulfide as catalyst poison. This allows for selective reductions of olefins in 
presence of carbonyls, aromatic halogens or N-Cbz groups.106 Interestingly, when 
methanol was used as solvent, a partial cleavage of the MOM-protecting group was 
observed. However, using chloroform instead of MeOH led to a clean reaction towards the 
desired products with high yields (78% for 92, 83% for 93, Scheme 25). 
3.1.4 Synthesis of linear diarylheptanoids via Claisen-Schmidt 
condensation 
The final step of the planned synthesis was the reaction of the C6-C6 ketones 92 and 93 
with C6-C1 units, represented by the MOM-protected aromatic aldehydes 79 and 80 
(Scheme 26). The combination of the two ketones (92, 93) with the two aldehydes (79, 
80) afforded four differently substituted, MOM-protected, diarylheptanoids. The reactions 
were carried out in the presence of sodium hydroxide as base, using a small excess of 
aldehydes (1.8 eq.) compared to ketones,101 yielding the products in moderate to 
reasonable yields (38 – 65%, Scheme 26).  
 
Scheme 26: Formation of the linear diarylheptanoids 94-97 
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3.1.5 Modifications of the aliphatic chain 
The acidic hydrolysis of the MOM-protecting groups, performed in methanol and HCl (aq.) 
at reflux temperature,107 resulted in four diarylheptanoids (98-101) with an enone moiety 
in the aliphatic chain in good yields (67 - 88%, Scheme 27). Such compounds, also known 
as monocarbonyl analogues of curcumin (MACs), 108 can further be modified on the 
aliphatic chain in regard to its oxidation state. Hence, the double bond of the α,β-
unsaturated carbonyl system was reduced using Pd/C-catalyzed hydrogenation with 
diphenyl sulfide as a catalyst poison.106 This reaction afforded four ketones 102, 103, 104 
and 8 (acerogenin G) in good to excellent yields (Scheme 27). Furthermore, reduction of 
the oxo-group of these compounds with sodium borohydride109 led to four linear 
diarylheptanoids with an alcohol moiety in position 3 (105, 106, 107 and 25, Scheme 27). 
No asymmetric reduction method was applied because the biological activity of the 
compounds was expected to be predominantly associated with the phenolic groups or the 
Michael system.97 
 
Scheme 27: Three types of acyclic diarylheptanoids with enone, ketone and alcohol structure 
 
Altogether, 12 linear diarylheptanoids (Scheme 27) with four various substitution 
patterns of the aromatic rings and three different oxidation states of the tethered chain 
were prepared in course of 8-10 steps with overall minimum yield of 7% for (±)-
centrolobol (25) and maximum 12% for alcohol 107. Among these 12 compounds, 
curcuminoids 103, 104, 106 and 107 were identified before as in vivo metabolites of 
demethoxycurcumin in rat feces110 and compound 25 as a metabolite of 
bisdemethoxycurcumin.111 Ketone 103 was isolated from Curcuma kwangsinensis112 and 
compound 102 was previously prepared by Lee et al.113 and found in Zingiber officinale.114 
Ketone 8 is also known as acerogenin G and occurs in various Acer species,11 as well as its 
reduced form centrolobol (25).115 Enones 98-101 have not been described so far. 
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3.1.6 Synthesis of further curcumin analogues 
To enlarge the scope of the synthesized curcuminoids, analogues with minor modifications 
were prepared. The common feature for above described open chained diarylheptanoids 
was the 4-hydroxy or 4-hydroxy-3-methoxy substitution of the aromatic rings. Hence, 
three new curcuminoids with 3,4-dimethoxy 108 and 3,4-dihydroxy (caffeoyl) motifs 109 
and 110 were prepared (Scheme 28). 
 
Scheme 28: Analogues of curcumin with modified aromatic rings 
 
The synthesis of the 3’,3’’,4’,4’’-tetramethoxy substituted derivative 108 was performed by 
methylation of ketone 102 with dimethyl sulfate as methylating agent and potassium 
carbonate as base (Scheme 28).116 The demethylation of enone 98 and curcumin (1) 
towards 3’,3’’,4’,4’’-tertahydroxy curcuminoids 109 and 110 (also di-O-
demethylcurcumin) was carried out under the same conditions, namely with 6.0 eq. of 
boron tribromide (Scheme 28).117 Sousa and Silva computationally proposed a mechanism 
involving a bimolecular reaction between two ether-BBr3 adducts,118 therefore the use of a 
BBr3 extent might be beneficial for the reaction outcome. Nevertheless, the conversion of 1 
into di-O-demethylcurcumin proceeded only in 11% yield, probably due to a possible 
photo-instability of the product.  
3.1.7 Synthesis of single ring analogues of curcumin 
To investigate, whether the diarylheptanoid scaffold or only its part was important for the 
biological activity, two ‘half-molecules’ consisting of a C6-C4 scaffold with a conjugated 
enone motif and 4-hydroxy-(3-methoxy) aromatic substitutions were prepared (Scheme 
29). 
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Scheme 29: Single ring analogues derived from natural curcuminoids 
 
The synthesis started, similar as in the case of the linear diarylheptanoids, with the 
protection of the hydroxyl group of vanillin (35) and 4-hydroxybenzaldehyde (78) under 
the conditions described in 3.1.2. Wittig olefination strategy was then applied for the 
formation of the 4-phenyl-but-3-en-2-one moiety, affording MOM-protected compounds 
111 and 112 in 42% and 70% yield, respectively. After the acidic hydrolysis of the 
methoxy-methyl ether groups, the desired single ring analogues 113 and 114 were 
obtained (Scheme 30). Ketone 113 is known in the literature under the name 
dehydrozingerone and naturally occurs in ginger (Zingiber officinale).119 Compound 114, 
first synthesized by Buck and Heilbron,120 is a biosynthetic precursor of raspberry ketone 
which can be found in raspberries and other fruits.121 
 
Scheme 30: Synthesis of single ring analogues 113 and 114 
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3.2 Synthesis of linear diarylheptanoids with cyclized C7-chain 
The term diarylheptanoids with cyclized C7-chain was introduced by Claeson et al.2 and 
was described in 1.1. Although the focus of this project was dedicated to linear and cyclic 
diarylheptanoids with a meta,meta-bridged biphenyl structure, two novel compounds 
with an unusual cyclization of the aliphatic chain (115 and 116) were serendipitously 
produced and fully characterized by means of 2D NMR spectroscopy. The formation of 
those compounds could be reproduced and a reaction mechanism was proposed. A 
literature review revealed that a similar tricyclic compound 24 was discovered before in 
the fruits of greater cardamom (Amomum subulatum Roxb.) (Fig. 11).21 
 
Fig. 11: Synthetic (115, 116) and natural (24) diarylheptanoids with cyclized C7-chain 
Originally, a synthesis of linear diarylheptanoids with an allylic alcohol moiety was aimed 
to obtain the fourth substitution type of the tethered chain (additionally to enone, ketone 
and alcohol). Two different approaches were tested, both of them starting from the MOM-
protected enones 94-97 (Scheme 31). At first, cleavage of the methoxymethyl ether 
groups was performed under acidic conditions gaining the unprotected enones 98-101. 
The subsequent reduction of the oxo group of the enone with sodium borohydride, 
however, afforded not the corresponding allylic alcohols 117-120 but instead a mixture of 
multiple products (Scheme 31). One possible explanation for this observation could be a 
low stability of diarylheptanoids with the allylic alcohol motif. 
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Scheme 31: Attempted synthesis of linear diarylheptanoids with allylic alcohol motif which led to 
compounds with cyclized C7-chain 
 
In the second pathway, the sequence of the steps was switched whereby the reduction of 
the oxo group was carried out at first using the MOM-protected diarylheptanoids 94-97 as 
substrates. This proceeded at 0 °C in the presence of sodium borohydride109 in good to 
excellent yields (70 - 95%). In contrast to their unprotected counterparts 117-120, allylic 
alcohols 121-124 exhibited sufficient stability and could be submitted to the following 
deprotection step (Scheme 31).  
The general procedure used for the MOM-ether cleavage incorporates aqueous HCl 
solution (30 eq. of H+) in methanol.107 It was observed in the deprotection reactions 
towards 98-101 (3.1.5) that the hydrolysis occurred in reasonable reaction rates only at 
elevated temperature. Allylic alcohols 122 and 124, bearing a 4’’-hydroxy substitution on 
the B-ring, reacted under a complete conversion of the starting material to a complex 
mixture of products. This was in accordance with the observations made in the first 
synthetic route towards 117 and 119 and confirmed the assumption of low stability of 
compounds with the 1-en-3-ol moiety (Scheme 31).  
Surprisingly, substrate 121 with the 4’’-hydroxy-3’’-methoxy substitution of the B-ring 
reacted even at r.t. towards a single product (based on TLC analysis) with a higher Rf value 
 Results and discussion  
36 
 
(0.43 vs. 0.09 compared to the starting material, SiO2; n-hexane/EtOAc 3:1) (Scheme 31). 
When the reaction was stopped and worked up at this stage, proton signals of the O-CH2-
O-groups were detected in the 1H-NMR indicating a change in the structure of the 
substrate but no hydrolysis of the MOM-groups. The same reaction, carried out at reflux 
temperature of methanol, resulted into a single product with a Rf value of 0.34 (TLC, SiO2; 
n-hexane/EtOAc 3:1) after 2 h. After aqueous work-up and CC and HPLC purification, 
compound 115 with unpredicted structure, elucidated in chapter 3.2.1, was obtained in 
34% yield (Scheme 31). The MOM-deprotection of the other 4’’-hydroxy-3’’-methoxy 
substituted diarylheptanoid 123 under the same conditions afforded the analogues 
product 116 in 49% yield (Scheme 31). 
3.2.1 Structure elucidation of diarylheptanoids with cyclized C7-chain 
The structure elucidation of compounds 115 and 116 was performed with the aid of mass 
spectrometry and NMR spectroscopy. 
 
Fig. 12: The expected 117 and the actual product 115 of the reduction-deprotection sequence of 
compound 94 
 
Compound 115 showed in HR ESI-MS the [MH]+ ion peak at m/z 341.1745 corresponding 
to the molecular formula C21H25O4. Further ion peaks in LR ESI-MS were identified as 
follows: m/z (%) 341 [MH]+ (100), 340 [M]+· (71) and 363 [MNa]+ (36). These results 
pointed at loss of m/z 18 [H2O] in comparison to expected allylic alcohol 117 (Fig. 12). The 
13C-NMR spectrum exhibited 21 carbon signals with four methylene carbons (δ 29.7, 30.1, 
35.5 and 36.8 ppm), three oxygenated aliphatic carbons (δ 49.1 overlapped with MeOD, 
56.4 and 56.6 ppm) and fourteen olefinic or aromatic carbons (δ 110.3, 115.2, 116.2 117.3, 
120.3, 130.7, 131.5, 131.8, 135.3, 138.4, 144.9, 146.5, 147.0 and 149.1 ppm). This was in 
agreement with expected double methoxylated diarylheptanoid without carbonyl 
functionality.  
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In contrast to expectations for the linear compound 117, the 1H-NMR showed only one 
ABC system at δ 6.96 ppm (d, J = 1.7 Hz, 1H), 6.81 ppm (dd, J = 8.1, 1.8 Hz, 1H) and 6.72 
ppm (d, J = 8.1 Hz, 1H) (Fig. 13). The protons at δ 6.13 ppm (d, J = 15.9 Hz, 1 H) and 6.35 
ppm (dd, J = 15.9, 6.7 Hz, 1H) were assigned to the trans substituted double bond in 
positions 1 and 2, respectively. However, only two more singlets remained in the aromatic 
region with δ 6.66 and 6.69 indicating a tetrasubstituted benzene ring which countered 
the structure of 117 with two ABC systems (Fig. 12). The aliphatic region consisted of two 
signals for the methoxy groups (δ 3.82 and 3.86 ppm), a triplett at δ 3.61 ppm (assigned to 
H-3), and further methylene groups at δ 2.75 (m, 2H), 1.74 - 1.95 (m, 4H) and 1.62 ppm 
(m, 2H). Striking was the difference to the MOM-protected precursor 121 (Scheme 31), 
where the multiplet of the proton in position 3 (geminal to the OH-group) showed a 
chemical shift of 4.20 - 4.37 ppm, hereby being more deshielded than the H-3 in the 
examined spectrum (3.61 ppm). The badly resolved multiplet of the benzylic methylene 
group (H-7, 2.76) (Fig. 13) was in contrast to the signals of typical linear diarylheptanoids, 
where the protons at C-7 usually exhibited a clear triplett. This could be explained by a 
restricted rotation of the system and gave a hint to the presence of additional ring. 
 
Fig. 13: 1H-NMR spectrum of compound 115. (MeOD, 600 MHz, 298 K) 
 
H-7 
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The final assignment of all carbons and protons was performed on the basis of HSQC and 
HMBC measurements, supported by NOESY and is summed up in Table 2. The best 
evidence for the attachment of the third ring was the HMBC correlations between H-5’’ (δ 
6.66 ppm) and C-3 (δ 49.1 ppm), as well as the NOE between H-2 and H-5’’ of the B-ring. 
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Table 2: 1H- and 13C-NMR data for 115. 
(MeOD, 600 MHz for 1H, 150 MHz for 13C, 298 
K, δ in ppm, J in Hz)  
 
 
 
 
Fig. 14: Key HMBC correlations for 115 
 
 
 
Fig. 15: Key NOESY correlations for 115 
  
Position δH δC 
1 6.13 (d, 15.9, 1H) 130.7 
2 6.35 (dd, 15.9, 6.7, 1H) 131.8 
3 3.61 (t, 6.2, 1H) 49.1 
4 1.78, 1.85 (m, m, 2H) 35.5 
5 1.78, 1.93 (m, m, 2H) 30.1 
6 1.62 (m, 2H) 29.7 
7 2.76 (m, 2H) 36.8 
1’  131.5 
2’ 6.96 (d, 1.7, 1H) 110.3 
3’  149.1 
3’-OCH3 3.86 (s, 3H) 56.4 
4’  147.0 
5’ 6.71 (d, 8.1, 1H) 116.2 
6’ 6.81 (dd, 8.1, 1.8, 1H) 120.3 
1’’  135.3 
2’’ 6.69 (s, 1H) 115.2 
3’’  146.5 
3’’-OCH3 3.82 (s, 3H) 56.6 
4’’  144.9 
5’’ 6.66 (s, 1H) 117.3 
6’’  138.4 
C5‘‘ 
H3 
H5‘‘ 
H3 
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The same elucidation approach was performed for compound 116 (Fig. 16). The ESI-MS 
showed an ion peak m/z (%) 311 [MH]+ (98) in the positive mode and m/z (%) 309 [M – 
H]- (15) in the negative mode. This result was confirmed by EI-MS (70 eV) wherein only 
the mass peak with m/z (%) 310 [M]+·(100) but not with m/z 326, expected for 119 
(Scheme 31), was detected.  The 13C-NMR revealed twenty carbons with one at δ 49.0 
interfering with the solvent peak of MeOD (confirmed by HSQC). In contrast to the MOM-
protected precursor 122, the signal at δ 73.0 ppm, belonging to the secondary allylic 
alcohol, vanished while a new peak at δ 49.0 ppm was observed (Fig. 16). 
 
Fig. 16: The expected 119 and the actual product 116 of reduction-deprotection sequence of 
compound 96 
 
Similar to above described compound 115, no 1,3,4-trisubstituted benzene ring was 
detected in the 1H-NMR. Instead, a tetrasubstituted B-ring with δ 6.69 (s, 1H) and 6.65 
ppm (s, 1H) and AA’BB’ 1,4-disubstituted A-ring (δ 7.21 (d, J = 8.6 Hz, 2H) and 6.71 ppm 
(d, J = 8.6 Hz, 2H)) were observed. The signal of proton H-3 attached to the allylic carbon, 
with a chemical shift of δ 4.24 ppm in the MOM-protected substrate 123, moved upfield to 
3.60 ppm in case of the deprotected product 116 (Fig. 16). This was an evidence for a new 
bond between position 6’’ of the B-ring and the position 3 of the aliphatic chain. The final 
proof provided the homonuclear (NOESY) and heteronuclear (HMBC) 2D NMR analysis, 
revealing long range correlations between C-6’’ and H-3 (Fig. 17) and NOE between H-5’’ 
and H-2 (Fig. 18). The assignment of all proton and carbon signals was supported by HSQC 
and COSY and is summed up in Table 3. 
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Table 3: 1H- and 13C-NMR data for 116. 
(MeOD, 600 MHz for 1H, 150 MHz for 13C, 298 
K, δ in ppm, J in Hz) 
 
 
Fig. 17: Key HMBC correlations for 116 
 
 
 
Fig. 18: Key NOESY correlation for 116 
 
   
Position δH δC 
1 6.13 (d, 15.9, 1H) 130.3 
2 6.33 (dd, 6.7, 15.9, 1H)  131.5 
3 3.60 (t, 6.0, 1H) 49.0 
4 1.78, 1.85 (m, m, 2H) 35.5 
5 1.78, 1.92 (m, m, 2H) 30.7 
6 1.61 (m, 2H) 29.7 
7 2.71, 2.78 (m, m, 2H) 36.8 
1’  130.9 
2’ 7.21 (d, 8.6, 1H) 128.2 
3’ 6.71 (d, 8.6, 1H) 116.3 
4’  157.7 
5’ 6.71 (d, 8.6, 1H) 116.3 
6’ 7.21 (d, 8.6, 1H) 128.2 
1’’  135.3 
2’’ 6.69 (s, 1H) 115.2 
3’’  146.6 
3’’-OCH3 3.82 (s, 3H) 56.6 
4’’  144.9 
5’’ 6.65 (s, 1H) 117.2 
6’’  138.5 
H-3 
C-1‘‘ 
H-2 
H-5‘‘ 
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3.2.2 Proposed mechanism for the formation of diarylheptanoids with 
cyclized C7-chain 
The unexpected outcome of the reactions described in 3.2 can be rationalized in 
consideration of the reaction conditions of the MOM-deprotection step and the nature of 
the substrates. The MOM-ether cleavage of compounds 121 and 123 takes place in 
presence of 30 eq. HCl. This leads to a protonation of the OH-group in position 3, making it 
a better leaving group. The carbocation in the allylic position resulting from the H2O-
cleavage is well stabilized in both resonance structures of 129 and 130. Each of them can 
undergo an electrophilic aromatic substitution on one of the rings. Position 6’’ of the B-
ring with the para methoxy group is the most activated one, thus allowing a 7-exo-trig 
cyclization (Scheme 32). Alternatively, a 5-exo-trig cyclization at the activated position 6’ 
of the A-ring in 115 can occur, nevertheless, no such indene product 131 could be 
identified probably due to a higher ring strain of such a molecule (Scheme 32). This type of 
reactions, involving acid-promoted carbocation formation, is also known as 
cyclodehydration.122 
 
Scheme 32: Proposed cyclization mechanism for compounds 115 and 116 
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3.3 Synthesis of cyclic diarylheptanoids 
The formation of cyclophane natural products represents a challenge in most cases, 
especially in small rigid 13-membred rings of biphenyl type cyclic diarylheptanoids.123 
Only a few methods for the synthesis of the latter have been described up to date in the 
literature27, 123 prompting for a new convenient synthetic strategy. 
3.3.1 Retrosynthetic approach towards cyclic diarylheptanoids 
In general, there are two possibilities to assess the targeted macrocycles. On one side, a 
precursor with the biphenyl structure within the aliphatic chain can be introduced and the 
cyclization takes place via the connection of the alkyl residues. According to literature, this 
strategy worked well in a few specific diphenyl-ether type cases,36 but there is no 
literature evidence for a synthesis of biphenyl diarylheptanoids (1.4).1 Therefore, it has 
been decided to prepare linear diarylheptanoids with suitable substituents which would 
allow for the macrocyclization via the biaryl-bond formation (Scheme 33). 
 
Scheme 33: General retrosynthetic analysis for the formation of meta,meta-bridged biphenyl 
macrocycles 
The cyclization approach (Scheme 34) was inspired by a pioneer publication from 
Semmelhack et al., who used a Ni(0) catalyzed Ullmann reaction of iodinated precursors 
for the first synthesis of alnusone (7) (Scheme 16).42 This strategy was then further 
modified by Zhu et al., replacing the zerovalent nickel catalyzed Ullmann coupling with a 
palladium-catalyzed domino sequence of Miyaura arylborylation and Suzuki reaction, 
which was used for a synthesis of cyclic tripeptide containing such a biphenyl moiety.45 
Finally in 2013, Ogura and Usuki applied Zhu’s strategy for the first total synthesis of 
acerogenins E and K (Scheme 19).29 
 
Scheme 34: Cyclization strategy for the synthesis of cyclic diarylheptanoids 
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3.3.2 Attempted synthesis via brominated precursors 
The Suzuki reaction, a palladium catalyzed coupling reaction between boronic acids and 
halides established in 1979 by Akira Suzuki,124 emerged to a method of the first choice for 
biaryl formations.125 Although there are a few examples for the use of aryl chlorides,126 the 
most applications incorporate aryl bromides and iodides due to their better reactivity in 
the oxidative addition step.125a Hence, the initial idea was to prepare brominated and 
borylated segments and assemble them to linear diarylheptanoids functionalized for the 
intramolecular Suzuki cross-coupling (Scheme 35). 
 
Scheme 35: Planned synthesis of functionalized precursors for the intramolecular cyclization 
 
In accordance to the strategy applied for the synthesis of linear diarylheptanoids, the 
reaction sequence started from brominated vanillin 132 and brominated 4-
hydroxybenzaldehyde 133. Whereas the first one was obtained in excellent yield out of 
vanillin (35) via bromination in presence of Br2/HOAc,127 the synthesis of the latter 
suffered from poor selectivity and mostly the dibrominated side product 134 was isolated 
(Scheme 36). Therefore, commercially available 3-bromo-4-hydroxybenzaldehyde 133 
was used in further reactions. 
 
Scheme 36: Bromination of vanillin (35) and 4-hydroxybenzaldehyde (78) 
After the protection of the phenolic OH-group as methoxymethylether,102 the next step on 
the planned synthetic route was the elongation of the aliphatic chain. Claisen-Schmidt 
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condensation and Wittig olefination were examined as methods for building of C6-C3 
aldehydes. Because of low yields (15%) and poor selectivity by the Claisen-Schmidt 
condensation between 5-bromovanillin 135 and acetaldehyde,33 olefination with 2-
(tristriphenylphosphoranylidene)-acetaldehyde103 was preferred and gave the desired 
products 137 and 138 in 47 and 48% yield, respectively (Scheme 37). 
 
Scheme 37: Synthesis of brominated C6-C3 aldehydes 137 and 138 
 
With the C6-C3 aldehydes 137 and 138 in hands, further extension of the aliphatic chain 
towards C6-C6 ketones 139 and 140 was aimed. Claisen-Schmidt condensation of 
substrate 137 with acetone catalyzed with NaOH101 gave the desired product 139 in 47% 
yield. A better yield (70%) was achieved with Wittig reaction, using 1-
(triphenylphosphoranylidene)-2-propanone as olefinating agent.103 Therefore, this 
strategy was used for the brominated cinnamaldehyde 138 affording ketone 140 in 59% 
yield (Scheme 38).  
 
Scheme 38: Formation of the brominated C6-C6 ketones 139 and 140 
 
The brominated C6-C6 ketones 139 and 140 were subsequently submitted to a 
hydrogenation reaction in order to reduce the two double bonds. Several methods had to 
be screened before reasonable yields were achieved. Hydrogenation catalyzed with Pd/C 
was tested, revealing a crucial role of the solvent and the catalyst type (Table 4). First 
experiments performed in CHCl3 at 1 bar hydrogen pressure with 10% (w/w) Pd/C41 
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resulted in moderate yield of 50% for 141 and 56% for 142. An improvement of the yields 
was targeted and so the reaction was repeated in EtOAc at elevated hydrogen pressure (5 
bar). This resulted, however, to a cleavage of the MOM-protecting group, as did the 
reaction in MeOH even at atmospheric pressure. Finally, the use of Ph2S (0.05 eq.) as a 
mild catalyst poison106 in CHCl3 allowed for the fine tuning of the catalyst activity, so that 
the saturated ketone 142 was obtained in excellent yield (91%) (Table 4).    
Table 4: Hydrogenation of brominated ketones 139 and 140 
 
Substrate Catalyst Additive Solvent H2 pressure 
[bar] 
Time 
[h ] 
Yield [%] 
/comment 
139 10% Pd/C - CHCl3 1 24 50 
140 10% Pd/C - CHCl3 1 21 56 
139 10% Pd/C - EtOAc 5 17 MOM-deprotection 
139 10% Pd/C - MeOH 1 1.5 MOM-deprotection 
140 10% Pd/C Ph2S 0.05 eq. CHCl3 1 3 91 
 
Parallel to the synthesis of brominated ketones 141 and 142, an effort was made towards 
a synthesis of benzaldehydes with arylboronic acid moiety as the second part of the final 
diarylheptanoids. The aromatic aldehyde 135 with bromide in position 5 was used as 
substrates and numerous borylation methods were screened. The first strategy was to 
perform a lithium-bromine exchange, followed by a reaction with suitable boronic acid 
ester. For this reaction, the aldehyde had to be protected as an acetal to avoid side 
reactions of the lithiating agent nBuLi with the carbonyl functionality. The aldehyde was 
acetalized with ethylene glycol in presence of triethyl orthoformate and 
tetrabutylammonium tribromide128 in 18% yield to give 143 and the MOM-deprotected 
acetal 144 as the major side product (47% yield). Compound 143 was then submitted to 
several borylation reactions with nBuLi and trimethyl-128 or triisopropylborate, which all 
failed to afford the desired product (Scheme 39). 
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Scheme 39: Protection of aldehyde 135 and attempted arylborylation of compound 143 
 
Instead of the unsuccessful lithiation/transmetalation sequence with nBuLi and the 
trialkyl borates (Scheme 39), an alternative approach using a palladium-catalyzed Miyaura 
aryl-borylation129 was applied. This method tolerates various functionalities such as 
carbonyls129 and thus allowed to avoid the acetalization-deacetalization steps. 
Furthermore, the use of bis(pinacolato)diboron as borylating agent gives directly the 
arylboronic acid pinacolates which are common substrates for Suzuki reactions.130 
Different reaction conditions, like the use of a proper catalyst, solvent and base, had to be 
tried to reach satisfactory yields. In most cases, debromination occurred as the major side 
reaction. All the methods required elevated temperatures whereby the best result was 
achieved when microwave irradiation (140 °C) was applied. In the end, borylated 
compound 147 was obtained in 26% and compound 148 in 44% yield (Table 5). 
  
 Results and discussion  
48 
 
Table 5: Miyaura arylborylation of aldehydes 135 and 136  
 
Substrate Catalyst (mol. eq.) Reaction conditions Lit. Yield 
[%] 
135 PdCl2(dppf) (0.05), Pd(OAc)2 (0.12) B2(pin)2, KOAc, dioxane, 4 h, 
100 °C131 
26 
135 PdCl2(dppf) (0.05), Pd(OAc)2 (0.05) B2(pin)2, KOAc, dioxane, 5 h, 
100 °C131 
0 
135 PdCl2(PPh3)2 (0.05) B2(pin)2, NaOAc, PEG400, 1.5 h, 
90 °C132 
0 
136 PdCl2(dppf) (0.05) B2(pin)2, KOAc, dioxane, 40 min, 
MWa 140 °C102 
44 
aMW, microwave 
 
With the both halfs of the desired precursors in hand, a Claisen-Schmidt condensation of 
the borylated benzaldehydes 147 or 148 and brominated C6-C6 ketones 141 or 142 was 
attempted. However, this reaction gave multiple side products but no linear 
diarylheptanoid under basic conditions (Scheme 40). 
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Scheme 40: Attempted Claisen-Schmidt condensation of the borylated aldehydes 147, 148  and 
brominated ketones 141, 142 
The failure of the aldol condensation towards brominated and borylated linear 
diarylheptanoids prompted a need for a new synthetic strategy for the macrocyclization 
precursors. Since the reaction conditions used in the arylborylation are identical with the 
conditions of Suzuki-Miyaura reaction (Pd catalyst, base, elevated temperature), a new 
idea was to combine the borylating and the coupling steps in one domino reaction, as Zhu 
et al45 did in the synthesis of peptide macrocycles. Dibrominated diarylheptanoids were 
supposed to act as a substrate and so the brominated ketones 141 and 142 were reacted 
with brominated aldehydes 135 and 136 in a Claisen-Schmidt condensation under basic 
conditions101 to afford the brominated diarylheptanoids 153 in 43% and 154 in 17% yield 
(Scheme 41).  
 
Scheme 41: Brominated linear diarylheptanoids 153 and 154 
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The unsaturated aliphatic chain was expected to be too rigid for a successful cyclization. 
Therefore, a reduction of the double bond was performed using Pd/C catalyzed 
hydrogenation in presence of Ph2S. Even though the sulfide was used to diminish the 
catalytic activity of the Pd/C, only low yield (10%) was achieved for 155 whilst the MOM-
deprotected compound 156 could be isolated (38% yield) as the major side product. The 
cleaved MOM-groups were not reinstalled, instead, a methylation of 156 was performed 
using Me2SO4/K2CO3116 to gain tetramethoxylated dibromide 157 in 88% yield (Scheme 
42). 
 
Scheme 42: Hydrogenation of compound 153 afforded saturated diarylheptanoid 155 and MOM-
deprotected substance 156, which was immediately methylated towards 157. 
 
After all the optimizations, only a small amount of dibrominated substrate 155 was 
obtained, so that the tetramethoxylated substance 157 was submitted for the 
arylborylation/biaryl formation sequence. This was carried out in presence of B2(pin)2, 
PdCl2(dppf) and KOAc as base, using 1,4-dioxane as solvent.45 Conventional heating, 
gradually increasing from r.t. to 80 °C, as well as microwave irradiation (120 °C) were 
tested but in both cases no product 155 could be isolated. A mass spectrometric 
investigation revealed molecular ion peaks of a brominated/borylated linear 
diarylheptanoid (156, m/z 608 [MNH4]+), borylated/debrominated linear diarylheptanoid 
(157, m/z 530 [MNH4]+) and mono-debrominated linear diarylheptanoid (158, m/z 482 
[MNH4]+) (Scheme 43). 
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Scheme 43: Attempted cyclization of dibrominated linear compound 157 yielded only side 
products 159-161 (proposed structures based on LC-MS) 
The identified side products indicate that the Miyaura borylation takes place, but it 
competes with a debromination reaction. The reactivity of the aryl-bromides is apparently 
not high enough to complete the ring closure and consequently the faster cleavage of the 
carbon-bromine bond occurs. While working on this project, Ogura and Usuki published 
their synthesis of acerogenin E (3) and K (16) where the same issues with brominated 
precursors are described.29 Therefore, attention was placed towards similar strategy using 
aryl-iodides instead of the bromides. 
3.3.3 Synthesis of cyclic diarylheptanoids from linear aryl-iodides 
Since the cyclization of the brominated linear precursors failed, the synthesis of linear 
aryl-iodide analogues was envisioned. Plenty of methods for iodination of aromatic 
compounds are known in the literature133 and the number is growing since aryl-iodides 
are useful substrates for metal-catalyzed C-C couplings.134 Some of the methods require 
harsh acidic conditions, e.g. I2 in H2SO4/HNO3,133 but there are also mild methods 
incorporating silver(I) salts.133 
Inspired by Semmelhacks synthesis of alnusone (7) (Scheme 16) and by the synthesis of 
acerogenin E (3) (Scheme 19), the iodination of already synthesized linear 
diarylheptanoids was investigated. The most attractive strategy was to directly iodinate 
the MOM-protected linear diarylheptanoids, which would lead to the actual substrates for 
the cyclization. Electrophilic aromatic substitution with I2/AgOTFA system according to 
Ogura and Usuki was applied (Scheme 44).29  
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Scheme 44: Hydrogenation and iodination of 4',4''-disubstituted linear diayrlheptanoid 97 
 
Unfortunately, this method worked only for 4’,4’’-di(methoxymethoxy) substituted 
compound 162 (Scheme 44) while the attempted iodination of compound 164, bearing 
additional methoxy groups in positions 3 and 3’, yielded substance 165 with iodide groups 
in positions 6’ and 6’’ (Scheme 45). This can be explained by a steric hindrance due to the 
methoxymethoxy substituent in position 4, directing the electrophilic attack in position 6, 
i.e. para to the 3-OMe group. 
 
Scheme 45: Iodination of 3-methoxy-4-methoxymethoxy-substituted substrates 
 
To overcome the selectivity problem during the iodination of 164, the MOM-groups were 
cleaved and the 4’,4’’-dihydroxy-3’,3’’-dimethoxy diarylheptanoid 102 was used as 
substrate for iodination experiments under various conditions. However, methods 
incorporating iodine with silver(I) salts (Ag2SO4,135 AgOTFA29) or N-iodosuccinimide as 
“I+”-donor136 as well as KI/I2 protocols, known from the iodination of vanillin137 or 
electron-poor phenols,138 failed to afford any iodinated product 166 (Table 6). 
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Table 6: Iodination of compound 102  
 
Reaction conditionsa Yield [%] 
I2 (4.0 eq.) AgOTFA, CHCl3 0 
I2 (2.5 eq.), Ag2SO4, EtOH 0 
NIS (2.0 eq.), TFA (solv.) 24 (mono-iodo)b 
NIS (2.2 eq.), TFA (cat.), MeCN 0 
NIS (2.0 eq.), p-TsOH (2.0 eq.), MeCN 0 
I2 (2.1 eq.), KI, NaOH, MeOH/H2O 0 
asolv., solvent;  b calculated yield, detected by ESI-MS 
 
The fact that only 4’,4’’-dihydroxy substituted linear diarylheptanoids could be iodinated, 
whereas compounds with 4-hydroxy-3-methoxy motif could not, prompted a need for a 
new strategy for the formation of the latter. 5-Iodovanillin (174) was selected as a 
common starting material for substances with 4-hydroxy-3-methoxy substitution, since 
the iodination of vanillin was known. This provided a quick access to the iodinated future 
B-ring via compound 170 which, combined with easily feasible iodinated ketone 172, 
allowed for the preparation of the linear precursor 167. On the other hand, compounds 
with the iodinated subsequent A-ring had to be prepared in 9 steps starting from 5-
iodovanillin 174. General approaches towards all the iodinated precursors of cyclic 
diarylheptanoids are summed up in the Scheme 46. 
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Scheme 46: General synthetic strategies towards iodinated linear precursors of cyclic 
diarylheptanoids 
  
 Results and discussion  
55 
 
Whereas the iodination of 4-hydroxy-3-methoxy substituted diarylheptanoids was an 
insurmountable challenge, the iodination of vanillin is well established.137, 139 However, the 
first iodination experiments towards 5-iodovanillin 174 using iodine in presence of 
Ag2SO4 according to Nair et al.139 did not lead to any of the desired product. A successful 
method was the iodination with I2/KI in aqueous solution buffered with H3BO3/NaOH to 
pH ≥ 8.5,137 affording 174 in 87% yield (Scheme 47). The 4-hydroxy group of this 
compound was subsequently protected as a MOM-ether 170 using MOM chloride and 
DIPEA102 as a base in a clean reaction with 90% yield (Scheme 47). 
 
Scheme 47: Iodination and MOM-protection of vanillin (35) 
 
The MOM-protected 5-iodovanillin 170 represented the B-ring of iodinated linear 
diarylheptanoids 167 and 169. Whilst the formation of the A-ring of 169 required whole 
new reaction sequence, the future A-ring moiety 172 of the open chained precursor 167 
was readily available by iodination of C6-C6 ketone 93 (prepared in 3.1.3). This was 
performed under the same conditions as the iodination of linear diarylheptanoid 162, 
namely with I2 and AgOTFA in chloroform (Scheme 48).29  
 
Scheme 48: Iodination of ketone 93 to form the A-ring precursor 172 for acyclic diarylheptanoid 
167 
 
The iodinated C6-C6 ketone 172 and the aldehyde 170 were then used as starting 
materials to assemble the iodinated linear diarylheptanoid 175 via Claisen-Schmidt 
condensation in presence of NaOH.101 This afforded the objected compound with an enone 
motif in 23% yield (Scheme 49). The product was accompanied by multiple side products 
with yellow fluorescence on TLC, which could not be exactly identified. 
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Scheme 49: Claisen-Schmidt condensation towards iodinated diarylheptanoid 175 
 
The double bond of enone 175 had to be hydrogenated to make the linear chain more 
flexible for the envisioned cyclization (Table 7). However, the standard hydrogenation 
protocol using the 10% Pd/C catalyst with Ph2S as a catalyst poison, readily applied in 
hydrogenation of linear diarylheptanoids 98-101 in 3.1.5, yielded no saturated product 
167. No reaction was observed even in absence of Ph2S, at elevated pressure (10 bar) or 
with methanol as solvent. Other hydrogenation systems were tested, for instance transfer 
hydrogenation methods with cyclohexene,140 Hantzsch ester (Fig. 19)141 or ammonium 
formate as hydrogen-donors, homogenous catalysis with Wilkinson’s catalyst 
(Rh(PPh3)Cl), hydrogenation with in situ formed indium hydride142 or a cationic reduction 
with hydrosilane,143 but none of the methods resulted in the saturated compound 167 
(Table 7). The literature generally lacks examples for hydrogenations of iodinated 
substrates. Therefore, a promising method seemed to be the one by Xing et al. where a 
double bond of an ortho-iodinated cinnamic ketone was reduced by tellurium and 
NaBH4.144 Such a sodium hydrogen telluride promoted reduction, originally developed by 
Derek Barton,145 failed when applied on the substrate 175. The final breakthrough was 
achieved by homogenous iridium(I)-catalyzed hydrogenation, inspired by a publication of 
Bennie et al.146 The use of Crabtree’s catalyst, a highly active iridium(I) complex with 1,5-
cyclooctadiene, tris-cyclohexylphosphine and pyridine, gave the desired saturated product 
167 in excellent yield (98%) (Table 7). 
  
 Results and discussion  
57 
 
Table 7: Hydrogenation of iodinated diarylheptanoid 175 
 
Reaction conditions Resulta 
H2 (1 bar), Pd/C, Ph2S, CHCl3, r.t., 28 h106 n.r. 
H2 (1 bar), Pd/C, CHCl3, r.t., 4 days n.r. 
H2 (10 bar), Pd/C, CHCl3, r.t., 3 h partial deiodination 
H2 (1 bar), Pd/C, MeOH, reflux, 16 h MOM-deprotection 
Pd(OH)2, cyclohexene, r.t., 24 h140 n.r. 
Pd/C, Hantzsch ester (Fig. 19), EtOH, r.t. – reflux, 24 h141 n.r. 
Pd/C, NH4HCO2, 100 °C, 2 h complete deiodination 
InCl3, NaBH4, MeCN, r.t., 2.5 h142  MOM-deprotection 
H2 (1 bar), Rh(PPh3)3Cl, CHCl3, 60 °C, 24 h n.r. 
TFA, Et3SiH, CHCl3, r.t., 19 h143 ketone reduction 
NaBH4, Te, EtOH, reflux, 3 h144-145 n.r. 
H2 (1 bar), Crabtree’s catalyst (Fig. 19), CH2Cl2, 2 h146 167 (98% yield) 
an.r., no reaction 
 
Fig. 19: Structures of Hantzsch ester and Crabtree’s catalyst applied in the hydrogenation of 175 
 
Whereas the iodinated linear diarylheptanoids with a 4-hydroxy substituted A-ring 163 
and 167 were obtained by established methods (Scheme 46), the remaining two 
compounds 168 and 169 required a new synthetic strategy for the formation of a 4-
hydroxy-5-iodo-3-methoxy substituted A-ring. Hence, the iodinated C6-C6 ketone 173 had 
to be build up from MOM-protected 5-iodovanillin 170 (Scheme 46). The first step 
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towards this ketone was the elongation of its alkyl chain. Instead of using low yielding 
aldol condensation or Wittig olefination, as described in chapter 3.3.2, a Knoevenagel-
Doebner condensation was incorporated (Scheme 50). This condensation reaction of 
aldehyde 170 with malonic acid, catalyzed with piperidine, was carried out in pyridine 
and resulted in the desired C6-C3 acid 176. The isolation of the product was rather difficult 
due to its high polarity and sensibility of the MOM-group towards acidification, hence only 
a moderate yield of 40% was achieved. 
 
Scheme 50: Knoevenagel-Doebner condensation towards C6-C3 acid 176 
 
To enable further extension of the aliphatic rest, the acid moiety had to be converted into 
an aldehyde (Scheme 51). This was achieved by a sequence of esterification to form 177, 
reduction to the alcohol 178 and oxidation to the aldehyde 179. The esterification to the 
ethyl ester of carboxylic acid 176 could not be performed under standard EtOH/H2SO4 
conditions due to the acid-labile MOM-protecting group. A valuable alternative offered a 
Steglich esterification, comprising activation by a carbodiimide and DMAP to form the 
active ester and subsequent substitution reaction with EtOH.147 This transformation 
proceeded cleanly without any undesired side products in 83% yield to get the ester 177. 
The following reduction was performed by diisobutylaluminium hydride (DIBAl-H)147 in 
practically quantitative yield (99% of 178). Finally, the allylic alcohol 178 was oxidized 
with an excess of MnO2 (18 mol eq.) to form the iodinated C6-C3 aldehyde 179 in 89% 
yield.105 
 
Scheme 51: The transformation of carboxylic acid 176 into aldehyde 179 in three steps 
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The reaction sequence continued in analogy to the synthesis described in 3.1.3 with the 
preparation of iodinated C6-C6 ketone 180 (Scheme 52). This was achieved by a Claisen-
Schmidt condensation with acetone in presence of sodium hydroxide.101 The unsaturated 
enone 180 was obtained in 54% yield and was subsequently submitted to hydrogenation. 
The reaction was accomplished using Crabtree’s catalyst (10 mol%) and 1 bar of hydrogen 
gas.146 The reaction rate was much lower compared to the reduction of 175, but a 
complete conversion was achieved after 16 days. 
 
Scheme 52: Transformation of aldehyde 179 to ketone 180, followed by a hydrogenation towards 
iodinated C6-C6 ketone 173 
 
The ketone 173, synthesized in eight steps from vanillin (35), represents the A-ring part 
of desired cyclic diarylheptanoids. The only missing part was the iodoaldehyde 171 
(Scheme 46), which was prepared in two steps, starting with the iodination of 4-
hydroxybenzaldehyde 78 with the aid of iodine monochloride and acetic acid,148 followed 
by a MOM-protection with MOM chloride and Hunig’s base (Scheme 53).102 
 
Scheme 53: Iodinated aldehyde 171 as the future B-ring of 168 
 
With the ketone 173 and the aldehydes 170 and 171 in hands, the remaining two linear 
precursors 168 and 169 could be formed (Scheme 54). The Claisen-Schmidt condensation, 
carried out in presence of sodium hydroxide,101 afforded enone 182 in 23% yield and 
enone 183 in 31% yield. These compounds were further hydrogenated under the 
iridium(I) homogenous catalysis (Crabtree’s catalyst)146 in good to excellent yields (62% 
and 82%, respectively). 
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Scheme 54: Synthesis of iodinated linear diarylheptanoids 168 and 169 
 
After all the iodinated linear diarylheptanoids 163, 167, 168 and 169 were prepared, the 
cyclization towards biphenyl type cyclic diarylheptanoids could be performed (Scheme 
55). The conditions were applied in accordance with the method of Ogura and Usaki, using 
pinacolato diboron (1.2 eq.) as borylating agent, PdCl2(dppf) as catalyst (0.1 eq.) and 
potassium acetate as base (10 eq.).29 The reaction took place in degassed DMSO under 
inert atmosphere (N2) at 100 °C. Three of four aimed cyclic diarylheptanoids were 
obtained, namely 184 in 27%, 185 in 16% and 186 in 8% yield. The last compound 187 
could be detected by LC-MS (ESI-MS m/z 467 [MNa]+) but due to a small batch size (64.0 
mg, 91.6 µmol of starting material 169) and generally low yields of the cyclization 
reactions, not enough product for further characterization and transformation could be 
isolated (Scheme 55).  
 
Scheme 55: Formation of cyclic diarylheptanoids 184-187; an.p., no product 
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The protecting groups of compounds 184-187 were subsequently cleaved under acidic 
conditions providing three cyclic diarylheptanoids, among them two natural products 
(acerogenin E (3) and  myricananin C (18)) and one new compound 188 (Scheme 56).  
 
Scheme 56: MOM group cleavage to obtain cyclic diarylheptanoids 188, 18 (myricananin C) and 3 
(acerogenin E) 
 
The last conversion was the reduction of the oxo group to form alcohol analogues of 3, 18 
and 188 (Scheme 57). This reaction was performed with acerogenin E and compound 
188, since the amount of myricananain C was only sufficient for its biological testing. The 
reduction was performed in analogy to the linear compounds with sodium borohydride. 
Interestingly, much more hydride equivalents were needed for the conversion of the cyclic 
compounds in comparison to their open chained counterparts. Using this method, 
acerogenin K (16) and alcohol 189 were obtained in 41% and 73% yield, respectively 
(Scheme 57). 
 
Scheme 57: Reduction of the cyclic ketones to alcohols 16 and 189 
 
All in all, five biphenyl type cyclic diarylheptanoids were synthetically prepared. Among 
these compounds, 3 and 16 are known natural products with published synthesis, 
myricananin C (18) is a natural product prepared for the first time and so were the two 
novel non-natural cyclic diarylheptanoids 182 and 183. 
3.3.3.1 Structure elucidation of cyclic diarylheptanoids 
The precise assignment of all carbons and protons of the final products was performed 
with the help of 1D (1H, 13C) and 2D (HSQC, HMBC, COSY, NOESY) NMR methods and is 
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summed up bellow. The difference between aliphatic signals of compounds with oxo-
group in position 11 (acerogenin E (3), 188, myricananin C (18)) and the derivatives with 
hydroxyl group at carbon 11 is worth mentioning. The first three compounds exhibit 
clearly resolved signals in the aliphatic region with chemically equivalent geminal protons 
whereas the second group of compounds shows multiplets with partially high geminal 
couplings for the protons of the connecting chain. These observations are in accordance to 
spectra presented in the literature and might be explained by the differences in the ring 
strain and rotation barriers. The strain of the compounds bearing a sp2 hybridized oxo-
group in the tethered chain is lower since the angle of such bond is 120° and thus the ring 
is less rigid and enables a movement of the geminal protons. On the other hand, due to the 
presence of sp3 hybridized carbon 11 with angle of approximately 109° the ring strain and 
rotation barrier are higher for acerogenin K and compound 189 and therefore the geminal 
protons of the latter appear with inequivalent chemical shifts.   
Acerogenin E (3) and the cyclic ketone 188 were crystallized from EtOH and crystals were 
submitted to X-ray analysis. The resulting structures revealed that both compounds are 
present in the crystal lattice as a mixture of two atropoisomers (Fig. 20, Fig. 21). Torsion 
angels of the biaryl units of 3 and 188 were 31.78° and 36.58°, respectively. 
 
Fig. 20: X-ray structure of acerogenin E (3) showing the two atropoisomers; ellipsoids are shown at 
the 50% probability level (Diamond 3.2 software) 
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Fig. 21: X-ray structure of diarylheptanoid 188 showing the two atropoisomers; ellipsoids are 
shown at the 50% probability level (Diamond 3.2 software) 
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Table 8: NMR spectral data of acerogenin E 
(3) (acetone-d6, 1H 400 MHz, 13C 101 MHz, 
298 K, δ in ppm, J in Hz) 
 
 
 
 
 
 
 
Table 9: NMR spectral data of compound 
188 (acetone-d6, 1H 600 MHz, 13C 151 MHz, 
298 K, δ in ppm, J in Hz) 
 
 
Position δH δC 
1, 2  126.8, 127.2 
3, 17  152.1, 152.2 
4, 16 6.86 (m, 2H) 116.8, 117.0 
5, 15 7.05 (m, 2H) 129.4, 130.4 
6  132.5 
7 2.75 (m, 2H) 32.0 
8 1.94 (m, 2H) 26.5 
9 1.76 (m, 2H) 22.9 
10 2.75 (m, 2H) 45.0 
11  212.7 
12 2.87 (m, 2H) 42.5 
13 2.96 (m, 2H) 28.4 
14  133.4 
18 6.96 (d, 1.9, 1H) 134.5 
19 6.76 (d, 1.8, 1H) 134.5 
Position δH δC 
1  125.9 
2  125.6 
3   152.2 
4 6.80 (d, 8.2) 116.7 
5 7.02 (dd, 2.4, 8.2) 129.6 
6  131.2 
7  2.74 (m, 2H) 31.1 
8 1.94 (m, 2H) 25.7 
9 
1.75 (dt, 7.2, 
14.4, 2H) 
22.0 
10 2.74 (m, 2H) 44.2 
11  211.6 
12 2.87 (m, 2H) 41.5 
13 2.97 (m, 2H) 28.0 
14  132.3 
15 6.84 (d, 2.0) 110.7 
16  147.7 
16-OMe 3.89 (s, 3H) 55.8 
17  140.2 
18 6.97 (d, 1.9) 133.2 
19 6.36 (d, 1.9) 125.4 
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Table 10: NMR spectral data of myricananin 
C (18) (acetone-d6, 1H 600 MHz, 13C 151 MHz, 
298 K, δ in ppm, J in Hz) 
 
 
 
Table 11: NMR spectral data of acerogenin K 
(16) (acetone-d6, 1H 600 MHz, 13C 151 MHz, 
298 K, δ in ppm, J in Hz). aSignals assigned 
according to published data.54 
 
 
 
 
Position δH δC 
1  126.9 
2  126.3 
3   141.3 
4  148.8 
4-OMe 3.85 (s, 3H) 56.7 
5 6.79 (m, 1H) 112.1 
6  132.3 
7 2.74 (m, 2H)  32.7 
8 1.91 (m, 2H) 26.4 
9 1.78 (m, 2H) 22.7 
10 2.74 (m, 2H) 45.3 
11  212.7 
12 2.86 (m, 2H) 42.6 
13 2.95 (m, 2H) 28.6 
14  132.9 
15 
7.03 (dd, 2.2, 8.2, 
1H) 
129.5 
16 6.79 (m, 1H) 117.4 
17  153.0 
18 6.54 (br s, 1H) 126.1 
19 6.77 (m, 1H) 134.0 
Position δH δC 
1a  127.1 
2a  126.9 
3, 17  152.17, 
152.18 
4, 16 6.86 (2 × d, 8.1, 2H) 116.95, 
116.97 
5, 15 7.04 (2 × dd, 2.2, 8.2, 
2H) 
130.16, 
130.26 
6a  131.9 
7 2.49, 2.92 (m, m, 2H) 30.6 
8 1.84, 2.01 (m, m, 2H) 27.4 
9 1.46, 1.66 (m, m, 2H) 23.8 
10 1.58, 1.84 (m, m, 2H) 40.6 
11 4.04 (t, 9.7, 1H) 68.4 
12 1.66, 2.27 (m, m, 2H) 35.6 
13 2.83, 2.95 (m, m, 2H) 27.4 
14a  132.3 
18 7.24 (br s, 1H) 135.0 
19 7.21 (br s, 1H) 134.6 
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Table 12: NMR spectral data of compound 
189 (CDCl3, 1H 600 MHz, 13C 151 MHz, 298 K, 
δ in ppm, J in Hz) 
 
 
 
 
 
 
 
 
 
Position δH δC 
1  124.5 
2  124.8 
3  7.12 (s, OH) 151.6 
4 6.90 (d, 8.2, 1H) 117.0 
5 7.06 (dd, 2.3, 8.2, 1H) 130.0 
6  130.9 
7 2.53, 2.96 (m, m, 2H)  30.0 
8 1.89, 2.01 (m, m, 2H) 26.7 
9 1.51, 1.67 (m, m, 2H) 22.7 
10 1.55, 1.93 (m, m, 2H) 39.7 
11 4.17 (t, 9.6, 1H) 69.0 
12 1.68, 2.31 (m, m, 2H) 34.9 
13 2.91 (m, 2H) 27.4 
14  131.4 
15 6.72 (d, 1.9, 1H) 110.2 
16  146.7 
16-OMe 3.94 (s, 3H) 56.3 
17 6.31 (s, OH) 139.1 
18 7.18 (br s, 1H) 133.4 
19 6.85 (br s, 1H) 126.4 
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3.4 Biological properties of synthesized diarylheptanoids - 
cytotoxicity 
The assessment of the biological properties of the diarylheptanoids was performed with 
the aid of cell based cytotoxicity assays. By this means, the toxicity of the compounds 
against immortalized mouse hippocampal neuronal cell line HT22 was determined, as well 
as the ability of the compounds to protect the cells against oxidative stress induced by 
high extent of glutamate. 
To determine the cytotoxicity of the synthesized diarylheptanoids, a quantitative 
colorimetric cell viability assay using the tetrazolium dye MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-tetrazolium bromide) was applied. In course of this assay, the HT22 cells 
were treated with the tested compounds at different concentrations, followed by addition 
of the water soluble MTT after 24 h of incubation. The yellow tetrazolium dye MTT is 
reduced only by viable cells due to the presence of mitochondrial NAD(P)H-dependent 
oxidoreductase enzymes, forming the insoluble violet formazan (Scheme 58). This 
reaction was finished after 3 h of incubation by a SDS-lysis and the intensity of the purple 
color was spectrophotometrically measured. The formazan absorbance, determined at 
560 nm, is direct proportional to the number of living cells and so the cell viability of the 
treated cells can be expressed in a relation to the untreated cells. 
 
Scheme 58: The principle of the MTT colorimetric cytotoxicity assay 
3.4.1 Cytotoxicity of linear diarylheptanoids 
The cytotoxicity of all compounds against the HT22 cell line was determined at four 
different concentrations (1, 5, 10 and 25 µM) by the MTT assay. The linear 
diarylheptanoids could be grouped either according to the oxidation state of their aliphatic 
chain (enone, alcohol, ketone) or with regard to the substituent pattern of their aromatic 
rings (derivatives of curcumin, demethoxycurcumin and bisdemethoxycurcumin). The 
comparison of the cytotoxicity and the neuroprotection data indicated a relationship 
between the substitution of the phenyl rings and the biological activity. Hence the 
substances were grouped and discussed with respect to this feature. 
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Diarylheptanoids with 4’,4’’-dihydroxy-3’,3’’-dimethoxy substitution of the aromatic rings 
(98, 102 and 105) could be considered as derivatives of curcumin (1). These compounds 
showed certain toxicity only at the highest 25 µM concentration (cell viability of 57% for 
98 and 53% for 105) but did not significantly affect the cell viability in the range from 1 to 
10 µM (65–89%) (Fig. 22). 
 
Fig. 22: Cytotoxicity of compounds 98, 102 and 105 on HT22 cells determined by MTT assay. 
Values are expressed as mean ± SD, n = 3. Levels of significance: ***, p < 0.001; **, p < 0.01; *, p < 
0.05. 
 
Curcuminoids 99, 103 and 106 lack the methoxy group at the B-ring in position 3’’ and 
could thus be seen as derivatives of demethoxycurcumin of type B. Among these 
compounds, ketone 103 significantly lowered the cell viability at all tested concentrations 
(67% at 1 µM, 37% at 25 µM) whereas alcohol 106 was toxic only at 25 µM (61%) and 
enone 99 showed a minor effect on the viability of the cells at 10 µM (73%) and a 
moderate effect at 25 µM (51%) (Fig. 23). 
 
Fig. 23: Cytotoxicity of demethoxycurcumin derivatives - type B 99, 103 and 106 on HT22 cells 
determined by MTT assay. Values are expressed as mean ± SD, n = 3. Levels of significance: ***, p < 
0.001; **, p < 0.01; *, p < 0.05. 
 
Demethoxycurcumin derivatives of type A were compounds without methoxy group at 
position 3’ of their A-ring. This group of compounds included enone 100, ketone 104 and 
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alcohol 107. Similar to the above discussed curcuminoids, these compounds exhibited no 
or only minor toxicity at lower concentrations. Significant effects on the cell viability were 
observed at higher concentrations of 10 and 25 µM (54% cell viability for enone 100 and 
alcohol 107, 66% for ketone 104) (Fig. 24). 
 
 
Fig. 24: Cytotoxicity of demethoxycurcuminoids - type A 100, 104 and 107 on HT22 cells 
determined by MTT assay. Values are expressed as mean ± SD, n = 3. Levels of significance: ***, p < 
0.001; **, p < 0.01; *, p < 0.05. 
 
Finally, diarylheptanoids 101, 8 and 25 which were lacking both methoxy groups in 
positions 3’ and 3’’, could be referred to as derivatives of bisdemethoxycurcumin. These 
compounds showed remarkable influence on the cell viability in a concentration 
dependent manner. Whereas the lowest concentrations of 1 and 5 µM had no or only small 
toxic effects, a concentration of 10 µM reduced the cell viability to approximately 50% and 
25 µM to 25% (Fig. 25). This was the highest toxicity observed within all tested 
diarylheptanoids, with the exception of compound 110. Interestingly, alcohol 25 was 
identified by Li et al. as a phase-1 metabolite of bisdemetoxycurcumin in rat feces.111 
 
Fig. 25: Cytotoxicity of bisdemethoxcurcuminoids 101, 8 and 25 on HT22 cells determined by MTT 
assay. Values are expressed as mean ± SD, n = 3. Levels of significance: ***, p < 0.001; **, p < 0.01; *, 
p < 0.05. 
 
 Results and discussion  
70 
 
Curcumin (1), demethoxycurcumin (190) and bisdemethoxycurcumin (191), as well as 
the natural-product like 3’,3’’,4’,4’’-tetrahydroxy derivative of curcumin 110, were tested 
to obtain information about biological properties of the model compounds for the 
synthesized curcuminoids. Curcumin (1) is generally considered as a non-toxic natural 
product which can be administrated at high doses.62 In the presented test system, 1 - 10 
µM concentration of 1 slightly reduced the viability of HT22 cells to 84-82% with a more 
significant effect at 25 µM (36% less viability in comparison to untreated cells). 
Compounds 110, 190 and 191 exerted higher toxicity in contrast to 1. Di-O-
demethylcurcumin 110 lowered the viability by 36-84% at 5 to 25 µM, while 
demethoxycurcumin (190) and bisdemethoxycurcumin (191) significantly influenced the 
cells from 10 µM (73% for 190, and 55% for 191) to 25 µM (53% for 190 and 32% for 
191) (Fig. 26). 
 
 
Fig. 26: Cytotoxicity of natural curcuminoids 1, 110, 190 and 191 on HT22 cells determined by 
MTT assay. Values are expressed as mean ± SD, n = 3. Levels of significance: ***, p < 0.001; **, p < 
0.01; *, p < 0.05. 
The last linear compounds to be tested were the non-natural curcuminoids 108 and 109, 
together with the single ring analogues of curcumin 113 and 114. Tetrahydroxylated 
enone 109 exhibited lower toxicity (98-72% cell viability) compared to tetramethoxylated 
ketone 108 (77-50%), while among the single ring compounds, the 3-methoxy-4-hydroxy 
substituted enone 113 was less toxic then its 4-hydroxy substituted counterpart 114 (Fig. 
27). 
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Fig. 27: Cytotoxicity of non-natural curcuminoids 108, 109 and single ring analogues 113, 114 on 
HT22 cells determined by MTT assay. Values are expressed as mean ± SD, n = 3. Levels of 
significance: ***, p < 0.001; **, p < 0.01; *, p < 0.05. 
3.4.2 Cytotoxicity of diarylheptanoids with cyclized C7-chain 
Compounds 115 and 116 were the only two representatives of this class of 
diarylheptanoids. Formally they derived from enones 98 and 100 by a formation of the 
additional seven-membered ring. In contrast to their precursors, diarylheptanoids 115 
and 116 showed no toxicity up to 10 µM and at 25 µM lowered the cell viability only to 79-
80% (Fig. 28). 
 
 
Fig. 28: Cytotoxicity of compounds 115 and 116 on HT22 cells determined by MTT assay. Values 
are expressed as mean ± SD, n = 3. Levels of significance: ***, p < 0.001; **, p < 0.01; *, p < 0.05. 
3.4.3 Cytotoxicity of cyclic diarylheptanoids 
Biphenyl type cyclic diarylheptanoids 3 (acerogenin E), 18 (myricananin C) and 188 were 
formal derivatives of linear ketones 8, 104 and 102, respectively. In contrast to the open 
chained compounds, the cyclic derivatives exhibited no or only low (76% cell viability for 
3 at 25 µM, 77% for 188 at 25 µM) cytotoxicity against HT22 neuronal cells (Fig. 29). This 
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result indicates that the cyclization removes or significantly reduces the toxicity of the 
diarylheptanoids.  
 
 
Fig. 29: Cytotoxicity of biphenyl type cyclic ketones 3, 18 and 188 on HT22 cells determined by 
MTT assay. Values are expressed as mean ± SD, n = 3. Levels of significance: ***, p < 0.001; **, p < 
0.01; *, p < 0.05. 
The last two compounds tested were the cyclic biphenyls with the 11-hydroxyl moiety, 
namely 16 (acerogenin K) and 189. Similar to the 11-oxo analogues, derivative 189 
possessed no significant toxic properties and compound 16 exerted only a minor effect at 
25 µM concentration (Fig. 30). 
 
Fig. 30: Cytotoxicity of biphenyl type cyclic alcohols 16 and 189 on HT22 cells determined by MTT 
assay. Values are expressed as mean ± SD, n = 3. Levels of significance: ***, p < 0.001; **, p < 0.01; *, 
p < 0.05. 
 
3.5 Biological properties of synthesized diarylheptanoids - 
neuroprotective activity 
In course of the further pharmacological characterization of the diarylheptanoids, the 
protective activity of the synthesized compounds against glutamate-induced neurotoxicity 
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was measured. Glutamate (Glu) is an endogenous excitatory neurotransmitter, ubiquitous 
in the spinal cord and brain. High concentrations of glutamate in the central nervous 
system are, however, toxic and thus thought to be involved in the development of 
neurodegenerative diseases, such as Parkinson’s diseases (PD) and Alzheimer’s diseases 
(AD).149  
The toxicity of glutamate is on one hand mediate by ionotropic receptors, most notably by 
the NMDA receptor, where glutamate acts as an agonist. In response to the activation by 
Glu, Na+ and Ca2+ ions can flow in the cell while K+ ions efflux outwards. In particular the 
increased concentration of the Ca2+ causes phospholipase A2 catalyzed initiation of the 
arachidonic acid cascade, stimulates the NO production and the formation of O2-· radical 
through xanthine metabolism. This Glu-induced, NMDA-mediated neurotoxicity is 
commonly referred to as excitotoxicity.149 
The neuronal cell line HT22 is a cloned sub-line from the HT4 cell line which was derived 
from primary mouse hippocampal neurons and immortalized by a temperature-sensitive 
small virus-40 T antigen.150 The HT22 cells lack the ionotropic NMDA receptors but upon 
exposure to high concentrations of glutamate, the glutamate/cystine antiporter is blocked 
and so is the uptake of cystine by the cell (Scheme 59). The lowered intracellular 
concentration of the amino acid cysteine, i.e. the oxidized form of cystine, leads to a 
depletion of glutathione (GSH) level and causes oxidative stress.151 The resulting cellular 
death shows morphological characteristics of both necrosis and apoptosis152 and is thus in 
some publications called oxytosis. At early stages (8 – 12 h), necrosis characteristics like 
the mitochondrial oxidative stress and dysfunction prevail, whereas at later time points 
(16 – 24 h), apoptosis is induced due to the release of apoptosis-inducing factor (AIF) from 
damaged mitochondria and the activation of MAPK cascades.153 
Tan et al. studied the relationship between the GSH depletion and the ROS production. The 
Glu-induced decrease of the GSH level causes only 5-10 fold increase of ROS at early stage. 
However, an explosive burst to 200-400 fold of ROS concentration above control values 
followed at later time point. This ROS burst originated from mitochondria and was 
accompanied by influx of extracellular Ca2+.154 The ROS mediated activation of 12-
lipoxygenase (12-LOX) led to the activation of soluble guanylylcyclase (s-GC), which 
catalyzed the conversion of GTP into c-GMP.155 The latter is responsible for the Ca2+-influx 
via opening of Ca2+-channels. The mechanism of glutamate-triggered cell death in HT22 
cells is summed up in Scheme 59, based on Fukui et al.153 and Tan et al.154 
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Scheme 59: Glutamate-induced toxicity in HT22 cells proposed by Fukui et al. and Tan et al. 
The actually proposed protective mechanism of some antioxidant natural products against 
Glu-induced oxytosis is rather debatable. Curcumin (1) attenuated HT22 cell death by 
suppression of MAP kinases JNK and p38 in nanomolar concentrations.156 Ishige and co-
workers screened a battery of flavonoids and could demonstrate that, depending on their 
structure, the flavonoids exerted the protective activity by three distinct mechanisms. 
Quercetin and related compounds increased basal GSH levels possibly due electrophile 
responsive element-mediated up-regulation of γ-GCS. The compounds of the galangin 
group (galangin, kaempferol etc.) did not affect the GSH level but reduced directly the ROS 
concentration. Finally, neat flavonol and its derivatives with hydroxyl groups in position 6 
or 7 neither maintained the GSH level nor did they act as antioxidants. Instead, these 
compounds inhibited the Ca2+ influx and thus protected the cells despite of elevated 
intracellular ROS levels.157 Resveratrol, investigated by Fukui et al. on neuroprotection in 
the HT22 cell model, exhibited its indirect antioxidant activity through the activation of 
PI3K/Akt signaling pathway which led to elevated expression of superoxide dismutase 
SOD2 within 1 h. This enzyme can catalyze the conversion of mitochondrial superoxide to 
hydrogen peroxide, which is then further detoxified by HO-1.158 Fukui’s findings are not 
completely in accordance with data collected by Yang et al. for cyclic diarylheptanoids 
juglanin A (2) and C. These compounds attenuated the Glu-induced neurotoxicity and 
restored the activity of glutathione reductase (GR) and glutathione peroxidase (GSH-Px), 
however, did not affect the activity of SOD (without specification of the enzyme type).4  
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3.5.1 Protective activity of the linear diarylheptanoids against Glu-
induced neurotoxicity 
HT22 cells were exposed to glutamate (5 mM) in presence of tested diarylheptanoids at 
four concentrations (1, 5, 10 and 25 µM). The cell viability was subsequently (after 24 h) 
determined by a MTT assay and was expressed as percentage of the untreated cells. Cells 
treated merely with glutamate (5 mM) underwent major morphological changes (Fig. 31 
B) and exhibited viability of about 13%. Importantly, some of the synthesized 
diarylheptanoids were able to increase the survival rate of the cells in a concentration 
dependent manner. 
 
Fig. 31: (A) HT22 neuronal cells; (B) HT22 neuronal cells 24 h after treatment with Glu (5 mM) 
Compounds derived from bisdemethoxycurcumin (enone 101, ketone 8 and alcohol 25) 
and demethoxycurcuminoids of type A (enone 100, ketone 104 and alcohol 107) showed 
no or only negligible protective properties within the tested concentration range (Fig. 32). 
The lack of activity was observed regardless weather the enone, the ketone or the alcohol 
moiety was present in the aliphatic chain. Common feature for both groups of compounds 
was the 4’-hydroxyl substitution of the A-ring (Fig. 32). 
(A) (B) 
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Fig. 32: Bisdemethoxycurcuminoids (101, 8 and 25) and derivatives of demethoxycurcumin of 
type A (100, 104 and 107) could not protect HT22 cells from Glu-induced toxicity. Values 
represent means ± SD, n ≥ 3. Significance levels: ***, p < 0.001, **, p < 0.01, *, p < 0.05 vs. Glu 
control. 
 
On the other side, diarylheptanoids derived from curcumin and desmethoxycurcumin of 
type B reduced, in some cases, the toxicity triggered by glutamate (Fig. 33). These 
compounds share the 4’-hydrox-3’-methoxy substitution of the A-ring. Most potent was 
enone 98 which increased the HT22 viability up to 44% at 5 µM and 63% at 10 µM. Ketone 
102 and alcohol 105 showed positive effect on the viability only at 25 µM (55-52%). 
Analogue to the described curcuminoids, the enone 99 was the most potent compound 
among demethoxycurcumin derivatives of type B with significant elevation of the viability 
to 28% at 10 µM and 47% at 25 µM. However, these concentrations of 99 were already 
considered as toxic for the HT22 cells (Fig. 23). The reduced forms of compound 99, 
namely the ketone 103 and the alcohol 106, showed comparably lower effect (Fig. 33). All 
in all, the results of the glutamate assay for these two kinds of diarylheptanoids indicated 
the importance of a Michael system in proximity of a 4-hydroxy-3-methoxy substituted 
aromatic ring (ferulic acid-like motif).  
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Fig. 33: Protective activity of diarylheptanoids derived from curcumin (98, 102, 105) and 
demethoxycurcuminoids of type B (99, 103, 106) against Glu-induced toxicity. Values represent 
means ± SD, n ≥ 3. Significance levels: ***, p < 0.001, **, p < 0.01, *, p < 0.05 vs. Glu control. 
 
Furthermore, the non-natural curcuminoids 108 and 109 as well as the single ring 
analogues 113 and 114 were examined on the neuroprotective activity against Glu-
induced oxidative damage (Fig. 34). Whereas the “half”-curcuminoids 113 and 114 and 
the tetramethoxylated ketone 108 showed no significant attenuation of the toxicity, the 
enone 109 increased the HT22 viability to 68% at non-toxic 25 µM concentration. 
Therefore, the α,β-unsaturated carbonyl unit conjugated with the 3’,4’-dihyroxyl 
substituted A-ring (caffeoyl moiety) was considered as an additional structural motif with 
beneficial properties against Glu-induced neurotoxicity. Moreover, since the single ring 
molecules 113 and 114 were inactive, the complete diarylheptanoid scaffold was essential 
for the neuroprotection (Fig. 34). 
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Fig. 34: Non-natural curcuminoids 108, 109 and the single ring analogues 113, 114 tested on 
protective activity against Glu-induced toxicity in HT22 cells. Values represent means ± SD, n ≥ 3. 
Significance levels: ***, p < 0.001, **, p < 0.01, *, p < 0.05 vs. Glu control. 
In addition, parent compounds of the synthesized curcuminoids, namely curcumin (1), 
demethoxycurcumin (190) and bisdemethoxycurcumin (191), were purchased from 
commercial sources and assayed on potential neuroprotectivity (Fig. 35). As expected, 1 
could reduce the toxicity within the complete concentration range, increasing the cell 
viability to 37% 1 µM and to 68% at 25 µM concentration. The remaining two natural 
curcuminoids 190 and 191 showed as well certain protective activity which was, 
however, at higher concentration (10, 25 µM) diminished by their own toxicity. This effect 
was observed in the case of di-O-demethylcurcumin 110 too, where the high toxicity of the 
compound was superior to the neuroprotection. 
 
 
Fig. 35: Protective activity of natural curcuminoids 1, 110, 190 and 191 against Glu-induced 
toxicity in HT22 cells. Values represent means ± SD, n ≥ 3. Significance levels: ***, p < 0.001, **, p < 
0.01, *, p < 0.05 vs. Glu control. 
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Altogether, the screening of twenty curcuminoids on potential protective activity against 
glutamate-induced toxicity in HT22 neuronal cells revealed the following findings: 
1. The complete diarylheptanoid scaffold is required for the neuroprotection 
2. A 4’-hydroxy substitution of the A-ring (p-cumaroyl motif) does not contribute to 
the protective activity 
3. The combination of a Michael system with the 4’-hydroxy-3’-methoxy substituted 
A-ring (feruloyl motif) is essential for the reduction of the cell viability by Glu 
4. The caffeoyl motif, i.e. a 3’,4’-dihydroxy substituted A-ring adjacent to the enone 
moiety, exhibits protective effects at higher concentrations 
3.5.2 Protective activity of curcuminoid 98 and 109 against t-BuOOH-
induced toxicity 
The neurotoxicity triggered by glutamate involves depletion of GSH-level, accumulation of 
ROS, increase of intracellular Ca2+ concentration and activation of MAPK cascades (Scheme 
59). To obtain more information about the actual protective mechanism of the 
curcuminoid 98 (ferulic acid-like substitution) and compound 109 (caffeic acid-like 
substitution), tert-butyl hydroperoxide (t-BuOOH) was utilized as toxic agent for the HT22 
cells instead of glutamate. t-BuOOH is a lipophilic radical donor which directly elevates 
ROS-level in the cells.159  
During this experiment, 50,000 cells/well were seeded in 96-well plates pre-coated with 
gelatin. This setup was optimized by Beata Kling160 in order to get confluent cell layers 
which were needed for the robustness of this assay. The cells were then treated with the 
tested compounds 3 h prior to the t-BuOOH addition to avoid direct reaction of the 
stressor with the potential radical scavengers in the supernatant. Substances were tested 
in the concentration range of 1 – 100 µM, while the t-BuOOH was used in excess (300 µM). 
Remarkably, enone 98 with two 4-hydroxy-3-methoxy substituted rings (feruloyl-like), 
which was the most potent synthetic compound in the reduction of the glutamate toxicity, 
was completely inactive against t-BuOOH-induced oxidative cell damage. On the other 
hand, enone 109 with two 3,4-dihyroxy aromatic rings (caffeoyl-like), which was active 
only at 25 µM against Glu, showed decent activity against t-BuOOH in a concentration 
dependent manner. This observation pointed to direct radical scavenging potential by the 
catechol units of 109 and to involvement of more complex pathways in case of feruloyl-
analogue 98 (Fig. 36). 
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Fig. 36: Protection of HT22 cells against t-BuOOH by compound 109 in contrast to inactive 
compound 98; Values are means ± SD of at least three independent experiments. Levels of 
significance: ***, p < 0.001; **, p < 0.01; *, p < 0.05 vs. t-BuOOH control. Experiments performed by 
F. S. Kücükoktay. 
 
Kling et al. examined different phenolic compounds on their neuroprotective effects 
against t BuOOH-induced toxicity in HT22 cells. Their MTT- and ECIS-based studies were 
in a good agreement with the results described in Fig. 36, showing an essential role of the 
catechol (caffeoyl) unit for the scavenging of ROS.160    
3.5.3 Stability of curcumin and its synthetic analogue 98 in cell culture 
medium 
The stability of curcumin (1) and its monocarbonyl analogue 98 in cell culture medium 
was the object of an HPLC-based test. Despite of the number of remarkable biological 
effects in vitro, curcumin (1) finds only a limited clinical application due to its poor water 
solubility and bioavailability.62 Curcumin (1) stability in buffer solutions and cell culture 
medium was investigated by Wang et al. Their study revealed that 1 decomposed fast 
under neutral and basic conditions as well as in culture medium. Addition of fetal calf 
serum was beneficial, nonetheless, more than 50% of 1 decomposed within 8 h of 
incubation.161 
Curcumin (1), incubated at 37 °C and 5% CO2 in cell culture medium, continuously 
decomposed while new peaks appeared in the HPLC chromatogram. The area of the 
curcumin peak decreased to 63% after 4 h and after 8 h down to 44%. No 1 was detected 
after 24 h of incubation (Fig. 37). On the other hand, curcuminoid 98 exhibited an 
outstanding stability in the cell culture medium, showing no decay during the tested 
period of time (24 h) (Fig. 38). 
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Fig. 37: Stability of curcumin (1) in DMEM cell culture medium determined by HPLC; CAPE used as 
an internal standard; complete data depicted in the Appendix 
 
Fig. 38: Stability of the synthetic curcuminoid 98 in DMEM cell culture medium determined by 
HPLC; CAPE used as an internal standard; complete data shown in the Appendix 
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3.5.4 Michael acceptor activity of curcumin and its analogue 98 
Curcumin (1) and its synthetic derivative 98 posses α,β-unsaturated carbonyl units and 
can be thus considered as Michael acceptors. The ability to react with cysteine residues of 
signal transduction proteins like Keap1 (an adaptor of Nrf2) and NF-κB in thia-Michael 
addition reactions is responsible for biological activity of different naturally occurring 
electrophiles.162 Such reactivity can be determined by a spectrophotometric screening 
assay developed by Sabine Amslinger and Nafisah Al-Rifai,163 providing information about 
electrophilicity of compounds 1 and 98. 
 
Scheme 60: Michael addition of cysteamine 192 on curcuminoid 98 
The optimized thiol assay measures the decay of the absorbtion band of the α,β-
unsaturated carbonyl during the reaction with cysteamine (192) in ethylene glycol/EDTA-
TRIS buffer (80:20).163 A general reactivity screening of curcumin (1) and curcuminoid 98 
was performed in presence of 300 fold of cysteamine, showing a comparable Michael 
acceptor activity of both enones (Fig. 39). The product of the Michael reaction between 
compound 98 and the thiol was confirmed by mass spectrometry (compound 193, m/z 
434 [MH]+) (Scheme 60). 
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Fig. 39: UV-Vis spectra of curcuminoid 98 and curcumin (1) (40 µM) in presence and absence of 
300 fold excess of cysteamine; 100 mM TRIS-HCl pH 7.4, 2 mM EDTA/ethylene glycole (20:80) at 25 
°C 
3.5.5 Protective activity of diarylheptanoids with cyclized C7-chain 
against glutamate-induced toxicity 
Synthetic diarylheptanoids 115 and 116, possessing a seven-membered ring adjacent to 
the B-ring, were tested in HT22 cells at four different concentrations (1-25 µM) on 
protective activity against glutamate-induced oxidative damage (Fig. 40). These 
compounds showed no activity at 1 µM, however, both substances exerted remarkable 
protective effects at 5-25 µM. The derivative 115 reassembled the cell viability up to 84% 
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at 5 µM and 67% at 25 µM, whereas diarylheptanoid 116 exhibited slightly lower activity 
at 5 µM with the cell viability of 59% but with 85% at 10 µM concentration. The slight 
decrease in the cell viability observed at 25 µM can be explained by some toxic effects of 
115 and 116 (Fig. 28) themselves.  
 
Fig. 40: Neuroprotective activity of diarylheptanoids 115 and 116 against Glu-induced toxicity in 
HT22 cells. Values represent means ± SD, n ≥ 3. Significance levels: ***, p < 0.001, **, p < 0.01, *, p < 
0.05 vs. Glu control. 
 
3.5.6 Protective activity of cyclic diarylheptanoids against glutamate-
induced toxicity 
Interesting structure-activity relationships were observed for the synthesized biphenyl 
type cyclic diarylheptanoids (Fig. 41). Acerogenin E (3) was inactive over the complete 
tested concentration range (1-25 µM). Its reduced derivative acerogenin K (16), bearing in 
position 11 a hydroxyl instead of oxo group, exhibited a moderate increase of cell viability 
(38%) at 25 µM but no effect at 1-10 µM. An almost identical result (39% at 25 µM) was 
obtained for myricananin C (18). However, the non-natural cyclic compound 188 
enhanced the cell viability to 44% at 5 µM and to 67-71% at 10 and 25 µM, whereas its 11-
hydroxyl derivative was potent first at 25 µM concentration (58% cell viability, Fig. 41). 
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Fig. 41: Neuroprotectiv activity of the cyclic diarylheptanoids against Glu-induced toxicity in HT22 
cells. Values represent means ± SD, n ≥ 3. Significance levels: ***, p < 0.001, **, p < 0.01, *, p < 0.05 
vs. Glu control. 
 
Although the group of examined derivatives is rather small, the combination of the 11-oxo 
group with the 17-hydroxy-16-methoxy substitution of the B-ring appears to be important 
for the protective activity. This observation is in partial agreement with the effects of 
linear diarylheptanoids, in which this type of substitution in combination with a Michael 
system was crucial for the neuroprotectivity. Interstingly, compound 188 exerted its 
biological effect despite of missing such a Michael system. 
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4 Summary 
Diarylheptanoids are natural products consisting of two aromatic rings connected by a 
seven carbon aliphatic chain which can be found in certain parts of various trees and 
shrubs as well as in rhizomes of some medicinal herbs. The most prominent 
representative of the diarylheptanoid class is curcumin (1), a linear diferuloyl methane 
from Curcuma longa L. with a broad spectrum of pharmacological effects. However, cyclic 
derivatives with a biphenyl or a diphenyl ether moiety, which were discovered in trees of 
Aceraceae, Juglandaceae and Myricaceae family, also exhibit promising anti-inflammatory 
and cytoprotective activity. 
This thesis was focused on the synthesis of linear diarylheptanoids along with their 
biphenyl type cyclic derivatives and compounds with cyclized C7-chain. A straight forward 
synthetic strategy towards monocarbonyl analogues of curcumin was developed and used 
for the synthesis of fourteen curcuminoids with four different substitution patterns of 
aromatic rings and three types of connecting chains. Additionally, two 4-phenylbut-3-en-
2-ones were prepared as single ring curcuminoids and di-(O)-demethylcurcumin was 
obtained from 1 to extend the structural variety of the compounds prior their biological 
testing. 
Moreover, five biphenyl type cyclic diarylheptanoids were prepared via a novel synthetic 
route which comprised formation of iodinated acyclic precursors followed by an 
intramolecular cyclization. The ring closing step was accomplished by a domino sequence 
of a Miyaura aryl borylation and a Suzuki reaction. Among the cyclic diarylheptanoids, 
three known natural products (acerogenin E (3), acerogenin K (16) and myricananin C 
(18)) were prepared, together with two non-natural derivatives 188 and 189. 
Myricananin C, a natural product from Myrica nana, was synthesized for the first time. 
 
Fig. 42: Novel diarylheptanoids synthesized in the course of this work 
 
 Summary  
88 
 
Finally, two diarylheptanoids with cyclized aliphatic chain (115, 116) were prepared by 
an unpredicted intramolecular electrophilic aromatic substitution and were fully 
characterized. Their structure showed a high analogy to a natural product 24 from greater 
cardamom (Amomum subulatum Roxb.), hence, the herein described methodology might 
serve to a total synthesis of the latter. 
The pharmacological testing of the synthesized diarylheptanoids was focused on their 
potential neuroprotective activity. Accordingly, the ability to attenuate glutamate-induced 
toxicity in HT22 neuronal cells was evaluated and revealed interesting structure-activity 
relationships for different classes of the diarylheptanoids (Fig. 43).  
In case of the linear compounds, the presence of an α,β-unsaturated carbonyl system 
conjugated with a 4-hydroxy-3-methoxy substituted aromatic ring (ferulic acid-like motif) 
was essential for the protective activity. Especially the compound 98 exhibited effects 
comparable with its parent compound curcumin (1) with significantly improved stability 
in the cell culture medium and comparable Michael acceptor activity. Furthermore, the 
radical scavenging properties of compound 98 and its di-(O)-demethyl derivative 109 
were tested in HT22 cells injured by t-BuOOH. Whereas the caffeic acid-like substituted 
diarylheptanoid 109 showed a protective effect in a concentration dependent manner, 
substance 98 was inactive. This fact indicates that the protective activity of the ferulic 
acid-like substituted diarylheptanoids against glutamate-induced toxicity in HT22 
neuronal cells is mediated by a different molecular mechanism than a simple ROS-
scavenging. 
Besides, the investigation of the cyclic diarylheptanoids showed an interesting analogy to 
the above described findings. The non-natural compound 188, bearing a 4-hydroxy-3-
methoxy substituted aromatic ring in proximity of the oxo functionality, exerted a 
protective activity from 5 µM concentration against oxidative damage triggered by 
glutamate. The other congeners showed no or only minor effects at 25 µM, thus, the 
presence of the (reduced) feruloyl motif appears to be important even in case of the cyclic 
diarylheptanoids. 
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Fig. 43: Structural requirements for the neuroprotective activity 
Lastly, the most potent diarylheptanoids among the synthesized compounds were the 
tricyclic derivatives 115 and 116. These substances could restore the cell viability of the 
HT22 cells injured by glutamate up to 85% at 5 µM concentration without showing any 
toxic effects towards the cells at this concentration. 
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5 Experimental part 
5.1 General synthetic methods and materials 
5.1.1 Chemicals and reagents 
All chemicals were purchased from commercial sources, namely: 
Vanillin, 4-hydroxybenzaldehyde, lithium aluminum hydride, manganese dioxide, Pd/C 
(10% palladium on charcoal), diphenyl sulfide, sodium borohydride, dimethylsulfate, 
potassium iodide, boric acid, iodine monochloride, malonic acid and potassium acetate 
from Merck (Darmstadt, Germany); chloromethyl methyl ether (MOM chloride), boron 
tribromide, iodine, diisobutylaluminum hydride, silver trifluoroacetate, TFA, 
(triphenylphosphoraneylidene)-2-propanone, pinacolato diboron and PdCl2(dppf) from 
Sigma Aldrich (Taufkirchen, Germany); p-coumaric acid and piperidine from Fluka (Neu-
Ulm, Germany); (formylmethylene)triphenylphosphoran and Crabtree’s catalyst from 
ABCR (Karlsruhe, Germany); diisopropylethylamine and DMAP from Acros/Fisher (Geel, 
Belgium), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimid (EDC·HCl) from Novabiochem 
(Merck group, Darmstadt, Germany) and ferulic acid from Carl Roth (Karlsruhe, Germany). 
Solvents were purchased in high quality from commercial sources or distilled before use 
when obtained in technical quality. Reactions were conducted under nitrogen atmosphere 
in oven-dried glassware (110 °C) and dry solvents when dry conditions were needed. 
5.1.2 Chromatography  
The reaction progress was monitored by TLC, using aluminum plates coated with silica 60 
F254 from Merck (Darmstadt, Germany) and detected by UV light (254 and 366 nm) or 
vanillin/H2SO4 staining reagent (15 g of vanillin in 250 ml EtOH + 2.5 ml conc. H2SO4). 
Column and flash chromatography was performed on silica gel 60 (0.063 – 0.200 mm pore 
size), the flash chromatography with the aid of Armen Spot instrument (VWR, Vannes, 
France) equipped with UV detector. All final products were purified with preparative 
HPLC before submission for biological testing. For that reason, a Varian Prostar 
instrument with DAD detector and Galaxie HPLC software was used, with following 
characteristics: 
Column: HPLC Knauer RP-18, Eurosphere 100 (7 µm; 16 × 250 nm) 
Solvents: MeOH (degassed, HPLC grade, Merck), H2O (degassed, Millipore) 
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Application: liquid injection in 100% MeOH, injection volume 500 µl, concentration 20 
mg/ml 
Method 1: gradient H2O/MeOH; 50% MeOH at t = 0 min, 100% MeOH at t = 20 min, 100% 
MeOH at t = 25 min; flow 10 ml/min 
Method 2: gradient H2O/MeOH; 50% MeOH at t = 0 min, 100% MeOH at t = 30 min, 100% 
MeOH at t = 35 min; flow 10 ml/min  
The stability test of 1 and curcuminoid 98 was performed on a Hitachi DAD L2455 
instrument with L2200 autosampler, L2130 pump, L2350 column oven, equipped with 
EZChrom Elite 3.1.7 software. 
Column: Hilbar®RT 250-4 cartridge with Purosphere®Star RP-18e (5 µm) (Merck, 
Darmstadt, Germany) 
Internal standard: CAPE, ≥99%, Carl Roth, Karlsruhe, Germany 
Method for curcumin (1): oven temperature: 40 °C; injection volume: 20 µl; flow: 1 
ml/min; solvent A: MeOH (35%) in H2O + 0.1% TFA; solvent B: H2O 
time (min) solvent A (%) solvent B (%) 
0 100 0 
20 0 100 
25 0 100 
27 100 0 
35 100 0 
 
Method for compound 98: oven temperature: 40 °C; injection volume: 20 µl; flow: 1 
ml/min; solvent A: MeOH; solvent B: H2O 
time (min) solvent A (%) solvent B (%) 
0 100 0 
20 0 100 
25 0 100 
27 100 0 
35 100 0 
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5.1.3 Mass spectrometry 
Low resolution (LR) ESI-MS and APCI-MS spectra were measured on a TSQ 7000 
(ThermoQuest Finnigan, Bremen, Germany), high resolution (HR) ESI-MS and APCI-MS on 
a Q-TOF 6540 UHD (Agilent, Santa Clara, USA), LR EI-MS on a MAT SSQ 710 (Finnigan) and 
HR EI-MS on MAT95 (Finnigan). 
5.1.4 NMR spectroscopy 
All 1H- and 13C-NMR spectra were recorded on a Bruker Avance 300 (measurement 
frequency 300.13 MHz for 1H, 75.47 MHz for 13C, temperature 296.1 K), Bruker Avance 
400 (400.13 MHz for 1H, 101 MHz for 13C, 296.1 K) and Bruker Avance III 600 (600.25 
MHz for 1H, 150.95 MHz for 13C, 298.0 K), all instruments supplied by Bruker Corporation 
(Billerica, USA). Samples were dissolved in deuterated solvents (MeOD, acetone-d6 from 
Deutero GmbH, Kastellaun, Germany and CDCl3 from Sigma Aldrich, Steinheim, Germany) 
and submitted for measurement in NMR tubes (507-HP, 203 mm) from Norell, Landisville, 
USA. 
1H-NMR spectra are referenced to residual non-deuterated solvent peaks (7.26 ppm for 
CDCl3, 3.31 ppm for MeOD and 2.05 ppm for acetone-d6). 13C-NMR spectra are referenced 
to solvent peaks: 77.0 ppm for CDCl3, 49.0 ppm for MeOD and 29.9 ppm for acetone-d6. 
The following abbreviations are used to explain the multiplicities: s, singlet; d, doublet; dd, 
doublet of doublets; t, triplet; sept, septet; m, multiplet. Coupling constants (J) are given in 
Hz. 
5.1.5 UV/Vis spectroscopy 
The UV spectra were recorded on a Varian Cary 300 in MeOH (>99.9%, Uvasol, Merck, 
Darmstadt, Germany). 
5.1.6 Melting points 
Melting points were determined using a Büchi Melting Point B-545 apparatus and are 
uncorrected. 
5.1.7 X-ray analysis 
The X-ray data were collected with SuperNova, Single source at offset, Atlas difractometer 
(Agilent, USA). The graphics were processed with Diamond 3.0 software. 
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5.1.8 Experimental procedures 
5.1.8.1 4-(Methoxymethyl)-3-methoxy-benzaldehyd (79)102 
 
Vanillin (35) (10.0 g, 65.7 mmol, 1.0 eq.) was dissolved in 100 ml CH2Cl2 and cooled to 0 
°C. Hunig’s base (DIPEA) (13.6 g, 18.3 ml, 105 mmol, 1.6 eq.) and MOM chloride (6.88 g, 
6.49 ml, 85.4 mmol, 1.3 eq.) were dropwise added and the solution was stirred at room 
temperature overnight. The reaction was then quenched with sat. aq. NH4Cl (45 ml) and 
the aqueous layer was extracted with EtOAc (3 × 30 ml). The combined organic layers 
were washed with brine (2 × 100 ml) and dried over MgSO4. After concentrating in vacuo, 
the residue was passed through a pad of silica to yield a white solid (79, 12.6 g, 64.2 mmol, 
98%). 
1H NMR (300 MHz, CDCl3) δ 9.85 (s, 1H), 7.49 – 7.34 (m, 2H), 7.25 (d, J = 8.7 Hz, 1H), 5.31 
(s, 2H), 3.93 (s, 3H), 3.50 (s, 3H). 
The 1H-NMR spectrum agrees with the literature.164 
5.1.8.2 4-(Methoxymethoxy)benzaldehyde (80)102 
 
4-Hydroxybenzaldehyde (78) (10.0 g, 81.9 mmol, 1.0 eq.) was dissolved in 100 ml CH2Cl2 
and cooled to 0 °C. Hunig’s base (22.8 ml, 16.9 g, 131 mmol, 1.6 eq.) was dropwise added, 
followed by dropwise addition of MOM chloride (8.09 ml, 8.57 g, 107 mmol, 1.3 eq.). The 
mixture was allowed to warm to room temperature and stirred under nitrogen. After 16 h, 
the reaction was quenched with 45 ml NH4Cl aq. solution (sat.) and the aqueous layer was 
extracted with EtOAc (2 × 75 ml). The combined organic layers were washed with brine 
(100 ml), dried with MgSO4 and concentrated under reduced pressure. The crude product 
was passed through a pad of silica (eluted by PE/EtOAc 2:1) to yield 12.9 g (77.8 mmol, 
95%) of pure 80 as yellowish oil. 
1H NMR (300 MHz, CDCl3) δ ppm 9.87 (s, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.12 (d, J = 8.8 Hz, 
2H), 5.22 (s, 2H), 3.46 (s, 3H). 
The 1H-NMR spectrum agrees with the literature.165 
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5.1.8.3 3-(3-Methoxy-4-(methoxymethoxy)phenyl)acrylaldehyde (81)103 
 
The MOM-protected vanillin 79 (8.00 g, 40.8 mmol, 1.0 eq.) was dissolved in 200 ml 
acetonitrile, followed by the addition of (formylmetylen)triphenylphosphorane (15.0 g, 
48.9 mmol, 1.2 eq.). The red mixture was stirred at 80 °C for 24 h, while the progress of the 
reaction was monitored by TLC analysis. The solvent was then removed in vacuo to yield a 
red solid, which was passed through a pad of silica. The resulting yellow oil was purified 
by flash chromatography (SiO2; PE/EtOAc 4:1), yielding 3.65 g (16.4 mmol, 40%) of the 
product 81 as yellow solid. 
1H NMR (300 MHz, CDCl3) δ ppm 9.59 (d, J = 7.7 Hz, 1H), 7.35 (d, J = 15.8 Hz, 1H), 7.18 – 
6.97 (m, 3H), 6.55 (dd, J = 15.8, 7.7 Hz, 1H), 5.21 (s, 2H), 3.85 (s, 3H), 3.44 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ ppm 193.5, 152.6, 149.9, 149.4, 128.3, 127.1, 123.0, 115.7, 
110.5, 95.1, 56.4, 55.9. 
EI-MS m/z (%) 222 [M]+· (23), 192 (6), 161 (7) 
HR EI-MS m/z 222.0889 [M]+· (calcd. for C12H14O4, 222.0892) 
mp: 67-69 °C 
UV λmax 236, 330 nm. 
5.1.8.4 (E)-3-(4-(Methoxymethoxy)phenyl)acrylaldehyde (82)103 
 
4-(Methoxymethoxy)-benzaldehyde 79 (5.16 g, 31.0 mmol, 1.0 eq.) and 
(formylmethylen)tri-phenylphosphine (13.2 g, 43.3 mmol, 1.4 eq.) were dissolved in 
100 ml acetonitrile and stirred at 80 °C for 8 days. Subsequently, the solvent was removed 
in vacuo and the red solid was passed through a pad of silica in order to remove 
triphenylphosphine oxide. The residue was purified by column chromatography (SiO2; 
PE/EtOAc 3:1) and preparative TLC (SiO2; petroleum ether (b.p. 40-60 °C)/EtOAc 7:1 + 
0.1% TFA) to yield 768 mg (4.00 mmol, 13%) of pure 82 as yellow oil. 
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1H NMR (300 MHz, CDCl3) δ ppm 9.64 (d, J = 7.7 Hz, 1H), 7.50 (d, J = 8.6 Hz, 2H), 7.41 (d, J = 
15.9 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 6.60 (dd, J = 15.9, 7.7 Hz, 1H), 5.21 (s, 2H), 3.47 (s, 
3H). 
13C NMR (75 MHz, CDCl3) δ ppm 193.6, 159.7, 152.5, 130.2 (2C), 127.7, 126.8, 116.5 (2C), 
94.0, 56.2. 
EI-MS m/z (%) 192 [M]+· (21), 131 (5) 
HR EI-MS m/z 192.0788 [M]+· (calcd. for C11H12O3 192.0786) 
UV λmax 230, 313 nm. 
5.1.8.5 (E)-Methoxymethyl-3-(3-methoxy-4-
(methoxymethoxy)phenyl)acrylate (86)102 
 
Ferulic acid 85 (5.87 g, 30.2 mmol, 1.0 eq.) and DIPEA (13.2 ml, 75.5 mmol, 2.5 eq.) were 
mixed in 37 ml CH2Cl2 and cooled to 0 °C, forming a yellowish slurry. Methoxymethyl 
chloride (5.96 ml, 78.5 mmol, 2.6 eq.) was dropwise added, resulting in the formation of a 
yellow solution. The ice bath was removed after 20 min and the mixture was further 
stirred at r.t.. After 3.5 h overall time, the reaction was stopped by the addition of 
saturated aqueous NH4Cl solution (50 ml). The CH2Cl2 layer was separated and the 
aqueous phase was extracted with EtOAc (2 × 70 ml). The organic layers (CH2Cl2 and 
EtOAc) were combined and dried with MgSO4 and the solvent was removed in vacuo, 
yielding 8.17 g (29.0 mmol, 96%) of 86 as white solid. 
1H NMR (300 MHz, CDCl3) δ ppm 7.68 (d, J = 15.9 Hz, 1H), 7.15 (d, J = 8.5 Hz, 1H), 7.12 – 
7.03 (m, 2H), 6.33 (d, J = 15.9 Hz, 1H), 5.35 (s, 2H), 5.26 (s, 2H), 3.91 (s, 3H), 3.50 (s, 3H), 
3.50 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ ppm 166.4, 149.7, 148.6, 145.4, 128.5, 122.3, 115.7 (CH), 115.7 
(CH), 110.3 (CH), 95.1 (CH2), 90.4 (CH2), 57.6 (CH3), 56.3 (CH3), 55.8 (CH3). 
EI-MS m/z (%) 282 [M]+· (19), 176 (24), 146 (12) 
HR EI-MS m/z 282.1108 [M]+· (calcd. for C14H18O6: 282.1103). 
m.p.: 46 °C. 
UV max 233, 294, 320 nm. 
 Experimental part 
97 
 
5.1.8.6 (E)-methoxymethyl 3-(4-(methoxymethoxy)phenyl)acrylate (87)102 
 
p-Coumaric acid 27 (4.08 g, 24.9 mmol, 1.0 eq.) was dissolved in 30 ml CH2Cl2 and cooled 
to 0 °C. DIPEA (14.8 ml, 84.5 mmol, 3.5 eq.) was added, followed by a slow addition of 
methoxymethyl chloride (6.98 ml, 92.0 mmol, 3.7 eq.). The mixture was stirred at r.t. until 
a complete conversion was reached after 9 h. The reaction mixture was then quenched 
with sat. aqueous NH4Cl solution (40 ml), the CH2Cl2 layer was separated and the aqueous 
residue was extracted with CH2Cl2 (2 × 30 ml). The combined organic layers were washed 
with brine (80 ml), dried with MgSO4 and concentrated under reduced pressure. The 
reaction afforded 6.20 g (24.6 mmol, 99%) of 87 as yellowish oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.68 (d, J = 16.0 Hz, 1H), 7.46 (d, J = 8.8 Hz, 2H), 7.02 (d, J 
= 8.7 Hz, 2H), 6.32 (d, J = 16.0 Hz, 1H), 5.33 (s, 2H), 5.18 (s, 2H), 3.49 (s, 3H), 3.45 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 166.5, 159.0, 145.1 (CH), 129.7 (2 × CH), 127.9, 116.4 (2 × CH), 
115.4 (CH), 94.0 (CH2), 90.3 (CH2), 57.5 (CH3), 56.0 (CH3). 
ESI-MS m/z (%) 253 [MH]+ (6), 191 [MH – CH3OCH2OH]+ (100), 145 (23) 
HR ESI-MS m/z 253.1068 [MH]+ (calcd. for C13H17O5, 253.1071). 
UV max 225, 306 nm. 
5.1.8.7 (E)-3-(3-Methoxy-4-(methoxymethoxy)phenyl)prop-2-en-1-ol 
(88)105 
 
The ester 86 (7.58 g, 26.9 mmol, 1.0 eq.) was dissolved in dry THF (150 ml) under 
nitrogen atmosphere and cooled to -78 °C. Lithium aluminium hydride (1.64 g, 43.2 mmol, 
1.6 eq.) was added in portions and the mixture was stirred until the conversion was 
complete (after 3 h). The reaction was slowly quenched with MeOH till gas evolution 
stopped, followed by addition of H2O (200 ml). The aqueous solution was neutralized by 1 
M HCl and extracted with EtOAc (2 × 200 ml). After drying with MgSO4, the solvent was 
evaporated to afford pure 88 (5.77 g, 25.8 mmol) as yellow oil in 96% yield. 
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1H NMR (300 MHz, CDCl3) δ ppm 7.08 (d, J = 8.3 Hz, 1H), 6.94 (d, J = 2.0 Hz, 1H), 6.89 (dd, J 
= 8.3, 2.0 Hz, 1H), 6.54 (d, J = 15.9 Hz, 1H), 6.24 (dt, J = 15.8, 5.8 Hz, 1H), 5.21 (s, 2H), 4.29 
(dd, J = 5.8, 1.4 Hz, 2H), 3.88 (s, 3H), 3.50 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ ppm 149.7, 146.2, 131.3, 130.9, 127.1, 119.5, 116.2, 109.3, 
95.4, 63.7, 56.2, 55.8. 
ESI-MS m/z (%) 175 [MH – H2O – MeOH]+ (100), 207 [MH – H2O]+ (67), 247 [MNa]+ (27). 
HR ESI-MS m/z 247.0940 [MNa]+ (calcd. for C12H16NaO4 247.0941). 
UV λmax 259 nm. 
5.1.8.8 (E)-3-(4-(Methoxymethoxy)phenyl)prop-2-en-1-ol (89)105 
 
The ester 87 (6.53 g, 24.9 mmol, 1.0 eq.) was dissolved in dry THF (120 ml) under N2 
atmosphere and cooled to -78 °C, followed by the addition of lithium aluminium hydride 
(1.96 g, 51.6 mmol, 2.1 eq.). The reaction was stopped after 60 min by quenching of 
unreacted LiAlH4 with MeOH (until the evolution of gas stopped). The mixture was then 
mixed with H2O (150 ml), acidified with 3 M HCl (aq.) and extracted with EtOAc (2 × 200 
ml). The combined organic layers were dried with MgSO4 and the solvent was removed by 
rotary evaporator, affording pure alcohol 89 (4.79 g, 24.7 mmol, 99%) as yellowish oil. 
1H NMR (300 MHz, CDCl3)  ppm 7.31 (d, J = 8.7 Hz, 1H), 6.99 (d, J = 8.8 Hz, 1H), 6.56 (dd, J 
= 15.9, 7.3 Hz, 1H), 6.24 (dt, J = 15.8, 5.9 Hz, 1H), 5.17 (s, 1H), 4.29 (dd, J = 5.9, 1.4 Hz, 2H), 
3.47 (s, 3H). 
13C NMR (75 MHz, CDCl3)  ppm 156.6, 130.5, 130.3, 127.5 (2C), 126.8, 116.2 (2C), 94.2, 
63.4, 55.9. 
ESI-MS m/z (%) 145 [MH – H2O – MeOH]+ (100), 177 [MH – H2O]+ (17), 217 [MNa]+ (3). 
HR ESI-MS m/z 177.0911 [MH – H2O]+ (calcd. for C11H13O2 177.0910). 
UV max 261 nm. 
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5.1.8.9 (E)-3-(3-Methoxy-4-(methoxymethoxy)phenyl)acrylaldehyde (81)105 
 
The allylic alcohol 88 (5.72 g, 23.5 mmol, 1.0 eq.) was dissolved in 300 ml CH2Cl2 and 
stirred at r.t. in a presence of manganese dioxide (37.5 g, 431 mmol, 18.4 eq.) until 
complete conversion of the starting material. The black slurry was filtered through a pad 
of celite while eluted by CH2Cl2. The solvent was then evaporated and the crude product 
was submitted to flash chromatography (SiO2; n-hexane/EtOAc 3:1, 50 ml/min) affording 
pure aldehyde 81 (3.58 g, 16.1 mmol, 69%) as pale yellow solid. 
1H NMR (300 MHz, CDCl3) δ ppm 9.59 (d, J = 7.7 Hz, 1H), 7.35 (d, J = 15.8 Hz, 1H), 7.18 – 
6.97 (m, 3H), 6.55 (dd, J = 15.8, 7.7 Hz, 1H), 5.21 (s, 2H), 3.85 (s, 3H), 3.44 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ ppm 193.5, 152.6, 149.9, 149.4, 128.3, 127.1, 123.0, 115.7, 
110.5, 95.1, 56.4, 55.9. 
EI-MS m/z (%) 222 [M]+·(23), 192 (6), 161 (7). 
HR EI-MS m/z 222.0889 [M]+· (calcd. for C12H14O4, 222.0892). 
UV λmax 236, 330 nm. 
m.p.: 67-69 °C. 
5.1.8.10 (E)-3-(4-(Methoxymethoxy)phenyl)acrylaldehyde (82)105 
 
The allylic alcohol 89 (4.74 g, 24.4 mmol, 1.0 eq.) was dissolved in 300 ml CH2Cl2 and 
stirred in presence of manganese dioxide (17.5 g, 198 mmol, 8.2 eq.) for 48 h. The resulted 
slurry was filtered through a short SiO2/celite column while eluted with CH2Cl2, 
concentrated in vacuo and purified by flash chromatography (SiO2; n-hexane/EtOAc 4:1) 
yielding pure aldehyde 82 (3.45 g, 17.9 mmol, 73%) as yellow oil. 
1H NMR (300 MHz, CDCl3)  ppm 9.64 (d, J = 7.7 Hz, 1H), 7.50 (d, J = 8.6 Hz, 2H), 7.41 (d, J = 
15.9 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 6.60 (dd, J = 15.9, 7.7 Hz, 1H), 5.21 (s, 2H), 3.47 (s, 
3H). 
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13C NMR (75 MHz, CDCl3)  ppm 193.6, 159.7, 152.5, 130.2 (2C), 127.7, 126.8, 116.5 (2C), 
94.0, 56.2. 
EI-MS m/z (%) 192 [M]+·(21), 131 (5). 
HR EI-MS m/z 192.0788 [M]+· (calcd. for C11H12O3 192.0786). 
UV max 230, 313 nm. 
5.1.8.11 (3E,5E)-6-(3-Methoxy-4-(methoxymethoxy)phenyl)hexa-3,5-dien-2-
one (90)101 
 
The aldehyde 81 (2.10 g, 9.47 mmol, 1.0 eq.) was dissolved in 7.5 ml acetone and 1.2 ml 
H2O and cooled to 0 °C. NaOH solution (aq., 10% w/w, 1.2 ml) was added dropwise and the 
mixture was allowed to warm up to r.t. and stirred overnight. The conversion of the 
reaction was monitored by TLC. After 19 hours, the mixture was neutralized by 1 M HCl, 
H2O was added (50 ml) and the aqueous solution was extracted with EtOAc (3 × 70 ml). 
The combined organic layers were dried with MgSO4 and concentrated under reduced 
pressure. The crude material was purified with CC (SiO2; PE/EtOAc 3:1) yielding 1.71 g 
(6.54 mmol, 69%) of pure 90 as yellow solid. 
1H NMR (400 MHz, CDCl3) δ ppm 7.27 (dd, J = 15.9, 10.3 Hz, 1H), 7.12 (d, J = 8.6 Hz, 1H), 
7.02 – 6.98 (m, 2H), 6.88 (d, J = 15.5 Hz, 1H), 6.76 (dd, J = 15.5, 10.5 Hz, 1H), 6.23 (d, J = 
15.5 Hz, 1H), 5.24 (s, 2H), 3.92 (s, 3H), 3.50 (s, 3H), 2.30 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ ppm 198.5, 150.0, 147.8, 143.8, 141.2, 130.7, 129.9, 125.4, 
121.2, 116.2, 109.9, 95.4, 56.4, 56.1, 27.4. 
ESI-MS m/z (%) 263 [MH]+ (100) 
HR ESI-MS m/z 263.1276 [MH]+ (calcd. for C15H19O4, 263.1278) 
mp: 77 °C 
UV λmax 254, 350 nm. 
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5.1.8.12 (3E,5E)-6-(4-(Methoxymethoxy)phenyl)hexa-3,5-dien-2-one (91)101 
 
To the cooled (0 °C) stirred solution of aldehyde 82 (388 mg, 2.02 mmol, 1.0 eq.) in 
acetone (1.6 ml) and H2O (0.3 ml), 10% aqueous NaOH solution (0.3 ml) was added 
dropwise. The mixture was stirred overnight at r.t. until a complete conversion and 
subsequently neutralized by addition of 1 M HCl aq. (the resulting pH was 6-7). The 
solution was mixed with H2O (10 ml) and extracted with EtOAc (3 × 10 ml). The combined 
organic layers were dried with MgSO4 and concentrated in vacuo. After the purification by 
flash chromatography (RP-18; MeOH/H2O 50 – 100% MeOH gradient over 30 min, then 10 
min 100% MeOH, flow 25-30 ml/min), 333 mg of 91 (1.44 mmol, 71%) was obtained as 
yellow solid (after evaporation of MeOH and lyophilization). 
1H NMR (300 MHz, CDCl3) δ ppm 7.42 (d, J = 8.7 Hz, 1H), 7.28 (dd, J = 15.5, 10.5 Hz, 1H), 
7.03 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 15.6 Hz, 1H), 6.77 (dd, J = 15.5, 10.6 Hz, 1H), 6.23 (d, J = 
15.5 Hz, 1H), 5.20 (s, 2H), 3.48 (s, 3H), 2.31 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ ppm 198.5, 158.1, 143.9, 140.9, 129.8, 129.7, 128.7 (2C), 125.0, 
116.5 (2C), 94.2, 56.1, 27.3. 
ESI-MS m/z (%) 233 [MH]+ (100) 
HR ESI-MS m/z 233.1170 [MH]+ (calcd. for C14H17O3, 233.1172) 
mp: 60 – 62 °C 
UV max 241, 340 nm. 
5.1.8.13 6-(3-Methoxy-4-(methoxymethoxy)phenyl)hexan-2-one (92)106 
 
The unsaturated ketone 90 (1.66 g, 6.34 mmol, 1.0 eq.) was dissolved in 40 ml of CHCl3 
and Pd/C (166 mg, 10% Pd on charcoal) and diphenyl sulfide (53 µl, 59 mg, 0.317 mmol, 
0.05 eq.) were added. The mixture was stirred for 24 h under H2 atmosphere (H2-balloon, 
~1 bar). After the completation of the reaction, Pd/C was filtered off through a pad of 
celite (eluted with EtOAc) and the solvent was removed in vacuo. The crude product was 
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purified by CC (SiO2; PE/EtOAc 2:1) yielding 1.33 g (4.98 mmol, 78%) of 92 as colorless 
oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.04 (d, J = 8.0 Hz, 1H), 6.71 (d, J = 1.8 Hz, 1H), 6.68 (dd, J 
= 8.0, 1.9 Hz, 1H), 5.18 (s, 2H), 3.86 (s, 3H), 3.50 (s, 3H), 2.56 (t, J = 7.1 Hz, 2H), 2.44 (t, J = 
6.8 Hz, 2H), 2.12 (s, 3H), 1.65 – 1.54 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ ppm 209.0, 149.5, 144.4, 136.7, 120.3, 116.5, 112.0, 95.6, 56.1, 
55.77, 43.5, 35.4, 31.0, 29.9, 23.4. 
ESI-MS m/z (%) 235 [MH - CH3OH]+, 284 [MNH4]+ 
HR ESI-MS m/z 266.1505 [M+·] (calcd. for C15H22O4, 266.1513) 
UV λmax 223, 277 nm. 
5.1.8.14 6-(4-(Methoxymethoxy)phenyl)hexan-2-one (93)106 
 
The unsaturated ketone 91 (316 mg, 1.36 mmol) was mixed with 32 mg Pd/C (10% Pd on 
charcoal) and 11 µl diphenyl sulfide (12.7 mg, 11.4 µl, 6.80 µmol, 0.05 eq.) in 8.5 ml CHCl3. 
The slurry was stirred under H2 atmosphere (H2-balloon, ~1 bar) until the completion of 
reaction (5 h). The mixture was subsequently passed through a pad of celite and 
concentrated under reduced pressure. The resulting oil was purified by CC (SiO2; 
PE/EtOAc 5:1) to yield 268 mg (1.14 mmol, 83%) of 93 as colorless oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.07 (d, J = 8.7 Hz, 2H), 6.94 (d, J = 8.7 Hz, 2H), 5.13 (s, 
2H), 3.45 (s, 3H), 2.55 (t, J = 7.1 Hz, 2H), 2.42 (t, J = 6.9 Hz, 2H), 2.10 (s, 3H), 1.68 – 1.49 (m, 
4H). 
13C NMR (75 MHz, CDCl3) δ ppm 208.8, 155.2, 135.4, 129.1 (2C), 116.0 (2C), 94.4, 55.7, 
43.4, 34.7, 30.9, 29.7, 23.2. 
EI-MS m/z (%) 236 [M]+· (19), 151 (8), 121 (31) 
HR EI-MS 236.1414 [M]+· (calcd for C14H20O3, 236.1412) 
UV max 220, 273 nm. 
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5.1.8.15 1,7-Bis(3-methoxy-4-(methoxymethoxy)phenyl)heptan-3-one 
(94)101 
 
Ketone 92 (200 mg, 0.751 mmol, 1.0 eq.) and MOM-protected vanillin 79 (265 mg, 
1.35 mmol, 1.8 eq.) were dissolved in 15 ml EtOH and stirred at r.t. Powdered NaOH 
(75.0 mg, 1.88 mmol, 2.5 eq.) was slowly added and the mixture was stirred at r.t. for 24 h. 
The reaction was stopped by acidification with 1 M HCl aq. (the pH was 3 – 4 afterwards), 
the solvent was removed in vacuo, 10 ml H2O was added and the aqueous solution was 
extracted with CH2Cl2 (2 × 15 ml). The combined organic layers were washed with brine 
(20 ml), dried over MgSO4 and concentrated under reduced pressure. The crude product 
was purified by CC (SiO2; PE/EtOAc 3:1) yielding 193 mg (0.434 mmol, 58%) of the 
diarylheptanoid 93 as yellow oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.46 (d, J = 16.1 Hz, 1H), 7.12 (d, J = 8.8 Hz, 1H), 7.09 – 
7.04 (m, 2H), 7.02 (d, J = 8.1 Hz, 1H), 6.71 (d, J = 1.9 Hz, 1H), 6.67 (dd, J = 8.1, 2.0 Hz, 1H), 
6.60 (d, J = 16.1 Hz, 1H), 5.23 (s, 2H), 5.15 (s, 2H), 3.88 (s, 3H), 3.83 (s, J = 4.5 Hz, 3H), 3.48 
(s, 3H), 3.47 (s, 3H), 2.65 (t, J = 7.0 Hz, 2H), 2.57 (t, J = 7.2 Hz, 2H), 1.78 – 1.57 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ ppm 200.0, 149.6, 149.4, 148.5, 144.3, 142.1, 136.6, 128.6, 
124.6, 122.3, 120.2, 116.4, 115.6, 111.9, 110.2, 95.4, 94.9, 56.1, 55.9, 55.69, 55.6, 40.3, 35.2, 
31.0, 23.8. 
ESI-MS m/z (%) 445 [MH]+ (100) 
HR ESI-MS m/z 445.2224 [MH]+ (calcd. for C25H33O7, 445.2221) 
UV λmax 220, 273 nm. 
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5.1.8.16 1-(3-Methoxy-4-(methoxymethoxy)phenyl)-7-(4-(methoxymethoxy) 
phenyl)heptan-3-one (95)101 
 
Ketone 93 (130 mg, 0.551 mmol, 1.0 eq.) and MOM-protected vanillin 79 (194 mg, 
0.991 mmol, 1.8 eq.) were dissolved in 11 ml EtOH, followed by addition of sodium 
hydroxide (77.0 mg, 1.93 mmol, 3.5 eq.). After stirring at r.t. for 46 h, the reaction was 
stopped by acidification with 1 M HCl aq. to give pH 5. The reaction mixture was mixed 
with 10 ml H2O and extracted with EtOAc (3 × 10 ml). The combined organic layers were 
dried with MgSO4 and concentrated under reduced pressure. Purification of the crude 
product was performed by flash chromatography (RP-18 silica; MeOH/H2O 50 – 100% 
over 30 min, 100% MeOH 10 min; flow 25 ml/min), yielding 121 mg (0.291 mmol, 53%) of 
95 as yellow oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.47 (d, J = 16.1 Hz, 1H), 7.15 (d, J = 8.9 Hz, 1H), 7.12 – 
7.04 (m, 4H), 6.94 (d, J = 8.6 Hz, 2H), 6.61 (d, J = 16.1 Hz, 1H), 5.26 (s, 2H), 5.13 (s, 2H), 
3.91 (s, 3H), 3.50 (s, 3H), 3.46 (s, 3H), 2.66 (t, J = 7.0 Hz, 2H), 2.59 (t, J = 7.2 Hz, 2H), 1.83 – 
1.54 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ 200.3, 155.3, 149.7, 148.6, 142.2, 135.6, 129.2 (2C), 128.7, 
124.7, 122.5, 116.1 (2C), 115.7, 110.3, 95.1, 94.5, 56.3, 55.8, 55.8, 40.4, 34.8, 31.2, 23.9. 
ESI-MS m/z (%) 415 [MH]+ (100) 
HR ESIMS m/z 415.2114 [MH]+ (calcd for C24H31O6, 415.2115) 
UV max 220, 328 nm. 
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5.1.8.17 (E)-7-(3-Methoxy-4-(methoxymethoxy)phenyl)-1-(4-
(methoxymethoxy)phenyl)hept-1-en-3-one (96)101 
 
To the stirred solution of the aldehyde 80 (264 mg, 1.59 mmol, 1.8 eq.) and the ketone 92 
(219 mg, 0.822 mmol, 1.0 eq.) in 16 ml EtOH, 82.0 mg of NaOH (2.06 mmol, 2.5 eq.) was 
added. The yellow to orange solution was stirred for 24 h at room temperature. The 
reaction was stopped by addition of 1 M HCl aq. to give pH 5 and the ethanol was removed 
in vacuo. The residue was diluted by 10 ml of H2O and extracted with CH2Cl2 (3 × 15 ml). 
The combined organic layers were washed with brine (30 ml), dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by CC (SiO2; 
petroleum ether (b.p. 40-60 °C)/EtOAc 2:1) to yield 221 mg (0.534 mmol, 65%) of 96 as 
yellow oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.55 – 7.44 (m, 3H), 7.08 – 7.01 (m, 3H), 6.73 (d, J = 1.8 
Hz, 1H), 6.70 (dd, J = 8.0, 2.0 Hz, 1H), 6.63 (d, J = 16.1 Hz, 1H), 5.21 (s, 2H), 5.19 (s, 2H), 
3.86 (s, 3H), 3.51 (s, 3H), 3.48 (s, 3H), 2.67 (t, J = 7.0 Hz, 2H), 2.60 (t, J = 7.3 Hz, 2H), 1.78 – 
1.64 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ ppm 200.3, 159.1, 149.6, 144.5, 142.0, 136.8, 129.8 (2C), 
128.2, 124.5, 120.4, 116.54, 116.49 (2C), 112.1, 95.7, 94.2, 56.2, 56.1, 55.8, 40.6, 35.5, 31.2, 
24.1. 
ESIMS m/z (%) 415 [MH]+ (100) 
HR ESIMS m/z 415.2122 [MH]+ (calcd. for C24H31O6, 415.2115) 
UV max226, 316 nm. 
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5.1.8.18 (E)-1,7-Bis(4-(methoxymethoxy)phenyl)hept-1-en-3-one (97)101 
 
Ketone 93 (130 mg, 0.551 mmol, 1.0 eq.) and aldehyde 80 (165 mg, 0.991 mmol, 1.8 eq.) 
were dissolved in 11 ml EtOH, followed by the addition of NaOH (77.0 mg, 1.93 mmol, 3.5 
eq.). The slurry was stirred for 52 h at room temperature. The reaction was stopped by 
addition of 1 M HCl aq. (resulting pH 5-6), the mixture was diluted with H2O (10 ml) and 
extracted with EtOAc (3 × 10 ml). The combined organic layers were dried with MgSO4 
and concentrated in vacuo. The crude product was purified by flash chromatography (RP-
18; MeOH/H2O 50 – 100% over 30 min, 100% MeOH 10 min; flow 25 ml/min) to yield 80 
mg (0.208 mmol, 38%) of pure 97 as yellow oil.  
1H NMR (300 MHz, CDCl3) δ ppm 7.49 (m, 3H), 7.10 (d, J = 8.7 Hz, 2H), 7.04 (d, J = 8.8 Hz, 
2H), 6.95 (d, J = 8.7 Hz, 2H), 6.63 (d, J = 16.1 Hz, 1H), 5.20 (s, 2H), 5.14 (s, 2H), 3.47 (s, 3H), 
3.47 (s, 3H), 2.66 (t, J = 7.jjj1 Hz, 2H), 2.60 (t, J = 7.2 Hz, 2H), 1.68 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ ppm 200.2, 159.0, 155.2, 141.9, 135.6, 129.8 (2C), 129.2 (2C), 
128.1, 124.4, 116.4 (2C), 116.1 (2C), 94.5, 94.0, 56.0, 55.8, 40.5, 34.8, 31.1, 23.9. 
ESI-MS m/z (%) 385 [MH]+ (100) 
HR ESI-MS m/z 385.2009 [MH]+ (calcd. for C23H29O5, 385.2010) 
UV λmax 223, 314 nm. 
5.1.8.19 (E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hept-1-en-3-one (98)107 
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Protected diarylheptanoid 94 (63 mg, 0.141 mmol, 1.0 eq.) was dissolved in 7.5 ml MeOH 
and an aqueous 3 M HCl solution was added dropwise (1.46 ml, 4.38 mmol, 31 eq.) at 
room temperature. The mixture was heated to reflux and stirred for 20 min reaching 
complete conversion. The solution was quenched with 30 ml ice cold H2O and extracted 
with CH2Cl2 (3 × 45 ml). The combined organic layers were washed with brine (100 ml) 
and dried over MgSO4. The solvent was removed in vacuo and the crude product was 
purified by preparative TLC (SiO2; PE/EtOAc 2:1) to yield 44.0 mg (0.124 mmol, 88%) of 
98 as yellow oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.46 (d, J = 16.1 Hz, 1H), 7.07 (dd, J = 8.2, 1.8 Hz, 1H), 
7.03 (d, J = 1.8 Hz, 1H), 6.91 (d, J = 8.1 Hz, 1H), 6.81 (d, J = 7.9 Hz, 1H), 6.70 – 6.63 (m, 2H), 
6.58 (d, J = 16.1 Hz, 1H), 6.30 (br s, 1H), 5.68 (br s, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 2.65 (t, J = 
7.1 Hz, 2H), 2.56 (t, J = 7.3 Hz, 2H), 1.81 – 1.54 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ ppm 200.5, 148.2, 146.8, 146.3, 143.5, 142.8, 134.2, 126.9, 
123.9, 123.4, 120.8, 114.8, 114.1, 110.9, 109.4, 55.9, 55.8, 40.4, 35.4, 31.3, 24.1. 
ESI-MS m/z (%) 357 [MH]+ (100) 
HR ESI-MS m/z 357.1697 [MH]+ (calcd. for C25H33O7, 357.1697) 
UV(MeOH) max (log ) 235 (4.96), 338 (5.23) nm. 
5.1.8.20 (E)-1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hept-1-en-
3-one (99)107 
 
Diarylheptanoid 95 (121 mg, 0.291 mmol) was dissolved in 17 ml MeOH, followed by a 
dropwise addition of 3 M aqueous HCl (2.91 ml, 8.73 mmol). The solution was heated to 
reflux for 45 min and subsequently quenched with 100 ml ice-cold H2O. The aqueous 
solution was extracted with EtOAc (2 × 100 ml), the combined organic layers were dried 
with MgSO4 and the solvent was removed in vacuo. The crude yellow oil was purified by CC 
(SiO2; PE/EtOAc 2:1 + 1% MeOH) to yield 64.0 mg (0.196 mmol, 67%) of 99 as yellow 
solid.  
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1H NMR (300 MHz, MeOD) δ ppm 7.56 (d, J = 16.1 Hz, 1H), 7.21 (d, J = 1.8 Hz, 1H), 7.12 (dd, 
J = 8.2, 1.9 Hz, 1H), 7.00 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 8.2 Hz, 1H), 6.72 – 6.61 (m, 3H), 3.90 
(s, 3H), 2.70 (t, J = 6.9 Hz, 2H), 2.55 (t, J = 6.9 Hz, 2H), 1.75 – 1.53 (m, 4H). 
13C NMR (101 MHz, MeOD) δ ppm 203.7, 156.3, 150.9, 149.4, 145.4, 134.4, 130.3 (2C), 
127.9, 124.6, 124.2, 116.6, 116.1 (2C), 112.0, 56.5, 41.2, 35.8, 32.5, 25.4. 
ESI-MS m/z (%) 327 [MH]+ (100) 
HR ESI-MS m/z 327.1592 [MH]+ (calcd for C20H23O24, 327.1591) 
UV(MeOH) max (log ) 228 (5.12), 338 (5.38) nm. 
5.1.8.21 (E)-7-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hept-1-en-
3-one (100)107 
 
Enone 96 (250 mg, 0.604 mmol, 1.0 eq.) was dissolved in 33 ml MeOH, followed by 
dropwise addition of 3 M HCl (6.04 ml, 18.1 mmol, 30 eq.). The solution was stirred under 
reflux for 2 h and subsequently quenched with 200 ml ice H2O. The aqueous solution was 
extracted with EtOAc (2 × 150 ml), the resulting organic layers were combined, dried with 
MgSO4 and concentrated in vacuo. The crude product was purified by CC (SiO2; PE/EtOAc 
2:1), yielding 143 mg (0.438 mmol, 73%) of 100 as yellow oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.50 (d, J = 16.1 Hz, 1H), 7.44 (d, J = 8.7 Hz, 2H), 6.86 (d, J 
= 8.6 Hz, 2H), 6.82 (d, J = 8.6 Hz, 1H), 6.70 – 6.65 (m, 2H), 6.61 (d, J = 16.1 Hz, 1H), 3.86 (s, 
3H), 2.67 (t, J = 7.1 Hz, 2H), 2.58 (t, J = 7.3 Hz, 2H), 1.82 – 1.54 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ 201.0, 158.1, 146.3, 143.5, 142.6, 134.2, 130.2 (2C), 127.1, 
123.8, 120.9, 116.0 (2C), 114.1, 110.9, 55.8, 40.6, 35.4, 31.3, 24.1. 
ESI-MS m/z (%) 327 [MH]+ (100) 
HR ESI-MS m/z 327.1595 [MH]+ (calcd. for C20H22O4, 327.1591) 
UV(MeOH) max (log ) 233 (5.21), 323 (5.48) nm. 
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5.1.8.22 (E)-1,7-Bis(4-hydroxyphenyl)hept-1-en-3-one (101)107 
 
The protected diarylheptanoid 97 (79.5 mg, 0.207 mmol) was dissolved in 11 ml MeOH. 3 
M HCl aq. was added dropwise (2.07 ml, 6.21 mmol) and the solution was heated to reflux. 
The reaction was stopped after 1 h by addition of ice-cold H2O (80 ml) and the aqueous 
solution was extracted with EtOAc (2 × 30 ml). The combined organic layers were dried 
with MgSO4 and concentrated in vacuo. The purification was carried out by CC (SiO2; 
PE/EtOAc + 1% MeOH) to yield 48.0 mg (0.162 mmol, 78%) of 101 as yellow solid. 
1H NMR (300 MHz, MeOD) δ 7.56 ppm (d, J = 16.2 Hz, 1H), 7.49 (d, J = 8.7 Hz, 2H), 7.00 (d, J 
= 8.5 Hz, 2H), 6.81 (d, J = 8.7 Hz, 2H), 6.68 (d, J = 7.7 Hz, 2H), 6.64 (d, J = 15.3 Hz, 1H), 2.69 
(t, J = 6.9 Hz, 2H), 2.55 (t, J = 6.9 Hz, 2H), 1.63 (dd, J = 6.8, 3.3 Hz, 4H). 
13C NMR (101 MHz, MeOD) δ 203.7, 161.5, 156.3, 145.1, 134.4, 131.5 (2C), 130.3 (2C), 
127.3, 124.0, 116.9 (2C), 116.1 (2C), 41.1, 35.8, 32.5, 25.3. 
EI-MS m/z (%) 296 [M]+· (29), 162 (30), 147 (100) 
HR EI-MS m/z 296.1415 [M]+· (calcd for C19H20O3, 296.1412) 
m.p.: 116 °C 
UV(MeOH) max (log ) 229 (5.10), 332 (5.39) nm. 
5.1.8.23 1,7-Bis(4-hydroxy-3-methoxy phenyl)heptan-3-one (102)106 
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Diarylheptanoid 98 (10 mg, 0.028 mmol), dissolved in CHCl3 (0.3 ml), was mixed with 
Pd/C (1.0 mg, 10% Pd on charcoal) and Ph2S (0.23 µl, 1.4 µmol, 0.05 eq.) and stirred at r.t. 
under H2 atmosphere (balloon, ~1 bar) for 16 h. The black slurry was passed through a 
pad of celite (eluted with EtOAc) and the solvent was removed under reduced pressure 
affording 102 (9.5 mg, 0.027 mmol, 96%) as colorless oil. 
1H NMR (400 MHz, CD3OD)  ppm 6.73 (d, J = 1.9 Hz, 1H), 6.70 (d, J = 1.9 Hz, 1H), 6.68 (d, J 
= 8.1 Hz, 2H), 6.58 (dd, J = 9.3, 1.9 Hz, 1H), 6.56 (dd, J = 8.0, 1.8 Hz, 1H), 3.80 (s, 3H), 3.79 
(s, 3H), 2.80 – 2.71 (m, 2H), 2.71 – 2.65 (m, 2H), 2.47 (t, J = 6.9 Hz, 2H), 2.40 (t, J = 6.7 Hz, 
2H), 1.57 – 1.44 (m, 4H) 
13C NMR (100 MHz, CD3OD)  ppm 213.5, 148.8, 148.8, 145.7, 145.4, 135.1, 134.0, 121.7 
(2C), 116.1, 116.0, 113.1, 113.0, 56.3 (2C), 45.4, 43.9, 36.2, 32.3, 30.6, 24.3 
ESI-MS m/z (%) 376 [MNH4]+ (100), 341 [MH – H2O]+ (51) 
HR ESI-MS m/z 341.1751 [MH – H2O]+ (calcd. for C21H24O4 341.1747) 
UV(MeOH) max (log ) 230 (5.01), 281 (4.79) nm. 
5.1.8.24 1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)heptan-3-one 
(103)106 
 
The unsaturated diarylheptanoid 99 (25 mg, 0.077 mmol) was dissolved in 0.4 ml CHCl3. 
Diphenyl sulfide (0.64 µl, 3.8 µmol, 0.05 eq.) and Pd/C (2.5 mg, 10% Pd on charcoal) were 
added and the mixture was stirred for 24 h under H2 atmosphere (balloon, ~1 bar). The 
catalyst residue was removed by filtration through a pad of celite and the solvent was 
removed in vacuo to yield 24.0 mg (0.073 mmol, 95%) of 103 as colorless oil. 
 1H NMR (300 MHz, CDCl3) δ ppm 7.00 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 7.9 Hz, 1H), 6.74 (d, J 
= 8.5 Hz, 2H), 6.70 – 6.61 (m, 2H), 5.49 (s, 1H), 4.89 (s, 1H), 3.85 (s, 3H), 2.87 – 2.76 (m, 
2H), 2.68 (m, 2H), 2.52 (t, J = 7.0 Hz, 2H), 2.39 (t, J = 6.9 Hz, 2H), 1.56 (m, 4H). 
UV(MeOH) max (log ) 226 (5.12), 279 (4.61) nm 
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The NMR data agree with the literature.110 
5.1.8.25 1-(4-Hydroxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)heptan-3-one 
(104)106 
 
The unsaturated diarylheptanoid 100 (93.0 mg, 0.285 mmol), dissolved in 4 ml CHCl3, was 
mixed with 14 mg Pd/C (10% Pd on charcoal) and 3.7 µl Ph2S (0.022 mmol, 0.08 eq.). The 
black slurry was stirred for 15 h at r.t. under H2 atmosphere (balloon, ~1 bar) until 
complete conversion of the starting material. The mixture was then passed through a pad 
of celite (eluted with 30 ml EtOAc) and after the evaporation of the solvent, pure 104 was 
obtained as colorless oil (74.0 mg, 0.225 mmol, 79%).  
1H NMR (300 MHz, CDCl3)  ppm 7.03 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 8.1 Hz, 1H), 6.73 (d, J = 
8.5 Hz, 2H), 6.67 – 6.60 (m, 2H), 5.46 (s, 1H), 4.74 (s, 1H), 3.87 (s, 3H), 2.91 – 2.74 (m, 2H), 
2.66 (t, J = 7.7 Hz, 2H), 2.52 (t, J = 7.1 Hz, 2H), 2.38 (t, J = 6.9 Hz, 2H), 1.72 – 1.45 (m, 4H) 
13C NMR (75 MHz, CDCl3)  ppm 210.9, 154.2, 146.3, 143.5, 134.1, 132.7, 129.3 (2C), 120.8, 
115.3 (2C), 114.1, 110.9, 55.8, 44.5, 42.9, 35.3, 31.2, 28.9, 23.3 
UV(MeOH) max (log ) 229 (5.07), 280 (4.70) nm 
The NMR data are in agreement with the literature.110 
5.1.8.26 1,7-Bis(4-hydroxyphenyl)heptan-3-one (acerogenin G, 8)106 
 
Ketone 101 (20 mg, 0.068 mmol) was dissolved in 0.4 ml CHCl3 and mixed with 0.6 mg 
diphenyl sulfide (3.4 µmol, 0.05 eq.) and 2 mg Pd/C (10% Pd on charcoal). The black 
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slurry was stirred for 5 h at r.t. under H2 atmosphere (balloon, ~1 bar). After completion 
of the reaction, the mixture was filtered through a pad of celite and the solvent was 
removed in vacuo, yielding 8 (16.5 mg, 0.055 mmol, 81%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ ppm 7.01 (d, J = 8.5 Hz, 2H), 6.99 (d, J = 8.6 Hz, 2H), 6.74 (d, J = 
8.5 Hz, 2H), 6.73 (d, J = 8.5 Hz, 2H), 4.76 (s, 2H), 2.81 (t, J = 7.5 Hz, 2H), 2.67 (t, J = 7.7 Hz, 
2H), 2.51 (t, J = 7.0 Hz, 2H), 2.38 (t, J = 7.0 Hz, 2H), 1.62 – 1.46 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ ppm 210.4, 153.5 (2C), 134.4, 133.3, 129.4 (4C), 115.3 (2C), 
115.1 (2C), 44.5, 42.9, 34.8, 31.1, 28.9, 23.3. 
EI-MS m/z (%) 298 [M]+· (10), 133 (21), 107 (100) 
HR EI-MS m/z 298.1565 [M]+· (calcd for C19H22O3, 298.1569) 
UV(MeOH) max (log ) 227 (5.00), 279 (4.54) nm. 
The NMR data is in agreement with previously reported spectra.29 
5.1.8.27 4,4'-(3-Hydroxyheptane-1,7-diyl)bis(2-methoxyphenol) (105)109  
 
 
Diarylheptanoid 102 (20 mg, 0.056 mmol) was dissolved under N2 atmosphere in 0.4 ml 
MeOH and cooled to 0 °C. Sodium borohydride (3.0 mg, 0.084 mmol, 1.5 eq.) was added 
and the mixture was stirred at 0 °C for 2 h until complete conversion of the starting 
material. The solution was then quenched by 10 ml H2O and extracted with EtOAc (3 × 10 
ml). The organic layers were combined, dried with MgSO4 and concentrated under 
reduced pressure. The crude product was purified by preparative HPLC (RP-18; 
MeOH/H2O gradient 50 – 100% MeOH over 20 min, 100% MeOH for 5 min, flow rate 10 
ml/min) to yield 105 (12 mg, 0.033 mmol, 59%) as colorless oil. 
1H NMR (300 MHz, MeOD) δ ppm 6.73 (d, J = 1.8 Hz, 2H), 6.68 (d, J = 8.0, 2H), 6.59 (dd, J = 
7.8, 1.8 Hz, 2H), 3.81 (s, 6H), 3.62 – 3.42 (m, 1H), 2.79 – 2.39 (m, 4H), 1.84 – 1.17 (m, 8H). 
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13C NMR (101 MHz, MeOD) δ ppm 148.8 (2C), 145.5, 145.4, 135.6, 135.3, 121.8 (2C), 116.1, 
116.0, 113.2, 113.2, 71.7, 56.4 (2C), 40.6, 38.2, 36.5, 33.0, 32.6, 26.3. 
ESI-MS m/z (%) 359 [M – H]- (100) 
 
HR ESIMS m/z 359.1860 [M - H]- (calcd for C21H27O5, 359.1864) 
 
UV(MeOH) max (log ) 227 (5.29), 281 (4.97) nm. 
The compound was described before in the literature.166 
5.1.8.28 4-(3-Hydroxy-7-(4-hydroxyphenyl)heptyl)-2-methoxyphenol 
(106)109  
  
Diarylheptanoid 103 (12 mg, 0.037 mmol) was dissolved in 0.2 ml MeOH. The solution 
was cooled to 0 °C and sodium borohydride (2.0 mg, 0.052 mmol, 1.4 eq.) was added. The 
reaction was quenched with H2O (10 ml) after 20 min. The aqueous solution was extracted 
with EtOAc (3 × 10 ml), the organic layers were combined and dried with MgSO4. The 
solvent was removed in vacuo and the crude colorless oil was purified by preparative 
HPLC (RP-18; MeOH/H2O gradient 50 – 100% MeOH over 30 min, 100% MeOH for 5 min, 
100 – 50% over 2 min, flow rate 10 ml/min), yielding 9.0 mg (0.027 mmol, 74%) of 106 as 
colorless oil. 
1H NMR (300 MHz, MeOD) δ ppm 6.97 (d, J = 8.5 Hz, 2H), 6.75 (d, J = 1.8 Hz, 1H), 6.72 – 
6.57 (m, 4H), 3.82 (s, 3H), 3.62 – 3.44 (m, 1H), 2.78 – 2.41 (m, 4H), 1.89 – 1.22 (m, 8H). 
13C NMR (101 MHz, MeOD) δ ppm 156.3, 148.8, 145.4, 135.4, 134.8, 130.3 (2C), 121.8, 
116.1, 116.0 (2C), 113.2, 71.7, 56.4, 40.6, 38.2, 36.0, 33.0, 32.6, 26.3. 
UV(MeOH) max (log ) 225 (5.45), 280 (4.98) nm 
The NMR data correspond to the literature.110 
 Experimental part  
114 
 
5.1.8.29 4-(5-Hydroxy-7-(4-hydroxyphenyl)heptyl)-2-methoxyphenol 
(107)109 
 
Compound 104 (11 mg, 0.033 mmol, 1.0 eq.) was dissolved in 0.4 ml MeOH and cooled to 
0 °C. Sodium borohydride (1.9 mg, 0.050 mmol, 1.5 eq.) was added and the solution was 
stirred at 0 °C until complete conversion (30 min). The reaction was quenched with 10 ml 
H2O and extracted with EtOAc (3 × 10 ml). The combined organic layers were dried with 
MgSO4 and the solvent was removed in vacuo. The crude product was purified by 
preparative HPLC (RP-18; MeOH/H2O gradient 50 – 100% MeOH over 20 min, 100% 
MeOH for 5 min, 100 – 50% over 2 min, flow rate 10 ml/min). Alcohol 107 (10.7 mg, 0.032 
mmol, 98%) was obtained as colorless oil. 
1H NMR (300 MHz, MeOD) δ ppm 6.98 (d, J = 8.4 Hz, 2H), 6.75 – 6.62 (m, 4H), 6.58 (dd, J = 
8.0, 1.8 Hz, 1H), 3.81 (s, 3H), 3.50 (m, 1H), 2.76 – 2.57 (m, 1H), 2.57 – 2.38 (m, 1H), 2.51 (t, 
J = 7.4 Hz, 2H), 1.82 – 1.20 (m, 8H). 
UV(MeOH) max (log ) 228 (5.05), 280 (4.73) nm. 
The NMR data agree with the literature.110 
5.1.8.30 4,4'-(3-Hydroxyheptane-1,7-diyl)diphenol ((±)-centrolobol, 25)109 
 
Ketone 8 (8.0 mg, 0.027 mmol, 1.0 eq.) was dissolved in 0.2 ml MeOH in and cooled to 0 °C. 
Sodium borohydride (1.4 mg, 0.037 mmol, 1.4 eq.) was added and the solution was stirred 
for 50 min at 0 °C. Subsequently, the reaction was stopped by addition of H2O (8 ml) and 
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the aqueous solution was extracted with EtOAc (3 × 10 ml). The combined organic layers 
were dried with MgSO4 and the solvent was removed in vacuo. The crude brown oil was 
purfied by preparative HPLC (RP-18; MeOH/H2O gradient 50 – 100% MeOH over 30 min, 
100% MeOH for 5 min, 100 – 50% over 2 min, flow rate 10 ml/min) to yield 7.3 mg of 25 
as colorless oil (0.024 mmol, 90%). 
1H NMR (300 MHz, MeOD) δ ppm 6.99 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 8.4 Hz, 2H), 6.68 (d, J 
= 8.5 Hz, 2H), 6.67 (d, J = 8.5 Hz, 2H), 3.56 – 3.45 (m, 1H), 2.74 – 2.39 (m, 4H), 1.77 – 1.21 
(m, 8H). 
UV(MeOH) max (log ) 228 (4.99), 280 (4.70) nm 
NMR data agree with the literature.111 
5.1.8.31 1,7-Bis(3,4-dimethoxyphenyl)heptan-3-one (108)116 
 
Diarylheptanoid 102 (22 mg, 0.061 mmol, 1.0 eq.) was dissolved in 0.3 ml acetone. 
Dimethyl sulfate (23 µl, 0.25 mmol, 4.0 eq) and K2CO3 (37 mg, 0.27 mmol, 4.4 eq) were 
added and the mixture was stirred for 5 h under reflux. The reaction was stopped by 
addition of H2O (10 ml), followed by extraction with EtOAc (3 × 15 ml). The combined 
organic layers were dried with MgSO4 and concentrated in vacuo to yield pure 108 (17 mg, 
0.044 mmol, 72%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ ppm 6.81 – 6.74 (m, 2H), 6.73 – 6.65 (m, 4H), 3.86 (s, 3H), 
3.85 (s, 3H), 3.85 (s, 3H), 3.84 (s, 3H), 2.83 (t, J = 7.5 Hz, 2H), 2.69 (t, J = 7.4 Hz, 2H), 2.54 (t, 
J = 7.2 Hz, 2H), 2.40 (t, J = 6.9 Hz, 2H), 1.65 – 1.52 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 210.2, 148.82, 148.75, 147.3, 147.1, 134.8, 133.7, 120.1, 
120.0, 111.7 (2C), 111.24, 111.15, 55.9 (2C), 55.8 (2C), 44.5, 42.9, 35.3, 31.1, 29.4, 23.3. 
ESI-MS m/z (%) 387 [MH]+ (87) 
HR ESI-MS m/z 387.2170 [MH]+ (calcd. for C23H31O5 387.2166) 
UV(MeOH) max (log ) 230 (5.05), 281 (4.82) nm. 
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5.1.8.32 (E)-1,7-Bis(3,4-dihydroxyphenyl)hept-1-en-3-one (109)117 
 
Diarylheptanoid 98 (38.0 mg, 0.107 mmol, 1.0 eq.) was dissolved in dry CH2Cl2 (1.5 ml) 
under nitrogen and cooled to -78 °C. Boron tribromide (632 µl of 1 M CH2Cl2 solution, 
0.632 mmol, 6.0 eq.) was added and the mixture was stirred at -78 °C. The cooling bath 
was removed after 75 min and the reaction was continued for 15 min at r.t. The reaction 
mixture was then poured into saturated sodium bicarbonate solution (30 ml) and 
extracted with EtOAc (3 × 30 ml). The combined organic layers were washed with H2O (2 
× 40 ml) and dried with MgSO4. The crude product was purified by CC (SiO2; PE/EtOAc 1:2 
+ 0.1% TFA) to yield 27 mg (0.082 mmol, 77%) of 109 as brown oil. 
1H NMR (400 MHz, MeOD) δ ppm 7.48 (d, J = 16.1 Hz, 1H), 7.07 (d, J = 2.0 Hz, 1H), 6.98 (dd, 
J = 8.2, 2.0 Hz, 1H), 6.79 (d, J = 8.2 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 6.62 (d, J = 2.0 Hz, 1H), 
6.60 – 6.54 (d, J = 16.1 Hz, 1H), 6.49 (dd, J = 8.0, 2.0 Hz, 1H), 2.67 (t, J = 7.0 Hz, 2H), 2.49 (t, J 
= 7.0 Hz, 2H), 1.69 – 1.53 (m, 4H). 
13C NMR (101 MHz, MeOD)  ppm 203.7, 149.9, 146.8, 146.1, 145.5, 144.2, 135.2, 127.8, 
123.9, 123.5, 120.7, 116.6, 116.5, 116.2, 115.3, 41.0, 36.0, 32.4, 25.4 
ESI-MS m/z (%) 329 [MH]+ (100) 
HR ESI-MS m/z 329.1386 [MH]+ (calcd. for C19H21O5, 329.1384) 
UV(MeOH) max (log ) 342 (5.08) nm. 
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5.1.8.33 (1E,6E)-1,7-Bis(3,4-dihydroxyphenyl)hepta-1,6-diene-3,5-dione 
(110)117 
 
Curcumin (1) (143 mg, 0.388 mmol), dissolved under N2 atmosphere in 5.8 ml CH2Cl2, was 
cooled to -78 °C and boron tribromide (2.33 ml of a 1 M sol. in CH2Cl2, 2.33 mmol, 6.0 eq.) 
was slowly added. The mixture was stirred for 2 h at -78 °C and further 16 h at r.t., 
followed by an aqueous work-up (40 ml sat. Na2CO3 aq.). After separation of the CH2Cl2 
layer, the aqueous solution was acidified with 1 M HCl aq. (pH 5) and extracted with EtOAc 
(2 × 50 ml). The CH2Cl2 and EtOAc layers were combined, dried with MgSO4 and 
concentrated in vacuo. The crude mixture was passed through a short SiO2 column (eluted 
with CH2Cl2/MeOH 4:1) and subsequently purified by semi-preparative HPLC (method 1, 
5.1.2) affording 13.9 mg (0.041 mmol, 11%) of 110 as orange solid. 
1H NMR (300 MHz, MeOD) δ ppm 7.51 (d, J = 15.8 Hz, 2H), 7.07 (d, J = 1.9 Hz, 2H), 6.99 (dd, 
J = 8.2, 1.9 Hz, 2H), 6.79 (d, J = 8.1 Hz, 2H), 6.53 (d, J = 15.8 Hz, 2H), 5.93 (s, 1H) 
ESI-MS m/z 341 [MH]+ (100).  
NMR data agree with the literature.117 
5.1.8.34 (E)-4-(3-Methoxy-4-(methoxymethoxy)phenyl)but-3-en-2-one 
(111)103 
 
MOM-protected vanillin 79 (100 mg, 0.510 mmol), dissolved in 4 ml THF, was mixed with 
1-(triphenylphosphoraneylidene)-2-propanone (186 mg, 0.585 mmol, 1.15 eq.) and 
stirred under reflux for 22 h. The reaction was then stopped and the solvent was removed 
under reduced pressure, followed by CC (SiO2; PE/EtOAc 3:1) to afford 50.0 mg 
(0.212 mmol, 42%) of 111 as white solid. 
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1H NMR (400 MHz, CDCl3) δ ppm 7.44 (d, J = 16.2 Hz, 1H), 7.14 (d, J = 8.9 Hz, 1H), 7.10 – 
7.05 (m, 2H), 6.60 (d, J = 16.2 Hz, 1H), 5.25 (s, 2H), 3.90 (s, 3H), 3.50 (s, 3H), 2.35 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ ppm 198.3, 149.8, 148.7, 143.3, 128.6, 125.7, 122.6, 115.7, 
110.2, 95.1, 56.3, 55.9, 27.3. 
m.p.: 71 °C 
APCI-MS m/z (%) 237 [MH]+ (100). 
HR APCI-MS m/z 237.1126 [MH]+ (calcd. for C13H17O4 237.1121). 
UV λmax 236, 328 nm. 
The compound has been described before in the literature.23 
5.1.8.35 (E)-4-(4-(Methoxymethoxy)phenyl)but-3-en-2-one (112)103 
 
4-(Methoxymethoxy)benzaldehyde 80 (100 mg, 0.602 mmol, 1.0 eq.) was dissolved in 4 
ml THF, followed by addition of 1-(triphenylphosphoraneylidene)-2-propanone (249 mg, 
0.808 mmol, 1.3 eq.). The mixture was stirred at 75 °C for 20 h, then the solvent was 
removed under reduced pressure and the residue purified by CC (SiO2; PE/EtOAc 3:1) 
affording 87.0 mg (0.422 mmol, 70%) of 112 as colorless oil. 
1H NMR (400 MHz, CDCl3) δ ppm 7.50 – 7.40 (m, 2H), 7.02 (d, J = 8.7 Hz, 1H), 6.58 (d, J = 
16.2 Hz, 1H), 5.17 (s, 2H), 3.44 (s, 3H), 2.32 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ ppm 198.2, 159.0, 142.9, 129.7 (2C), 127.9, 125.28, 116.4 
(2C), 94.0, 56.0, 27.2. 
APCI-MS m/z (%) 207 [MH]+ (100). 
HR APCI-MS m/z 207.1020 [MH]+ (calcd. for C12H15O3 207.1016). 
UV max 228, 313 nm. 
5.1.8.36 (E)-4-(4-Hydroxy-3-methoxyphenyl)but-3-en-2-one (113)107 
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Ketone 111 (50.0 mg, 0.212 mmol) was dissolved in MeOH and 3 M HCl aq. (1.06 ml, 3.18 
mmol, 15 eq.) was dropwise added. The solution was stirred under reflux for 90 min, 
subsequently quenched by ice-cold H2O (17 ml) and extracted with EtOAc (3 × 20 ml). The 
organic layers were combined, dried with MgSO4 and after evaporating the solvent, the 
residue was purified by CC (SiO2; petroleum ether/EtOAc 2:1) yielding 113 (21.0 mg, 
0.109 mmol, 52%) as yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 16.1 Hz, 1H), 7.07 (m, 2H), 6.93 (d, J = 8.1 Hz, 1H), 
6.58 (d, J =16.1 Hz, 1H), 3.93(s, 3H), 2.36(s, 3H). 
13C NMR (101 MHz, CDCl3) δ ppm 198.4, 148.3, 146.9, 143.7, 126.8, 124.9, 123.5, 114.8, 
109.3, 56.0, 27.3. 
NMR data agree with the literature.167 
5.1.8.37 (E)-4-(4-Hydroxyphenyl)but-3-en-2-one (114)107 
 
Ketone 112 (87.0 mg, 0.422 mmol) was dissolved in 22.5 ml MeOH, followed by the 
addition of 3 M HCl aq. (2.11 ml, 6.33 mmol). The mixture was stirred under reflux for 2 h, 
then H2O (20 ml) was added and the aqueous solution was extracted with EtOAc (3 × 50 
ml). The organic layers were dried with MgSO4 and the solvent was removed under 
reduced pressure. The crude product was purified by CC (SiO2; PE/EtOAc 2:1) yielding 
59.6 mg (0.368, 87%) of 114 (yellow oil). 
1H NMR (400 MHz, CDCl3)  ppm 7.52 (d, J = 16.0 Hz, 1H), 7.43 (d, J = 8.7 Hz, 2H), 6.92 (d, J 
= 8.7 Hz, 2H), 6.60 (d, J = 16.0 Hz, 1H), 2.39 (s, 3H) 
13C NMR (101 MHz, CDCl3)  ppm 200.5, 159.3, 145.2, 130.5 (2C), 126.1, 124.0, 116.2 (2C), 
27.2. 
The NMR spectra match the data published in the literature.168 
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5.1.8.38 (E)-1,7-Bis(3-methoxy-4-(methoxymethoxy)phenyl)hept-1-en-3-ol 
(121) 
 
Diarylheptanoid 94 (160 mg, 0.360 mmol) was dissolved in 3 ml MeOH and cooled to 0 °C. 
Sodium borohydride (18.0 mg, 0.468 mmol, 1.3 eq.) was added in one portion and the 
mixture was stirred at 0 °C until complete conversion of the starting material. The reaction 
was stopped after 20 min by addition of H2O (20 ml). The aqueous solution was extracted 
with EtOAc (3 × 25 ml), the combined organic layers were dried (MgSO4) and after the 
evaporation of the solvent, pure product 121 (160 mg, 359 mmol, 99%) was obtained as 
colorless oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.06 (d, J = 8.3 Hz, 1H), 7.01 (d, J = 8.1 Hz, 1H), 6.91 (d, J = 
1.9 Hz, 1H), 6.86 (dd, J = 8.3, 1.9 Hz, 1H), 6.70 – 6.62 (m, 2H), 6.46 (d, J = 15.8 Hz, 1H), 6.07 
(dd, J = 15.8, 6.9 Hz, 1H), 5.19 (s, 2H), 5.15 (s, 2H), 4.22 (q, J = 6.3 Hz, 1H), 3.86 (s, 3H), 3.82 
(s, 3H), 3.48 (s, 6H), 2.58 – 2.50 (m, 2H), 1.69 – 1.54 (m, 4H), 1.54 – 1.35 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ ppm 149.6, 149.4, 146.0, 144.2, 137.0, 131.3 (CH), 131.1, 129.7 
(CH), 120.2 (CH), 119.4 (CH), 116.5 (CH), 116.2 (CH), 112.0 (CH), 109.2 (CH), 95.5 (CH2), 
95.3 (CH2), 72.8 (CH), 56.0 (CH3), 55.9 (CH3), 55.7 (CH3), 55.6 (CH3), 37.1 (CH2), 35.4 (CH2), 
31.4 (CH2), 25.0 (CH2). 
ESI-MS m/z (%) 469 [MNa]+ (100). 
HR ESI-MS m/z 469.2199 [MNa]+ (calcd. for C25H34NaO7 469.2197). 
UV λmax 274 nm. 
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5.1.8.39 (E)-7-(3-methoxy-4-(methoxymethoxy)phenyl)-1-(4-
(methoxymethoxy) phenyl)hept-1-en-3-ol (123) 
  
To a stirred, cooled (0 °C) solution of diarylheptanoid 96 (123 mg, 0.297 mmol) in 2.5 ml 
MeOH, sodium borohydride (15.0 mg, 0.386 mmol, 1.3 eq.) was added in one portion. The 
reaction was stopped after 20 min by addition of H2O (20 ml) and the resulting aqueous 
solution was extracted with EtOAc (3 × 25 ml). The organic layers were dried with MgSO4 
and concentrated in vacuo to yield pure 123 (91.0 mg, 0.219 mmol, 74%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ ppm 7.30 (d, J = 8.7 Hz, 2H), 7.04 (d, J = 8.1 Hz, 1H), 6.99 (d, J = 
8.7 Hz, 2H), 6.72 (d, J = 1.9 Hz, 1H), 6.69 (dd, J = 8.1, 2.0 Hz, 1H), 6.50 (d, J = 15.9 Hz, 1H), 
6.09 (dd, J = 15.9, 7.0 Hz, 1H), 5.19 (s, 2H), 5.17 (s, 2H), 4.33 – 4.18 (m, 1H), 3.85 (s, 3H), 
3.51 (s, 3H), 3.47 (s, 3H), 2.60 – 2.54 (m, 2H), 1.71 – 1.57 (m, 4H), 1.53 – 1.37 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ ppm 156.8, 149.6, 144.4, 137.1, 130.8, 130.6, 129.7, 127.5, 
120.3, 116.6, 116.3, 112.1, 95.6, 94.3, 73.0, 56.0, 55.9, 55.8, 37.2, 35.5, 31.5, 25.1. 
ESI-MS m/z (%) 439 [MNa]+ (30), 399 [MH – H2O]+ (35). 
HR ESI-MS m/z 439.2093 [MNa]+ (calcd. for C24H32NaO6 439.2091). 
UV λmax 260 nm. 
5.1.8.40 (E)-9-(4-Hydroxy-3-methoxystyryl)-3-methoxy-6,7,8,9-tetrahydro-
5H-benzo[7]annulen-2-ol (115) 
 
 Experimental part  
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MOM-protected allylic alcohol 121 (82.0 mg, 0.184 mmol) was dissolved in 12 ml MeOH. 3 
M HCl aq. (1.84 ml, 5.52 mmol, 30 eq.) was slowly added and the mixture was heated to 75 
°C. After 2 h, the reaction was stopped by the addition of ice-cold H2O (30 ml), followed by 
an extraction with EtOAc (3 × 40 ml). The combined organic layers were dried with MgSO4, 
the solvent was removed on a rotary evaporator and the crude mixture was submitted to a 
purification by preparative HPLC (RP-18; MeOH/H2O 50-100%, 37 min, 10 ml/min) 
affording 115 (21.0 mg, 0.062 mmol, 34%) as orange solid 
m.p.: 80 – 82 °C. 
1H NMR (600 MHz, MeOD) δ ppm 6.96 (d, J = 1.7 Hz, 1H), 6.81 (dd, J = 8.1, 1.8 Hz, 1H), 6.72 
(d, J = 8.1 Hz, 1H), 6.69 (s, 1H), 6.65 (s, 1H), 6.35 (dd, J = 15.9, 6.7 Hz, 1H), 6.13 (d, J = 15.9 
Hz, 1H), 3.86 (s, J = 5.8 Hz, 3H), 3.82 (s, J = 5.2 Hz, 3H), 3.64 – 3.58 (m, 1H), 2.86 – 2.68 (m, 
2H), 1.98 – 1.75 (m, 4H), 1.69 – 1.54 (m, 2H).  
13C NMR (151 MHz, MeOD) δ ppm 149.1, 147.0, 146.5, 144.9, 138.4, 135.3, 131.8, 131.5, 
130.7, 120.3, 117.3, 116.2, 115.2, 110.3, 56.6, 56.4, 36.8, 35.5, 31.6, 29.7, 26.3. 
ESI-MS m/z (%) 341 [MH]+ (100), 340 [M]+· (71), 363 [MNa]+ (16). 
HR ESI-MS m/z 341.1745 [MH]+ (calcd. for C21H25O4 341.1747). 
UV λmax 280 nm. 
5.1.8.41 (E)-9-(4-Hydroxystyryl)-3-methoxy-6,7,8,9-tetrahydro-5H-benzo 
[7]annulen-2-ol (116) 
 
Diarylheptanoid 123 (91.0 mg, 0.219 mmol) was dissolved in 15 ml MeOH, mixed with 3 
M HCl aq. (2.19 ml, 6.57 mmol, 30 eq.) and stirred under reflux for 1 h. When the reaction 
was finished, H2O (30 ml) was added and the resulting aqueous solution was extracted 
with EtOAc (3 × 40 ml). The organic layers were combined, dried with MgSO4 and 
concentrated under reduced pressure. The crude product was purified by CC (SiO2; 
PE/EtOAc 2:1) yielding 24 mg (0.077 mmol, 35%) of 116 as colorless oil. 
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1H NMR (600 MHz, MeOD) δ ppm 7.21 (d, J = 8.6 Hz, 2H), 6.71 (d, J = 8.6 Hz, 2H), 6.69 (s, 
1H), 6.65 (s, 1H), 6.33 (dd, J = 15.9, 6.7 Hz, 1H), 6.13 (d, J = 15.9 Hz, 1H), 3.82 (s, 3H), 3.60 
(t, J = 6.0 Hz, 1H), 2.84 – 2.69 (m, 2H), 1.93 – 1.78 (m, 2H), 1.86 (m, 2H), 1.62 (s, 2H). 
13C NMR (151 MHz, MeOD) δ ppm 157.7, 146.5, 144.9, 137.8, 135.3, 131.5, 130.9, 130.4, 
128.2 (2C), 117.2, 116.3 (2C), 115.2, 56.6, 49.0, 36.8, 35.5, 30.7, 29.7. 
ESI-MS m/z (%) 311 [MH]+ (100), 333 [MNa]+ (45). 
HR ESI-MS m/z 311.1639 [MH]+ (calcd. for C20H23O3 311.1642). 
5.1.8.42 4-Hydroxy-3-iodo-5-methoxybenzaldehyde (174)137 
 
Boric acid (2.00 g, 32.9 mmol, 5.0 eq.) was dissolved in 100 ml H2O and alkalized with 1 M 
NaOH (aq.) till pH > 8.5. Potassium iodide (3.27 g, 19.7 mmol, 3.0 eq.), iodine (5.00 g, 19.7 
mmol, 3.0 eq.) and vanillin (33) (1.00 g, 6.57 mmol, 1.0 eq.) were added and stirred for 17 
h at r.t. The mixture was then acidified with 2 M H2SO4 (pH ~ 2-3) and extracted with 
EtOAc (2 × 100 ml). The combined organic layers were washed with 5% aqueous Na2S2O3 
solution (3 × 100 ml) until the organic solution turned to pale yellow and additionally 
washed with brine (100 ml). The organic fraction was dried with MgSO4 and concentrated 
in vacuo, affording pure 5-iodovanillin 174 (1.59 g, 5.72 mmol, 87%) as yellowish solid. 
m.p.: 180-183 °C 
1H NMR (300 MHz, CDCl3) δ ppm 9.77 (s, 1H), 7.82 (d, J = 1.7 Hz, 1H), 7.38 (d, J = 1.7 Hz, 
1H), 6.68 (s, 1H), 3.97 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ ppm 189.5, 151.4, 146.5, 136.2, 131.1, 108.6, 80.5, 56.5. 
EI-MS m/z (%) 278 [MH]+ (100). 
NMR spectroscopic data are in accordance with the literature.169 
5.1.8.43 4-Hydroxy-3-iodobenzaldehyde (181)148 
 
4-Hydroxybenzaldehyde (78) (154 mg, 1.26 mmol, 1.0 eq.) was stirred in CH2Cl2 (2.5 ml) 
while ICl (72.7 µl, 1.39 mmol, 1.1 eq.), mixed with HOAc (0.13 ml), was slowly added. The 
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reaction was quenched after 20 h with 20 ml H2O and the aqueous layer was extracted 
with CH2Cl2 (2 × 25 ml). The yellow organic phases were combined and washed with an 
aqueous solution of Na2S2O3 (5%w/v, 40 ml), whilst turning to a colorless solution. This 
mixture was then dried (MgSO4) and evaporated. The crude product was purified by CC 
(SiO2; CH2Cl2/MeOH 80:1) to yield 181 (147 mg, 0.593 mmol, 47%) as white solid. 
1H NMR (300 MHz, CDCl3) δ ppm 9.80 (s, 1H), 8.23 (d, J = 1.9 Hz, 1H), 7.79 (dd, J = 8.4, 1.9 
Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H). 
The 1H NMR spectrum is in accordance with previously reported data.170 
5.1.8.44 3-Iodo-4-(methoxymethoxy)benzaldehyde (171) 
 
3-Iodo-4-hydroxybenzaldehyde 181 (320 mg, 1.29 mmol, 1.0 eq.) was dissolved in 4 ml 
CH2Cl2 and the solution was cooled to 0 °C. Subsequently, DIPEA (266 mg, 361 µl, 2.06 
mmol, 1.6 eq.) was slowly added, followed by MOMCl (135 mg, 127 µl, 1.68 mmol, 1.3 eq.). 
The reaction was allowed to warm up to the ambient temperature and proceed until 
complete conversion (6.5 h). A saturated aqueous solution of NH4Cl (10 ml) was used to 
quench the reaction and the aqueous solution was extracted with CH2Cl2 (2 × 15 ml). After 
drying with MgSO4 and removal of the solvent, the pure product 171 was obtained as 
colorless oil (375 mg, 1.29 mmol, quantitative yield). 
1H NMR (300 MHz, CDCl3) δ ppm 9.83 (s, 1H), 8.31 (d, J = 2.0 Hz, 1H), 7.82 (dd, J = 8.5, 2.0 
Hz, 1H), 7.17 (d, J = 8.5 Hz, 1H), 5.34 (s, J = 3.5 Hz, 2H), 3.52 (s, J = 3.1 Hz, 3H). 
The obtained 1H NMR spectrum agrees with the literature.171 
5.1.8.45 3-Iodo-5-methoxy-4-(methoxymethoxy)benzaldehyde (170) 
 
5-Iodovanillin 174 (3.63 g, 13.1 mmol, 1.0 eq.) was stirred in 20 ml CH2Cl2 at 0 °C, while 
DIPEA (3.67 mmol, 21.0 mmol, 1.6 eq.) was dropwise added, followed by a slow addition 
of MOMCl (1.12 g, 14.8 mmol, 1.3 eq.). The mixture was stirred for 2 h at 0 °C, then the ice 
bath was removed and the reaction was continued at r.t. for 1 h. The reaction mixture was 
quenched with sat. aq. NH4Cl solution (30 ml), the layers were separated and the aqueous 
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phase was extracted with CH2Cl2 (2 × 30 ml). The combined organic layers were dried 
(MgSO4) and concentrated in vacuo, before being submitted to a purification by CC (SiO2; 
PE/EtOAc 3:1). The product 170 was obtained as a white solid in 94% yield (3.97 g, 12.3 
mmol). 
1H NMR (400 MHz, CDCl3) δ ppm 9.82 (s, 1H), 7.86 (d, J = 1.8 Hz, 1H), 7.40 (d, J = 1.8 Hz, 
1H), 5.29 (s, 2H), 3.90 (s, 3H), 3.65 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ ppm 189.6, 152.4, 151.2, 135.1, 133.8, 111.1, 98.8, 92.1, 58.5, 
56.1. 
EI-MS m/z (%) 322 [MH]+ (100). 
m.p.: 87 – 88 °C. 
UV λmax 225, 280 nm. 
NMR data are in agreement with the literature.172 
5.1.8.46 (E)-3-(3-Iodo-5-methoxy-4-(methoxymethoxy)phenyl)acrylic acid 
(176) 
 
The MOM-protected 5-iodovanillin 170 (8.19 g, 25.4 mmol), dissolved in 38 ml pyridine, 
was mixed with malonic acid (3.67 g, 38.1 mmol, 1.5 eq.) and piperidine (433 g, 0.503 ml, 
5.09 mmol, 0.2 eq.) and stirred under reflux (90 °C) for 1 h. The reaction was then 
quenched with saturated aqueous solution of NH4Cl (100 ml) and extracted with EtOAc (3 
× 100 ml). The organic layers were dried with MgSO4, concentrated under reduced 
pressure and purified by flash chromatography (RP-18; MeOH/H2O gradient, 50 - 100% 
MeOH for 20 min, 100% MeOH for 5 min) and CC (SiO2; PE/EtOAc 3:1), respectively. MOM-
protected 5-iodo-ferulic acid 176 (3.68 g, 10.1 mmol, 40%) was obtained as white solid. 
1H NMR (300 MHz, MeOD) δ ppm 7.60 (d, J = 1.9 Hz, 1H), 7.54 (d, J = 16.0 Hz, 1H), 7.27 (d, J 
= 1.9 Hz, 1H), 6.44 (d, J = 15.9 Hz, 1H), 5.17 (s, 2H), 3.88 (s, 3H), 3.63 (s, 3H). 
13C NMR (75 MHz, MeOD) δ ppm 170.2, 153.6, 149.0, 144.4, 134.0, 132.4, 119.8, 113.0, 
99.9, 93.3, 58.8, 56.6. 
EI-MS m/z (%) 364 [MH]+ (67), 332 [MH - MeOH]+ (100). 
HR EI-MS m/z 362.9743 [MH]- (calc. for C12H12IO5 362.9735). 
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mp: 144 - 145 °C. 
UV λmax 232, 287 nm. 
5.1.8.47 (E)-Ethyl 3-(3-iodo-5-methoxy-4-(methoxymethoxy)phenyl) 
acrylate (171)147 
 
5-Iodo-ferulic acid 176 (225 mg, 0.618 mmol) was stirred in 1.2 ml CH2Cl2, while DMAP 
(8.0 mg, 0.062 mmol, 0.10 eq.) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimid-
hydrochloride (EDC·HCl, 125 mg, 0.649 mmol, 1.05 eq.) were added. The resulting orange 
solution was then mixed with EtOH (360 µl, 6.18 mmol, 10.0 eq.) and the reaction 
proceeded to complete conversion within 21 h. After removing the solvent in vacuo, the 
residue was mixed with H2O (20 ml) and extracted with EtOAc (3 × 30 ml). The combined 
organic layers were washed with saturated aqueous solution of NH4Cl (80 ml), saturated 
aqueous solution of Na2CO3 (80 ml) and brine (80 ml), concentrated under reduced 
pressure and purified by CC (SiO2; n-hexane/EtOAc 4:1) to afford 177 as white solid (212 
mg, 0.515 mmol) in 83% yield. 
1H NMR (300 MHz, CDCl3) δ ppm 7.55 (m, 1H), 7.52 (d, J = 15.8 Hz, 1H), 7.01 (d, J = 1.8 Hz, 
1H), 6.33 (d, J = 16.0 Hz, 1H), 5.20 (s, 2H), 4.25 (q, J = 7.1 Hz, 2H), 3.85 (s, 3H), 3.66 (s, 3H), 
1.32 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ ppm 166.6, 152.0, 147.5, 142.5, 132.3, 131.2, 118.4, 111.5, 
98.7, 92.8, 60.6), 58.5, 55.9, 14.3. 
EI-MS m/z (%) 393 [MH]+ (100). 
HR EI-MS m/z 393.0195 [MH]+ (calcd. for C14H18IO5 393.0193). 
m.p.: 73-74 °C. 
UV λmax 235, 296 nm. 
5.1.8.48 (E)-3-(3-Iodo-5-methoxy-4-(methoxymethoxy)phenyl)prop-2-en-1-
ol (178)147 
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Ester 177 (147 mg, 0.375 mmol) was dissolved in 0.8 ml dry CH2Cl2 and cooled to -78 °C, 
followed by a dropwise addition of DIBAl-H solution (1 M DIBAl-H in CH2Cl2, 787 µl, 0.787 
mmol, 2.1 eq.). A TLC control showed a complete conversion after 10 min. The reaction 
was quenched after 20 min with 10% NaOH (aq.) at -78 °C and subsequently allowed to 
warm to r.t. The mixture was divided between H2O (10 ml) and CH2Cl2 (10 ml), the layers 
were separated and the aq. phase was repeatedly extracted with CH2Cl2 (3 × 10 ml). The 
combined organic layers were washed with brine (30 ml), dried with MgSO4 and 
concentrated under reduced pressure, yielding pure allylic alcohol 178 (130 mg, 0.371 
mmol, 99%) as colorless oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.33 (d, J = 1.9 Hz, 1H), 6.83 (d, J = 1.9 Hz, 1H), 6.40 (d, J = 
15.9 Hz, 1H), 6.21 (dt, J = 15.8, 5.4 Hz, 1H), 5.12 (s, 2H), 4.25 (m, 2H), 3.79 (s, 3H), 3.64 (s, 
3H), 2.37 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ ppm 151.9, 145.1, 134.9, 129.2, 128.9, 128.6, 110.3, 98.6, 92.6, 
63.1, 58.3, 55.8. 
EI-MS m/z (%) 351 [MH]+ (16), 332 [MH - H2O]+ (100). 
HR EI-MS m/z 351.0086 [MH]+ (calc. for C12H16IO4 351.0088). 
UV λmax 228, 262, 298 nm  
5.1.8.49 (E)-3-(3-Iodo-5-methoxy-4-(methoxymethoxy)phenyl)acrylaldehyde 
(179) 
 
Allylic alcohol 178 (1.33 g, 3.79 mmol) was dissolved in 30 ml CH2Cl2 and stirred in 
presence of manganese dioxide (5.88 g, 68.2 mmol, 18 eq.) for 3.5 h at r.t. The solid residue 
was then removed by filtration through short celite column (eluted with CH2Cl2) and the 
filtrate was evaporated to afford pure aldehyde 179 (1.18 g, 3.38 mmol, 89%) as white 
solid. 
1H NMR (300 MHz, CDCl3) δ ppm 9.67 (d, J = 7.6 Hz, 1H), 7.59 (d, J = 1.9 Hz, 1H), 7.33 (d, J = 
15.9 Hz, 1H), 7.06 (d, J = 1.9 Hz, 1H), 6.61 (dd, J = 15.9, 7.6 Hz, 1H), 5.24 (s, 2H), 3.88 (s, 
3H), 3.66 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ ppm 193.2, 152.2, 150.6, 148.4, 132.1, 131.8, 128.6, 111.6, 
98.8, 92.9, 58.6, 56.1. 
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EI-MS m/z (%) 348 [M]+· (8), 221 [M – I]+· (11). 
HR EI-MS m/z 347.9856 [M]+· (calcd. for C12H13IO4 347.9859). 
m.p. 73-76 °C 
UV λmax 236, 307 nm. 
5.1.8.50 (3E,5E)-6-(3-Iodo-5-methoxy-4-(methoxymethoxy)phenyl)hexa-3,5-
dien-2-one (180) 
 
Aldehyde 179 (1.18 g, 3.38 mmol) was dissolved in acetone/H2O mixture (7:1, 3.2 ml) and 
cooled to 0 °C, followed by addition of 10% w/v aqueous NaOH solution (0.4 ml). The 
reaction proceeded overnight at r.t. Then it was neutralized by 1 M HCl (aq.), mixed with 
H2O (20 ml) and extracted with EtOAc (3 × 30 ml). The organic phases were dried (MgSO4) 
and the solvent was evaporated. The crude mixture was submitted to CC (SiO2; PE/EtOAc 
3:1) and flash chromatography (RP-18; MeOH/H2O 50-100% MeOH within 25 min, 100% 
MeOH for 5 min, 20 ml/min), respectively, and ketone 180 (710 mg, 1.83 mmol, 54%) was 
obtained as white solid. 
1H NMR (300 MHz, CDCl3) δ ppm 7.40 (d, J = 1.8 Hz, 1H), 7.23 – 7.11 (m, 1H), 6.89 (d, J = 
1.7 Hz, 1H), 6.72 – 6.66 (m, 2H), 6.18 (d, J = 15.5 Hz, 1H), 5.12 (s, 2H), 3.79 (s, 3H), 3.60 (s, 
3H), 2.24 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ ppm 198.0, 151.8, 146.4, 142.7, 138.8, 133.8, 130.4, 129.9, 
126.7, 110.7, 98.5, 92.7, 58.2, 55.7, 27.2. 
EI-MS m/z (%) 388 [M]+· (11), 261 [M – I]+· (13). 
HR EI-MS m/z 388.0172 [M]+· (calcd. for C15H17IO4 388.0172). 
UV λmax 257, 336 nm. 
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5.1.8.51 6-(3-Iodo-5-methoxy-4-(methoxymethoxy)phenyl)hexan-2-one 
(173) 
 
The unsaturated ketone 180 (635 mg, 1.64 mmol) was dissolved in 33 ml dry CH2Cl2 
under N2, followed by addition of (tricyclohexylphosphine)(1,5-
cyclooxadiene)(pyridine)iridium(I) hexa-fluorophosphate (Crabtree’s catalyst, 132 mg, 
0.164 mmol, 0.1 eq.). The mixture was cooled to -78 °C and the N2 atmosphere was 
replaced by H2, applied via a balloon. The reaction slowly proceeded at r.t., reaching a 
complete conversion after 16 days (determined by TLC). The solvent was evaporated and 
the crude mixture was purified by CC (SiO2; PE/EtOAc 3:1) to give 173 (520 mg, 1.33 
mmol, 81%) as yellow oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.17 (d, J = 1.8 Hz, 1H), 6.67 (d, J = 1.8 Hz, 1H), 5.11 (s, 
2H), 3.81 (s, 3H), 3.66 (s, 3H), 2.51 (t, J = 7.0 Hz, 2H), 2.44 (t, J = 6.7 Hz, 2H), 2.13 (s, 3H), 
1.69 – 1.48 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ ppm 208.9, 152.0, 143.8, 140.4, 130.4, 113.1, 98.7, 92.4, 58.3, 
55.9, 43.4, 35.0, 30.7, 29.9, 23.3. 
ESI-MS m/z (%) 415 [MNa]+ (31), 410 [MNH4]+ (54), 361 [MH – MeOH]+ (100). 
HR ESI-MS m/z 410.0828 [MNH4]+ (calcd. for C15H25INO4, 410.0823). 
5.1.8.52 6-(3-Iodo-4-(methoxymethoxy)phenyl)hexan-2-one (172)29 
 
Ketone 93 (721 mg, 3.05 mmol) was dissolved in 28 ml CHCl3, followed by addition of 
silver trifluoroacetate (1.35 g, 6.10 mmol, 2.0 eq.). Iodine (1.55 g, 6.10 mmol, 2.0 eq.) was 
meanwhile dissolved in CHCl3 (28 ml) and then slowly added to the stirred slurry of 
ketone 93 via a dropping funnel. The reaction was stopped after 2 h, solid residues were 
filtered off (celite pad, elution with 100 ml CHCl3) and the yellow filtrate was washed with 
saturated aqueous solution of Na2SO3 (100 ml). The organic layer was subsequently dried 
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with MgSO4 and concentrated in vacuo. The crude product was purified with CC (SiO2; 
PE/EtOAc 3:1), affording 172 (1.01 g, 2.78 mmol, 91%) as yellow oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.58 (d, J = 2.1 Hz, 1H), 7.06 (dd, J = 8.4, 2.1 Hz, 1H), 6.96 
(d, J = 8.4 Hz, 1H), 5.19 (s, 2H), 3.50 (s, 3H), 2.51 (t, J = 7.0 Hz, 2H), 2.43 (t, J = 6.8 Hz, 2H), 
2.12 (s, 3H), 1.65 – 1.49 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ ppm 208.9, 154.1, 139.0, 137.8, 129.3, 114.8, 95.1, 87.2, 56.4, 
43.4, 34.3, 30.9, 29.9, 23.2. 
ESI-MS m/z (%) 331 [MH – MeOH]+ (100), 380 [MNH4]+ (35), 385 [MNa]+ (27). 
HR ESI-MS m/z 380.0710 [MNH4]+ (calcd. for C14H23INO3, 380.0717). 
5.1.8.53 (E)-1-(3-Iodo-4-(methoxymethoxy)phenyl)-7-(3-iodo-5-methoxy-4-
(methoxymethoxy)phenyl)hept-1-en-3-one (183) 
 
Ketone 173 (296 mg, 0.754 mmol) was dissolved in 15 ml EtOH and was stirred in 
presence of NaOH (76.0 mg, 1.89 mmol, 2.5 eq.) while aldehyde 171 (397 mg, 1.36 mmol, 
1.8 eq.) was added in small portions. The mixture was stirred for 20 h at r.t., then, the 
solvent was removed and the residue mixed with 20 ml of saturated aqueous solution of 
NH4Cl. The aqueous solution was extracted with EtOAc (3 × 15 ml), the combined organic 
layers were dried with MgSO4 and EtOAc was removed on a rotary evaporator. The crude 
mixture was purified with flash chromatography (RP-18; MeOH/H2O 50-100% MeOH 
within 25 min, 100% MeOH for 5 min, 20 ml/min) providing 183 as yellowish oil (157 mg, 
0.236 mmol) in 31% yield. 
1H NMR (300 MHz, CDCl3) δ ppm 7.97 (d, J = 2.0 Hz, 1H), 7.47 – 7.42 (dd, J = 8.9, 2.1 Hz,  
1H), 7.39 (d, J = 16.3 Hz, 1H), 7.17 (d, J = 1.8 Hz, 1H), 7.04 (d, J = 8.6 Hz, 1H), 6.68 (d, J = 1.7 
Hz, 1H), 6.60 (d, J = 16.1 Hz, 1H), 5.25 (s, 2H), 5.10 (s, 2H), 3.79 (s, 3H), 3.65 (s, 3H), 3.48 (s, 
3H), 2.64 (t, J = 6.9 Hz, 2H), 2.53 (t, J = 7.3 Hz, 2H), 1.77 – 1.53 (m, 4H). 
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13C NMR (75 MHz, CDCl3) δ ppm 199.7, 157.5, 151.8, 143.7, 140.3, 140.2, 139.0, 130.3, 
130.0, 129.7, 125.1, 114.3, 113.0, 98.5, 94.6, 92.4, 87.4, 58.2, 56.4, 55.8, 40.6, 34.9, 30.8, 
23.7. 
ESI-MS m/z (%) 667 [MH]+ (100), 689 [MNa]+ (17) 
HR ESI-MS m/z 667.0043 [MH]+ (calcd. for C24H29I2O6, 667.0048) 
5.1.8.54 (E)-1,7-Bis(3-iodo-5-methoxy-4-(methoxymethoxy)phenyl)hept-1-
en-3-one (182) 
 
To a stirred solution of ketone 173 (191 mg, 0.487 mmol) and sodium hydroxide (48.7 mg, 
1.22 mmol, 2.5 eq.) in EtOH (10 ml), aldehyde 170 (282 mg, 0.877 mmol, 1.8 eq.) was 
added in portions. After stirring at r.t. for 20 h, the reaction was stopped, EtOH was 
evaporated and 20 ml of saturated aqueous solution of NH4Cl were added. The aqueous 
solution was extracted with EtOAc (3 × 30 ml), the combined organic layers were dried 
with MgSO4 and the solvent was removed in vacuo. The crude product was purified with 
by flash chromatography (RP-18; MeOH/H2O 50-100% MeOH in 25 min, 100% MeOH for 5 
min), which provided 182 (78.0 mg, 0.122 mmol, 23%) as yellowish oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.57 (d, J = 1.8 Hz, 1H), 7.37 (d, J = 16.1 Hz, 1H), 7.18 (d, J 
= 1.8 Hz, 1H), 7.02 (d, J = 1.8 Hz, 1H), 6.68 (d, J = 1.8 Hz, 1H), 6.61 (d, J = 16.1 Hz, 1H), 5.20 
(s, 2H), 5.10 (s, 2H), 3.85 (s, 3H), 3.80 (s, 3H), 3.65 (s, 3H), 3.65 (s, 3H), 2.66 (t, J = 6.9 Hz, 
2H), 2.55 (t, J = 7.3 Hz, 2H), 1.77 – 1.53 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ ppm 199.7, 152.0, 151.9, 147.6, 143.7, 140.4, 140.3, 132.3, 
131.3, 130.3, 126.2, 113.0, 111.7, 98.7, 98.6, 92.8, 92.4, 58.4, 58.3, 55.9, 55.8, 40.5, 35.0, 
30.8, 23.7. 
ESI-MS m/z (%) 718 [MNa]+ (100), 697 [MH]+ (24), 664 [MH – MeOH]+ (39). 
HR ESI-MS m/z 718.9968 [MNa]+ (calcd. for C25H30I2NaO7, 718.9973). 
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5.1.8.55 (E)-7-(3-Iodo-4-(methoxymethoxy)phenyl)-1-(3-iodo-5-methoxy-4-
(methoxymethoxy)phenyl)hept-1-en-3-one (175) 
 
Ketone 172 (797 mg, 2.20 mmol) and NaOH (220 mg, 5.50 mmol, 2.5 eq.), dissolved in 44 
ml EtOH, were mixed with aldehyde 170 (1.28 g, 3.96 mmol) and stirred for 23 h at r.t. 
EtOH was then removed on a rotary evaporator, saturated aqueous solution of NH4Cl (40 
ml) was added to the residue and the aqueous solution was extracted with EtOAc (3 × 40 
ml). After drying with MgSO4 and removal of EtOAc under reduced pressure, the crude 
product was purified by flash chromatography (RP-18; MeOH/H2O 50-100% MeOH within 
25 min, 100% MeOH for 5 min) and column chromatography (SiO2; PE/EtOAc 3:1) to get 
175 (333 mg, 0.50 mmol, 23%) as white solid. 
1H NMR (300 MHz, CDCl3) δ ppm 7.59 (d, J = 2.1 Hz, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.37 (d, J = 
16.1 Hz, 1H), 7.11 – 7.04 (m, 1H), 7.02 (d, J = 1.8 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.61 (d, J = 
16.1 Hz, 1H), 5.21 (s, J = 3.0 Hz, 2H), 5.19 (s, J = 2.5 Hz, 3H), 3.86 (s, 3H), 3.66 (s, J = 4.3 Hz, 
3H), 3.49 (s, J = 2.4 Hz, 4H), 2.65 (t, J = 7.0 Hz, 2H), 2.54 (t, J = 7.2 Hz, 2H), 1.77 – 1.54 (m, 
4H). 
13C NMR (101 MHz, CDCl3) δ ppm 199.7, 154.1, 152.1, 147.7, 140.4, 139.0, 137.7, 132.4, 
131.4, 129.3, 126.2, 114.9, 111.8, 98.7, 95.1, 92.8, 87.2, 58.4, 56.3, 56.0, 40.6, 34.3, 30.9, 
23.7. 
ESI-MS m/z (%) 667 [MH]+ (100). 
HR ESI-MS m/z 667.0052 [MH]+ (calcd. for C24H29I2O6, 667.0048). 
m.p.: 99 °C 
UV λmax 227, 290, 306 nm 
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5.1.8.56 1-(3-Iodo-4-(methoxymethoxy)phenyl)-7-(3-iodo-5-methoxy-4-
(methoxymethoxy)phenyl)heptan-3-one (168) 
 
The unsaturated diarylheptanoid 183 (157 mg, 0.236 mmol) was dissolved in dry CH2Cl2 
under N2 atmosphere. (Tricyclohexylphosphine)(1,5-cyclooxadiene)(pyridine)iridium(I) 
hexafluoro-phosphate (Crabtree’s catalyst, 14.2 mg, 17.7 µmol, 0.075 eq.) was added, the 
mixture was cooled to -78 °C and the N2 was replaced by H2 atmosphere. The cooling bath 
was removed after 30 min and the reaction was allowed to stirr for 4.5 h. After finishing 
the reaction, the solvent was removed and the residue purified by CC (SiO2; PE/EtOAc 2:1) 
affording 97.8 mg (0.146 mmol, 62%) of 168 as colorless oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.58 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 1.8 Hz, 1H), 7.06 (dd, J 
= 2.2, 8.4 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.66 (d, J = 1.8 Hz, 1H), 5.18 (s, 2H), 5.11 (s, 2H), 
3.80 (s, 3H), 3.66 (s, 3H), 3.48 (s, 3H), 2.78 (t, J = 8.0 Hz, 2H), 2.70 – 2.59 (m, 2H), 2.49 (t, J 
= 7.2 Hz, 2H), 2.38 (m, 2H), 1.63 – 1.48 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ ppm 209.5, 154.3, 151.9, 143.7, 140.3, 139.0, 136.5, 130.3, 
129.3, 114.8, 113.0, 98.6, 95.0, 92.4, 87.2, 58.3, 56.3, 55.9, 44.1, 42.6, 34.9, 30.7, 28.2, 23.2. 
ESI-MS m/z (%) 691 [MNa]+ (100), 686 [MNH4]+ (36). 
HR ESI-MS m/z 691.0031 [MNa]+ (calcd. for C24H30I2NaO6, 691.0024). 
 Experimental part  
134 
 
5.1.8.57 1,7-Bis(3-iodo-5-methoxy-4-(methoxymethoxy)phenyl)heptan-3-
one (169) 
 
Enone 182 (78.0 mg, 0.112 mmol), dissolved in dry CH2Cl2, was mixed with 
(tricyclohexylphosphine)(1,5-cyclooxadiene)(pyridine)iridium(I) hexafluorophosphate 
(Crabtree’s catalyst, 9.0 mg, 11 µmol, 0.1 eq.) and the orange solution was cooled to -78 °C. 
The Schlenk flask was filled with H2 atmosphere, the reaction was stirred for 30 min at -78 
°C and further 1.5 h at r.t. The solvent was evaporated and the crude product was purified 
with CC (SiO2; PE/EtOAc 3:1), providing 169 (64 mg, 0.092 mmol, 82%) as colorless oil. 
1H NMR (400 MHz, CDCl3) δ ppm 7.17 (d, J = 1.6 Hz, 2H), 6.70 (d, J = 1.9 Hz, 1H), 6.67 (d, J = 
1.8 Hz, 1H), 5.11 (s, 4H), 3.81 (s, 3H), 3.79 (s, 3H), 3.66 (s, 3H), 3.65 (s, 3H), 2.79 (t, J = 7.2 
Hz, 2H), 2.72 – 2.64 (m, 2H), 2.54 – 2.46 (m, 2H), 2.45 – 2.35 (m, 2H), 1.63 – 1.48 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ ppm 209.4, 151.99, 151.96, 144.1, 143.9, 140.3, 139.3, 130.4, 
130.3, 113.3, 113.1, 98.6 (2C), 92.5, 92.4, 58.3 (2C), 55.9 (2C), 44.0, 42.7, 35.0, 30.8, 28.9, 
23.2. 
ESI-MS m/z (%) 716 [MNH4]+ (40), 721 [MNa]+ (100). 
HR ESI-MS m/z 721.0131 [MNa]+ (calcd. for C25H32I2NaO7, 721.0130). 
5.1.8.58 7-(3-iodo-4-(methoxymethoxy)phenyl)-1-(3-iodo-5-methoxy-4-
(methoxymethoxy)phenyl)heptan-3-one (167) 
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Diarylheptanoid 175 (329 mg, 0.494 mmol, 1.0 eq.) was dissolved in dry CH2Cl2 under N2 
atmosphere and mixed with (tricyclohexylphosphine)(1,5-
cyclooxadiene)(pyridine)iridium(I) hexafluorophosphate (Crabtree’s catalyst, 39 mg, 
0.049 mmol, 0.1 eq.). The orange solution was cooled to -78 °C, the reaction vessel was 
filled with H2 (balloon, ~1 bar) and the reaction was stirred for 2 h at r.t. until complete 
conversion of the starting material. The solvent was subsequently removed under reduced 
pressure and the crude product was purified by CC (SiO2; PE/EtOAc 2:1) affording 167 
(325 mg, 0.487 mmol, 98%) as yellowish oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.58 (d, J = 2.0 Hz, 1H), 7.17 (d, J = 1.8 Hz, 1H), 7.06 (dd, J 
= 8.4, 2.0 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 1.8 Hz, 1H), 5.20 (s, 2H), 5.12 (s, 2H), 
3.80 (s, 3H), 3.66 (s, 3H), 3.51 (s, 3H), 2.79 (m, 2H), 2.67 (m, 2H), 2.51 (t, J = 7.0 Hz, 2H), 
2.40 (t, J = 6.8 Hz, 2H), 1.70 – 1.46 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ ppm 209.5, 154.2, 152.0, 144.1, 139.3, 139.0, 137.7, 130.3, 
129.3, 114.8, 113.3, 98.6, 95.1, 92.5, 87.2, 58.4, 56.4, 55.9, 44.1, 42.8, 34.3, 30.9, 28.9, 23.2. 
ESI-MS m/z (%) 686 [MNH4]+ (100). 
HR ESI-MS m/z 691.0030 [MNH4]+ (calcd. for C24H30I2NaO6, 691.0024). 
UV λmax 281, 339 nm. 
5.1.8.59 1,7-Bis(4-(methoxymethoxy)phenyl)heptan-3-one (162) 
 
The unsaturated diarylheptanoid 97 (108 mg, 0.281 mmol), dissolved in 2 ml CHCl3, was 
mixed with 10% Pd/C (11 mg) and diphenyl sulfide (2.4 µl, 0.014 mmol, 0.05 eq.). The 
black slurry was stirred under H2 atmosphere (balloon, ~1 bar) for 19 h, followed by 
filtration through a pad of celite (eluted with CHCl3). The crude mixture was purified with 
the aid of CC (SiO2; n-hexane/EtOAc 5:1), yielding 84.5 mg (0.219 mmol, 78%) of 162 as 
colorless oil. 
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1H NMR (400 MHz, CDCl3) δ ppm 7.12 – 7.05 (m, 4H), 6.98 – 6.93 (m, 4H), 5.15 (s, 2H), 
5.14 (s, 2H), 3.48 (s, 3H), 3.47 (s, 3H), 2.84 (t, J = 7.5 Hz, 2H), 2.68 (t, J = 7.5 Hz, 2H), 2.55 (t, 
J = 7.1 Hz, 2H), 2.39 (t, J = 6.9 Hz, 2H), 1.69 – 1.45 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ ppm 210.0, 155.5, 155.3, 135.5, 134.4, 129.2 (4C), 116.3 (2C), 
116.1 (2C), 94.51, 94.47, 55.8 (2C), 44.3, 42.7, 34.8, 31.0, 28.9, 23.2. 
ESI-MS m/z (%) 323 [MH – 2MeOH]+ (100), 404 [MNH4]+ (63), 409 [MNa]+ (37). 
HR ESI-MS m/z 404.2421 [MNH4] (calcd. for C23H34NO5, 404.2431). 
5.1.8.60 1,7-Bis(3-iodo-4-(methoxymethoxy)phenyl)heptan-3-one (163) 
 
Silver trifluoroacetate (96.0 mg, 0.434 mmol, 4.0 eq.) was added to a stirred solution of 
162 (42.0 mg, 0.109 mmol, 1.0 eq.) in 1 ml CHCl3. The resulting slurry was cooled to 0 °C 
and iodine solution (110 mg, 0.434 mmol, 4.0 eq., in 2 ml CHCl3) was added dropwise. The 
mixture was stirred for 30 min at 0 °C, subsequently, it was passed through a pad of celite 
(eluted with CHCl3, 50 ml) and the resulting CHCl3 solution was washed with saturated 
aqueous solution of Na2SO3 (20 ml). The organic solvent was then dried (MgSO4) and 
removed under reduced pressure. The purification with CC (SiO2; n-hexane/EtOAc 4:1) 
gained 163 (63.0 mg, 0.099 mmol, 91%) as colorless oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.59 (d, J = 2.1 Hz, 1H), 7.57 (d, J = 2.1 Hz, 1H), 7.08 (dd, J 
= 8.3, 2.1 Hz, 1H), 7.05 (dd, J = 8.3, 2.1 Hz, 1H), 6.96 (d, J = 8.5 Hz, 2H), 5.19 (s, 2H), 5.19 (s, 
2H), 3.50 (s, 3H), 3.49 (s, 3H), 2.82 – 2.75 (m, 2H), 2.70 – 2.62 (m, 2H), 2.50 (t, J = 7.1 Hz, 
2H), 2.38 (t, J = 6.8 Hz, 2H), 1.63 – 1.46 (m, 4H).  
13C NMR (75 MHz, CDCl3) δ ppm 209.5, 154.3, 154.1, 139.0 (2 × CH), 137.7, 136.6, 129.4 
(CH), 129.3 (CH), 114.8 (CH), 114.8 (CH), 95.02 (OCH2O), 94.97 (OCH2O), 87.2, 87.1, 56.3 
(2 × OCH3), 44.1 (CH2), 42.7 (CH2), 34.3 (CH2), 30.9 (CH2), 28.2 (CH2), 23.1 (CH2). 
EI-MS m/z (%) 638 [M]+· (8), 561 (100), 308 (33). 
HR EI-MS m/z 638.0026 [M]+· (calcd. for C23H28I2O5, 638.0026). 
UV λmax 224, 282 nm 
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5.1.8.61 3,17-Dimethoxymethoxy-tricyclo[12.3.1.12,6]nonadeca-1(17),2(19), 
3,5,14(18),15-hexaen-9-one (184) 
 
The diiodinated diarylheptanoid 163 (583 mg, 0.914 mmol, 1.0 eq.), 
bis(pinacolato)diboron (279 mg, 1.10 mmol, 1.2 eq.), [1,1’-bis(diphenylphosphino) 
ferrocene]dichloropalladium(II) (74 mg, 0.091 mmol, 0.1 eq.) and potassium acetate (897 
mg, 9.14 mmol, 10 eq.) were loaded into a Schlenk flask under N2 atmosphere. Degassed, 
dried DMSO (95 ml) was added and the cyclization was started by stirring at 100 °C. After 
19 h, the reaction was allowed to cool to ambient temperature, saturated aqueous solution 
of NH4Cl (200 ml) was added and subsequently extracted with EtOAc (4 × 200 ml). 
Combined organic layers were dried with MgSO4 and liberated of solvent under reduced 
pressure. The crude mixture was passed through a short column (SiO2; eluted with 
PE/EtOAc 2:1), concentrated in vacuo and finally purified with CC (SiO2; PE/EtOAc 3:1), 
affording 184 (94.9 mg, 0.247 mmol, 27%) as white solid. 
1H NMR (400 MHz, CDCl3) δ ppm 7.12 – 7.03 (m, 4H), 6.77 (d, J = 1.5 Hz, 1H), 6.64 (d, J = 
1.8 Hz, 1H), 5.17 (s, 2H), 5.14 (s, 2H), 3.46 (s, 3H), 3.43 (s, 3H), 3.32 – 2.49 (m, 8H), 2.00 – 
1.50 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ ppm 213.5, 152.9, 152.4, 134.7, 134.3, 133.9, 132.9, 130.2, 
129.3, 129.3, 128.2, 115.4, 115.2, 95.0 (2C), 55.74, 55.69, 46.8, 42.5, 31.8, 29.6, 25.3, 20.9. 
ESI-MS m/z (%) 402 [MNH4]+ (100), 353 [MH – MeOH]+ (80) 
HR ESI-MS m/z 402.2273 [MNH4]+ (calcd. for C23H32NO5, 402.2275). 
UV λmax 285 nm. 
m.p. 102 °C. 
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5.1.8.62 16-Methoxy-3,17-dimethoxymethoxy-tricyclo[12.3.1.12,6]nonadeca-
1(17),2(19), 3,5,14(18),15-hexaen-9-one (185) 
 
Diiodinated linear diarylheptanoid 167 (236 mg, 0.353 mmol, 1.0 eq.), 
bis(pinacolato)diboron (109 mg, 0.430 mmol, 1.2 eq.), [1,1’-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (29 mg, 0.035 mmol, 0.1 eq.) and 
potassium acetate (346 mg, 3.53 mmol, 10 eq.) were mixed with degassed dry DMSO (35 
ml) in a Schlenk flask and stirred at 100 °C for 39 h. The black solution was then allowed 
to cool to r.t., saturated aqueous NH4Cl solution (90 ml) was added and subsequently 
extracted with EtOAc (4 × 100 ml). The organic phase was dried with MgSO4, the solvent 
was evaporated and the crude mixture was purified by CC (SiO2; PE/EtOAc 2:1), yielding 
22.9 mg (55.2 µmol, 16%) of the product 185 as colorless oil. 
1H NMR (400 MHz, CDCl3) δ ppm 7.04 (s, 2H), 6.81 (s, 1H), 6.69 (d, J = 1.7 Hz, 1H), 6.21 (d, J 
= 1.8 Hz, 1H), 5.14 (s, 2H), 4.99 (br s, 2H), 3.88 (s, 3H), 3.44 (s, 3H), 3.20 (s, 3H), 3.00 – 2.47 
(m, 8H), 1.91 – 1.68 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ ppm 213.3, 152.1, 152.1, 141.5, 135.8, 134.5, 134.3, 132.8, 
129.5, 129.4, 126.1, 115.1, 111.3, 97.9, 94.8, 56.6, 55.8, 46.5, 42.0, 31.9, 29.9, 25.5, 21.0. 
ESI-MS m/z (%) 432 [MNH4]+ (100), 437 [MNa]+ (37). 
HR ESI-MS m/z 432.2383 [MNH4]+ (calcd. for C24H34NO6, 432.2381). 
UV λmax 284 nm. 
5.1.8.63 4-Methoxy-3,17-dimethoxymethoxy-tricyclo[12.3.1.12,6]nonadeca-
1(17),2(19), 3,5,14(18),15-hexaen-9-one (186) 
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Compound 168 (97.0 mg, 0.145 mmol, 1.0 eq.), together with bis(pinacolato)diboron (44.2 
mg, 0.174 mmol, 1.2 eq.), [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(II) 
(12 mg, 0.015 mmol, 0.1 eq.) and potassium acetate (142 mg, 1.45 mmol, 10 eq.), was 
loaded into a Schlenk flask under protective atmosphere (N2). Degassed and dry DMSO 
was added (14.5 ml) and the mixture was stirred at 100 °C. After 21 h, the reaction was 
allowed to cool to ambient temperature, to be subsequently quenched with 40 ml of 
saturated aqueous solution of NH4Cl. The resulting aqueous solution was extracted with 
EtOAc (4 × 40 ml), the organic phase was then dried (MgSO4) and the solvent evaporated. 
The crude product was purified by CC (SiO2; PE/EtOAc 3:1) and preparative HPLC (RP-18, 
MeOH/H2O, method 1, 5.1.2), providing after lyophilisation 186 (4.7 mg, 11 µmol, 8%) as 
amorphous powder. 
1H NMR (400 MHz, CDCl3) δ ppm 7.05 (d, J = 1.4 Hz, 2H), 6.70 – 6.64 (m, 2H), 6.35 (d, J = 
2.1 Hz, 1H), 5.17 (s, 2H), 4.95 (s, 2H), 3.86 (s, 3H), 3.47 (s, 3H), 3.14 (s, 3H), 3.05 – 2.47 (m, 
8H), 1.68 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ ppm 213.7, 152.7, 152.3, 141.2, 135.1, 134.1, 133.9, 133.5, 
130.4, 128.3, 126.4, 115.0, 112.1, 98.0, 94.8, 56.6, 56.0, 55.9, 47.3, 42.7, 32.6, 29.9, 25.2, 
21.0. 
ESI-MS m/z (%) 339 (100), 383 [MH – MeOH]+ (76), 432 [MNH4]+ (51), 437 [MNa]+ (51). 
HR ESI-MS m/z 432.2383 [MNH4]+ (calcd. for 432.2381, C24H34NO6). 
5.1.8.64  3,17-Dihydroxy-tricyclo[12.3.1.12,6]nonadeca-
1(17),2(19),3,5,14(18),15-hexaen-9-one (acerogenin E, 3) 
 
The MOM-protected acerogenin E 184 (61.4 mg, 0.160 mmol, 1.0 eq.) was dissolved in 8 
ml MeOH, mixed with 1.60 ml of 3 M HCl aq. solution (4.79 mmol, 30 eq.) and stirred under 
reflux for 1.5 h. After this time, the mixture was allowed to cool to r.t., MeOH was 
evaporated and the residue was mixed with ice-cold H2O (30 ml). The aqueous solution 
was extracted with EtOAc (3 × 30 ml), the combined organic layers were dried with MgSO4 
and concentrated in vacuo, yielding pure acerogenin E (3) (46.5 mg, 0.157 mmol, 98%) as 
yellowish solid. 
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1H NMR (400 MHz, acetone-d6) δ ppm 7.04 (m, 2H), 6.96 (d, J = 1.9 Hz, 1H), 6.86 (m, 2H), 
6.76 (d, J = 1.8 Hz, 1H), 2.96 (m, 2H), 2.87 (m, 2H), 2.74 (t, J = 6.2 Hz, 4H), 1.94 (m, 2H), 
1.84 – 1.68 (m, 2H). 
13C NMR (101 MHz, acetone-d6) δ ppm 212.7, 152.2, 152.1, 134.5, 134.4, 133.3, 132.5, 
130.3, 129.4, 127.16, 126.8, 117.0, 116.8, 45.0, 42.5, 32.0, 28.4, 26.5, 22.9. 
ESI-MS m/z (%) 297 [MH]+ (100). 
HR ESI-MS m/z (%) 297.1488 [MH]+ (calcd. for C19H21O3, 297.1485). 
For the exact assignment of the NMR data, see 3.3.3.1. 
5.1.8.65  16-Methoxy-3,17-dihydroxy-tricyclo[12.3.1.12,6]nonadeca-
1(17),2(19), 3,5,14(18),15-hexaen-9-one (188) 
 
Compound 185 (23 mg, 55 µmol, 1.0 eq.), dissolved in 2.8 ml MeOH, was stirred under 
reflux for 30 min in presence of 3 M HCl aq. (55.3 µl, 1.66 mmol, 30 eq.). Subsequently, the 
solvent was evaporated and ice cold H2O (20 ml) was added, followed by the extraction 
with EtOAc (3 × 25 ml). The combined organic phases were dried with MgSO4 and after 
removal of the EtOAc under reduced pressure, 188 was obtained as yellowish oil (16.1 mg, 
49.3 µmol, 89%). 
1H NMR (600 MHz, acetone-d6) δ ppm 7.02 (dd, J = 8.2, 2.3 Hz, 1H), 6.97 (d, J = 1.9 Hz, 1H), 
6.84 (d, J = 2.0 Hz, 1H), 6.80 (d, J = 8.2 Hz, 1H), 6.36 (d, J = 1.9 Hz, 1H), 3.89 (s, 3H), 2.99 – 
2.96 (m, 2H), 2.87 (m, 2H), 2.74 (m, 4H), 1.94 (m, 2H), 1.75 (dt, J = 14.4, 7.1 Hz, 2H). 
13C NMR (151 MHz, acetone-d6) δ 211.6, 152.2, 147.7, 140.2, 133.1, 132.4, 131.2, 129.6, 
125.9, 125.7, 125.4, 116.7, 110.7, 55.8, 44.2, 41.5, 31.1, 28.0, 25.7, 22.0. 
ESI-MS m/z (%) 327 [MH]+ (100). 
HR ESI-MS m/z 327.1593 [MH]+ (calcd. for C20H23O4, 327.1591). 
For the exact assignment of the NMR data, see 3.3.3.1. 
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5.1.8.66 4-Methoxy-3,17-dihydroxy-tricyclo[12.3.1.12,6]nonadeca-
1(17),2(19), 3,5,14(18),15-hexaen-9-one (myricananin C, 18) 
 
Substrate 186 (4.0 mg, 9.7 µmol, 1.0 eq.) and 3 M HCl aq. (96.5 µl, 0.290 mmol, 30 eq.) 
were stirred under reflux for 45 min in 0.5 ml MeOH. The reaction was then finished by 
the addition of ice cold H2O (10 ml), followed by the extraction with EtOAc (3 × 10 ml). The 
combined organic layers provided after drying (MgSO4) and evaporation of the solvent 
crude myricananin C, which was immediately purified with preparative HPLC (RP-18; 
MeOH/H2O, method 2, 5.1.2). The purification afforded myricananin C (18) in 73% yield 
(2.3 mg, 7.1 µmol). 
1H NMR (600 MHz, acetone-d6) δ ppm 7.03 (dd, J = 8.2, 2.2 Hz, 1H), 6.80 (m, 2H), 6.77 (d, J 
= 2.1 Hz, 1H), 6.54 (br s, 1H), 3.85 (s, 3H), 2.94 (m, 2H), 2.74 (m, 4H), 1.95 – 1.88 (m, 2H), 
1.82 – 1.75 (m, 2H). 
13C NMR (151 MHz, acetone-d6) δ ppm 211.9, 152.2, 148.0, 140.5, 133.1, 132.1, 131.5, 
128.6, 126.2, 125.6, 125.3, 116.5, 111.5, 55.8, 44.6, 41.7, 31.7, 27.8, 25.6, 22.0. 
ESI-MS m/z (%) 327 [MH]+ (100). 
HR ESI-MS m/z 327.1590 [MH]+ (calcd. for C20H23O4, 327.1591). 
For the exact assignment of the NMR data, see 3.3.3.1. 
5.1.8.67 3,17-Dihydroxy-tricyclo[12.3.1.12,6]nonadeca-
1(17),2(19),3,5,14(18),15-hexaen-9-ol (16) 
 
Acerogenin E (3) (4.9 mg, 17 µmol, 1.0 eq.), dissolved in 0.4 ml MeOH, was stirred in 
presence of NaBH4 (96 mg, 2.5 mmol, 150 eq.) at 0 °C and subsequently at r.t. for 18 h. The 
reaction was stopped by the addition of 10 ml H2O, followed by the extraction with EtOAc 
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(3 × 15 ml). Combined organic layers were dried with MgSO4 and concentrated in vacuo. 
The crude product was purified by a preparative HPLC (RP-18; MeOH/H2O, method 2) 
providing acerogenin K (16) as white amorphous powder in 41% yield (2.0 mg, 6.7 µmol). 
1H NMR (600 MHz, acetone-d6) δ ppm 7.25 (br s, 1H), 7.21 (br s, 1H), 7.06 (dd, J = 8.2, 2.2 
Hz, 1H), 7.03 (dd, J = 8.2, 2.2 Hz, 1H), 6.88 (d, J = 8.1 Hz, 1H), 6.86 (d, J = 8.1 Hz, 1H), 4.05 (t, 
J = 9.7 Hz, 1H), 2.93 (m, 2H), 2.83 (m, 1H), 2.49 (m, 1H), 2.27 (m, 1H), 2.01 (m, 1H), 1.85 
(m, 2H), 1.66 (m, 2H), 1.58 (m, 1H), 1.48 (m, 1H).  
13C NMR (151 MHz, acetone-d6) δ ppm 152.18, 152.17, 135.1, 134.7, 132.3, 131.9, 130.4, 
130.3, 127.1, 126.9, 116.97, 116.95, 68.5, 40.7, 35.7, 30.7, 27.6, 27.5, 23.8. 
ESI-MS m/z (%) 299 [MH]+ (6), 281 [MH – H2O]+ (100). 
HR ESI-MS m/z (%) 281.1539 [MH – H2O]+ (calcd. for C19H21O2, 281.1536). 
For the exact assignment of the NMR data, see 3.3.3.1. 
5.1.8.68 16-Methoxy-3,17-dihydroxy-tricyclo[12.3.1.12,6]nonadeca-
1(17),2(19), 3,5,14(18),15-hexaen-9-ol (189) 
 
Diarylheptanoid 188 (2.1 mg, 6.4 µmol, 1.0 eq.) was dissolved in 0.2 ml MeOH, followed by 
the addition of NaBH4 (24 mg, 0.64 mmol, 100 eq.) at 0 °C. The ice bath was removed after 
15 min and the reaction was allowed to continue at ambient temperature. H2O (10 ml) was 
used to stop the reaction after 3.5 h. The aqueous solution was extracted with EtOAc (3 × 
15 ml), combined organic layers were concentrated at reduced pressure and the crude 
mixture was directly submitted to purification with preparative HPLC (RP-18; MeOH/H2O, 
method 2, 5.1.2). This afforded 189 as colorless oil (1.5 mg, 4.7 µmol, 73%). 
1H NMR (600 MHz, CDCl3) δ ppm 7.18 (br s, 1H), 7.12 (s, 1H, OH), 7.06 (dd, J = 8.2, 2.3 Hz, 
1H), 6.91 (d, J = 8.2 Hz, 1H), 6.85 (br s, 1H), 6.72 (d, J = 1.9 Hz, 1H), 6.31 (s, 1H, OH), 4.17 (t, 
J = 9.6 Hz, 1H), 3.94 (s, 3H), 2.95 (m, 3H), 2.52 (m, 1H), 2.31 (m, 1H), 2.01 (m, 1H), 1.91 (m, 
1H), 1.89 (m, 1H), 1.68 (m, 2H), 1.55 (m, 1H), 1.51 (m, 1H). 
13C NMR (151 MHz, CDCl3) δ ppm 151.6, 146.7, 139.1, 133.3, 131.4, 130.9, 130.0, 126.4, 
124.9, 124.5, 117.0, 110.2, 69.1, 56.4, 39.7, 34.9, 30.0, 27.4, 26.8, 22.7. 
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ESI-MS m/z (%) 311 [MH – H2O]+ (100), 329 [MH]+ (25). 
HR ESI-MS m/z 311.1647 [MH – H2O]+ (calcd. for C20H23O3, 311.1642). 
For the exact assignment of the NMR data, see 3.3.3.1. 
5.2 General cell culture materials and methods 
5.2.1 Cell culture chemicals and reagents 
Following chemicals and reagents were used during the biological testing in the cell 
culture: 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco®, Life technologies corporation, New 
York, USA) 
Dulbecco’s Phosphate Buffered Saline (PBS, Sigma Aldrich, Steinheim, Germany) 
Fetal Calf Serum (FCS, Superior, Biochrom, Berlin, Germany) 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT, ~98%, used as 4 
mg/ml solution in PBS, Sigma Aldrich, Steinheim, Germany) 
Trypan blue (~37% dye content, Sigma Aldrich, Steinheim, Germany) 
Sodium dodecyl sulfate (92.5 – 100.5%, used as 10% (w/v) solution, Sigma Aldrich, 
Steinheim, Germany) 
Trypsin ((1:250)/EDTA (0.5%/0.2%), used as 10% solution (v/v) in PBS, Merck, 
Darmstadt, Germany) 
Quercetin (≥98%, Sigma Aldrich, Steinheim, Germany) 
Curcumin (97%, Roth, Karlsruhe, Germany) 
Demethoxycurcumin (≥98%, Sigma Aldrich, Steinheim, Germany) 
Bisdemethoxycurcumin (98%, ABCR, Karlsruhe, Germany) 
DMSO (Uvasol®, Merck, Darmstadt, Germany) 
5.2.2 Cell culture instruments and consumables 
Autoflow IR Direct Heat CO2 incubator, Nuaire™, Integra Biosciences, Fernwald, Germany 
Megafuge 1.0R, Thermo Scientific, Waltham, USA 
Laminar flow bench HERAsafe KS, Thermo SK 1200, BDK, Sonnenbühl, Germany 
Multiwell plate reader, Tecan, Crailsheim, Germany 
Cell culture flasks (40 and 200 ml), TPP, Trasadingen, Switzerland 
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Centrifuge tubes (15 and 50 ml), TPP, Trasadingen, Switzerland 
Safe lock tubes (1.5 and 2 ml), Eppendorf, Hamburg 
96-well microtiter plates, TPP, Trasadingen, Switzerland 
Pipette tips (200 µl and 1000 µl), Sarstedt, Nümbrecht, Germany 
Pipette tips (10 µl), Axygen, Union City, New Jersey, USA 
Serological pipettes, TPP, Trasadingen, Switzerland 
Neubauer hemocytometer, Brand, Wertheim, Germany 
5.2.3 Cultivation of cells 
The HT22 cells were cultivated in an incubator at 37 °C in 5% CO2 atmosphere using 
Dulbecco’s Modified Eagle Medium (DMEM) with 10% heat inactivated FCS (inactivation: 
56 °C, 30 min). Cell splitting was performed three times a week when confluence was 
reached. For this matter, the old medium was aspired and the cells were rinsed with 10 ml 
PBS, followed by trypsinization (1 ml trypsin/EDTA solution, 1 min at 37 °C in the 
incubator). The cells detached upon this treatment and were suspended in additional 9 ml 
medium, transferred into a falcon tube and centrifuged for 3 min at 700 × “g”. The 
supernatant was aspired after the centrifugation and the cell pellet was re-suspended in 5 
ml medium. The cell suspension was then reseeded in 1:20 suspension/medium dilution 
ratio in a new cell culture flask. 
For the testing, the actual cell number had to be determined in order to a seed defined 
amount of cells. The cell suspension was therefore diluted in a 1:10 ratio with medium and 
trypan blue solution (70 µl medium/20 µl trypan blue solution/10 µl cell suspension) and 
transferred into a Neubauer hemocytometer. Living cells can be distinguished from the 
damaged since only the latter can be stained by the trypan blue dye. The cell number was 
calculated according to following equation: 
           
  
  
           
 
 
N number of counted cells in the eight squares of the hemacytometer 
f dilution factor (10) 
The calculated cell number was used to prepare cell suspensions in DMEM with defined 
cell concentrations and 100 µl of this suspension were then seeded in every well of a 96-
well microtiteter plate (5000 cell/well for the Glu assay; 50,000 cell/well for the t-BuOOH 
assay). 
 Experimental part 
145 
 
5.2.4 MTT cell viability assay – set-up 1 
The HT22 cells were treated 24 h after the seeding in the microtiter plate with the tested 
substances. All compounds were stored in form of a 100 mM DMSO stock solution at 4 °C 
and were diluted with the cell culture medium to the desired concentrations before being 
transferred onto the cells. The cells were then incubated with the compounds at 37 °C and 
5% CO2 for 24 h. The supernatant was subsequently replaced with MTT solution in DMEM 
(1:10 dilution, MTT used as a 4 mg/ml solution in PBS), the cells were incubated with MTT 
under the above described conditions for additional 3 h and finally treated with the SDS 
lysis buffer after removal of the untransformed MTT. The read-out was performed with a 
multiwell plate reader at 560 nm 24 h after the SDS lysis. 
5.2.5 Glutamate assay 
The neuroprotectivity of the compounds against Glu-induced toxicity was assessed via the 
MTT assay described above (5.2.4). The HT22 cells were in this case treated at the same 
time with the tested substances and glutamate (100 µl/well, final concentration of Glu 5 
mM). 
5.2.6 MTT cell viability assay – set-up 2 
Gelatin solution (0.5% in H2O) was used for pre-coating of the microtiter plates prior to 
the seeding of the HT22 cells. Therefore, a concentrated gelatin solution (5% v/v) was 
warmed to 37 °C and diluted with sterile H2O (Millipore) in 1:10 ratio. In each well, 40 µl 
of the gelatin solution was added and the plate was incubated for 1 h. The supernatant H2O 
was removed and the cells were then seeded in the density of 50,000 cell/well (100 µl cell 
suspension per well). 
The cell viability assay was carried out 24 h after the seeding. The old medium was 
removed and 100 µl of the compounds in DMEM at defined concentrations (1-100 µM) 
were added to each well. The MTT/DMEM addition (1:10 dilution, MTT used as a 4 mg/ml 
solution in PBS) took place after 23 h of incubation at 37 °C and 5% CO2 and the removal 
of the supernatant. The dye was used in 1:10 dilution of the stock solution (4 mg/ml MTT 
in PBS) with DMEM. The cells were subsequently incubated (37 °C, 5% CO2) for 1 h with 
MTT, the untransformed residue was then removed and the SDS lysis was performed (100 
µl SDS solution per well). Absorbance of the produced formazan dye was measured at 560 
nm by a Tecan reader (10 s shaking, 10 s settle time). 
5.2.7 t-BuOOH assay 
The protective activity of the compounds against t-BuOOH toxicity was determined by the 
cell viability assay in the set-up 2 (5.2.6). Briefly, the cells were seeded in the gelatin-pre-
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coated microtiter plates and treated with the compounds after 24 h. The t-BuOOH (1 µl of 
30 mM t-BuOOH, final concentration in the wells 300 µM) was added to the cells 3 h after 
the treatment of the cells with the substances. The supernatant was removed after 
additional 20 h (23 h after the treatment with the compounds) and replaced with the MTT 
solution in DMEM medium (1:10 dilution, MTT used as a 4 mg/ml solution in PBS). The 
removal of MTT/DMEM supernatant and the SDS lysis was performed after 1 h of 
incubation (37 °C, 5% CO2), since the cell number was higher compared to the Glu-assay 
(set-up 1, 5.2.4). The optical density was measured after 24 h by Tecan reader at 560 nm 
(see 5.2.6)  
5.2.8 Statistical analysis 
All experiments were performed in quadruplicate and repeated independently three times 
or more. The results are expressed as mean ± SD, the untreated cells represent 100% 
values. The statistical analysis was carried out with the aid of GraphPad Prism 6 software, 
using one-way analysis of variances (ANOVA) to determine significant differences. Post 
hoc analysis was done using the Dunnett’s test. Statistic significant levels: p < 0.05 (*), p < 
0.01 (**) and p < 0.001 (***). 
5.3 Michael acceptor activity assay 
The Michael acceptor activity assay was performed in 96-well plates (ELISA Microplates, 
MICROLON 200, Greiner Bio-one, Germany), covered by PCR foil (Viewseal transparent, 80 
× 140 mm, Greiner Bio-one, Germany) to avoid the evaporation of the reaction medium 
during the measurement. 100 mM TRIS-HCl buffer pH 7.4 with 2 mM EDTA/ethylene 
glycol (20:80), filtered and degassed before use, was used as a solvent system. Cysteamine 
hydrochloride (192) was purchased from Alfa Aeasar (Karslruhe, Germany). The 
measurement was conducted at 25 °C in a Thermo Scientific Multiskan Spectrum UV/Vis 
microplate and cuvette spectrophotometer (Thermo Fisher Scientifc Inc., Finland).  
The assay was carried out as follows: Stock solutions of compound 1 and 98 (100 mM in 
DMSO) were dilued in the buffer/ethylene glycol mixture to 80 µM. Thiol 192 was 
dissolved in the same reaction medium to form a 24 mM solution. The instrument was set 
up for photoscans between 280-700 nm in defined time intervals and allowed to 
equilibrate. Equal amonuts (100 µl) of compound and thiol solutions were mixed in the 
96-well plate directly prior the measurement, providing 40 µM solutions of the 
elctrophiles with 300 fold excess of the thiol (12 mM). At the same time, 100 µl of the 80 
µM substance solution was mixed with 100 µl of the buffer/ethylene glycol mixture as a 
positive control and 100 µl of the 24 mM cysteamine solution was mixed with 100 µl of the 
solvent system providing a negative control. The wells were covered with the PCR foil and 
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the plate was submitted to the spectrophotometric measurement. The collected data were 
evaluated using MS Excel 2010 and expressed UV spectra of the compounds at different 
times (Fig. 39). 
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7 Appendix 
7.1 NMR spectra 
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(E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hept-1-en-3-one (98) 
1H-NMR 
 
13C-NMR 
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(E)-1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hept-1-en-3-one (99) 
1H-NMR 
 
13C-NMR 
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(E)-7-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hept-1-en-3-one (100) 
1H-NMR 
 
13C-NMR 
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(E)-1,7-Bis(4-hydroxyphenyl)hept-1-en-3-one (101) 
1H-NMR 
 
13C-NMR 
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1,7-Bis(4-hydroxy-3-methoxy phenyl)heptan-3-one (102) 
1H-NMR 
 
13C-NMR 
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1-(4-Hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)heptan-3-one (103) 
1H-NMR 
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1-(4-Hydroxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)heptan-3-one (104) 
1H-NMR 
 
13C-NMR 
 
 Appendix 
163 
 
1,7-Bis(4-hydroxyphenyl)heptan-3-one (acerogenin G, 8) 
1H-NMR 
 
 
 
 Appendix  
164 
 
4,4'-(3-Hydroxyheptane-1,7-diyl)bis(2-methoxyphenol) (105) 
1H-NMR 
 
13C-NMR 
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4-(3-hydroxy-7-(4-hydroxyphenyl)heptyl)-2-methoxyphenol (106) 
1H-NMR 
 
13C-NMR 
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4-(5-Hydroxy-7-(4-hydroxyphenyl)heptyl)-2-methoxyphenol (107) 
1H-NMR 
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4,4'-(3-Hydroxyheptane-1,7-diyl)diphenol ((±)-centrolobol, 25) 
1H-NMR 
 
13C-NMR 
 
 Appendix  
168 
 
1,7-Bis(3,4-dimethoxyphenyl)heptan-3-one (108) 
1H-NMR 
 
13C-NMR 
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(E)-1,7-Bis(3,4-dihydroxyphenyl)hept-1-en-3-one (109) 
1H-NMR 
 
13C-NMR 
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(1E,6E)-1,7-Bis(3,4-dihydroxyphenyl)hepta-1,6-diene-3,5-dione (110) 
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(E)-4-(4-Hydroxy-3-methoxyphenyl)but-3-en-2-one (113) 
1H-NMR 
 
13C-NMR 
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(E)-4-(4-Hydroxyphenyl)but-3-en-2-one (114) 
1H-NMR 
 
13C-NMR 
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(E)-9-(4-Hydroxy-3-methoxystyryl)-3-methoxy-6,7,8,9-tetrahydro-5H-
benzo[7]annulen-2-ol (115) 
1H-NMR 
 
13C-NMR 
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(E)-9-(4-Hydroxystyryl)-3-methoxy-6,7,8,9-tetrahydro-5H-benzo [7]annulen-2-ol 
(116) 
1H-NMR 
 
13C-NMR 
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3,17-Dihydroxy-tricyclo[12.3.1.12,6]nonadeca-1(17),2(19),3,5,14(18),15-hexaen-9-
one (acerogenin E, 3) 
1H-NMR 
 
13C-NMR 
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16-Methoxy-3,17-dihydroxy-tricyclo[12.3.1.12,6]nonadeca-1(17),2(19), 
3,5,14(18),15-hexaen-9-one (188) 
1H-NMR 
 
13C-NMR 
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4-Methoxy-3,17-dihydroxy-tricyclo[12.3.1.12,6]nonadeca-1(17),2(19), 3,5,14(18),15-
hexaen-9-one (myricananin C, 18) 
1H-NMR 
 
13C-NMR 
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3,17-Dihydroxy-tricyclo[12.3.1.12,6]nonadeca-1(17),2(19),3,5,14(18),15-hexaen-9-ol 
(axerogenin K, 16) 
1H-NMR 
 
13C-NMR 
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16-Methoxy-3,17-dihydroxy-tricyclo[12.3.1.12,6]nonadeca-1(17),2(19), 
3,5,14(18),15-hexaen-9-ol (189) 
1H-NMR 
 
13C-NMR 
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7.2 X-ray data 
7.2.1 Acerogenin E (3) crystallized from EtOH 
 
Dihedral angle between the two aromatic rings is 31.78° 
Empirical formula  C19H20O3 
Formula weight 296.35 
Temperature/K 123.01(10) 
Crystal system monoclinic 
Space group C2/c 
a/Å  
 
 
15.13045(17) 
b/Å 11.38773(14) 
c/Å 17.5489(2) 
α/°  90 
β/° 103.2355(12) 
γ/° 90 
Volume/Å3 2943.39(6) 
Z 8 
ρcalcg/cm3 1.338 
μ/mm-1 0.716 
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F(000) 1264.0 
Crystal size/mm3 0.08 × 0.07 × 0.03 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 9.818 to 141.372 
Index ranges -18 ≤ h ≤ 18, -13 ≤ k ≤ 13, -20 ≤ l ≤ 21 
Reflections collected 13596 
Independent reflections 2810 [Rint = 0.0258, Rsigma = 0.0152] 
Data/restraints/parameters 2810/0/201 
Goodness-of-fit on F2 1.045 
Final R indexes [I>=2σ (I)] R1 = 0.0343, wR2 = 0.0909 
Final R indexes [all data] R1 = 0.0358, wR2 = 0.0924 
Largest diff. peak/hole / e Å-3  
 
 
0.23/-0.19 
Using Olex2 [1], the structure was solved with the ShelXS [2] structure solution program 
using Direct Methods and refined with the ShelXL [3] refinement package using Least 
Squares minimisation. 
1. Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, Howard, J.A.K. & Puschmann, H. (2009), J. 
Appl. Cryst. 42, 339-341. 
2. Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122. 
3. Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122. 
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7.2.2 Compound 188 crystallized from EtOH 
 
Dihedral angle between the two aromatic rings is 36.58°. The crystal contains two 
molecules of EtOH per molecule of 188. 
Empirical formula  
 
C22H28O5 
 
Formula weight 372.44 
Temperature/K 122.95(10) 
Crystal system triclinic 
Space group P-1 
a/Å  
 
 
 
9.07755(15) 
 
b/Å 10.39210(18) 
c/Å 11.6256(2) 
α/°  85.4133(14) 
β/° 70.1186(16) 
γ/° 67.9417(16) 
Volume/Å3 954.41(3) 
Z 2 
ρcalcg/cm3 
 
1.296 
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μ/mm-1 
 
0.737 
 
F(000) 
 
400.0 
 
Crystal size/mm3 0.339 × 0.23 × 0.099 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.1 to 133.522 
Index ranges -10 ≤ h ≤ 10, -12 ≤ k ≤ 12, -13 ≤ l ≤ 13 
Reflections collected 16148 
Independent reflections 3360 [Rint = 0.0194, Rsigma = 0.0133] 
Data/restraints/parameters 3360/36/274 
Goodness-of-fit on F2 1.037 
Final R indexes [I>=2σ (I)] R1 = 0.0334, wR2 = 0.0873 
Final R indexes [all data] R1 = 0.0365, wR2 = 0.0901 
Largest diff. peak/hole / e Å-3  
 
 
0.22/-0.17 
Using Olex2 [1], the structure was solved with the SIR2004 [2] structure solution program 
using Direct Methods and refined with the ShelXL [3] refinement package using CGLS 
minimisation. 
1. Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, Howard, J.A.K. & Puschmann, H. (2009), J. 
Appl. Cryst. 42, 339-341. 
2. Burla, M.C., Caliandro, R., Camalli, M., Carrozzini, B., Cascarano, G.L., De Caro, L., 
Giacovazzo, C., Polidori, G., Siliqi, D., Spagna, R. (2007). J. Appl. Cryst. 40, 609-613. 
3. Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122. 
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7.3 HPLC-based stability test of curcumin (1) and compound 98 
 
 
Fig. 44: Curcumin (1) + CAPE in cell culture medium 
CAPE 
curcumin (1) 
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Fig. 45: Compound 98 + CAPE in cell culture medium 
 
compound 98 
CAPE 
compound 98 
CAPE 
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7.4 Michael acceptor activity assay – MS data 
UV spectrum of curcuminoid-cysteamine adduct 193 
 
Mass spectrum of adduct 193 
 
 
  
 
 
 
 
 
 
